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1.1 THE BURDEN OF THE DISEASE – OBESITY  
 
Adiposity is classified using the Body Mass Index (BMI), measured as body 
weight (kilograms) divided by square length (meters). Normal weight is defined as a 
BMI of 18-25 kg/m2, overweight is defined as a BMI of 25-29.9 kg/m2 and obesity is 
present when the BMI exceed 30 kg/m2 or more. Since 1980, the mean BMI level 
increased with 0.4 kg/m2 for men and 0.5 kg/m2 for women per decade worldwide. This 
resulted in an estimated number of adult patients suffering from overweight and obesity 
of 2.1 billion globally in 2013.1 If this trend continues unabated, these numbers increase 
to 3.3 billion (2.2 billion overweight and 1.1 billion obese individuals) by 2030.2 In the 
Netherlands approximately 42% of the adult population is overweight of which 10% 
suffers from obesity.3  
This epidemic has become a major health problem and obesity has become an 
important risk factor, contributing to the overall disease burden worldwide.4,5 In high-
income countries, overweight and obesity are in the top 3 of leading causes of loss of 
healthy life, together with tobacco use and high blood pressure.6,7 Raised BMI is an 
established risk factor for diseases such as type 2 diabetes mellitus (T2DM), 
hypertension, dyslipidemia, and certain types of cancer.8,9 The composite risk profile 
of an obese person results in a markedly reduced life expectancy, especially in younger 
adults.10,11 The consequences of this obesity epidemic entails huge healthcare 
costs.12,13 
 
1.2 COVENTIONAL MANAGEMENT OF OBESITY 
 
Facing the rising problem of the health risks induced by obesity resulting in these 
co-morbidities is challenging and complex. Intervening the postulated drivers for the 
obesogenic environment, such as the changing global food system, marketing systems 
and economic systems promoting consumption, are strategies to prevent an increase 
of this global problem. Simultaneously, implementation of behavioral intervention 
strategies, such as stimulation of physical activity and lower energy consumption, are 
priorities to counteract the energy imbalance.14 
Next to prevention of this epidemic, treatment of obese patients is an important 
issue. The main goal of therapeutic interventions is to achieve sustained weight loss 
with reducing the obesity related diseases and improving quality of life. A moderate 
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total weight loss of 5-10% already improves obesity-related risk factors including 
glycemia, blood pressure, and the patients’ lipid profile.15-17 Treatment options for 
obesity include conventional strategies (lifestyle modification and pharmacotherapy) 
and surgical interventions. Lifestyle modification including dietary changes (caloric 
restriction) and behavioral changes (increased physical activity) can result in adequate 
weight loss,18 nevertheless, maintaining these weight changes and prevention of 
weight regain on the long-term is challenging.19-21 Several weight loss medications 
have been introduced, however, adherence is limited by tolerability and most are not 
suited for long-term use.17 Due to the disappointing results of the conventional 
treatment options, more successful but invasive therapeutic interventions are 
increasingly used.  
 
1.3 BARIATRIC/ METABOLIC SURGERY 
 
Patients with morbid obesity (MO), defined as a BMI over 40 kg/m2 or a BMI of 
35 kg/m2 or more with an obesity related co-morbidity such as T2DM, hypertension, 
dyslipidemia, musculoskeletal disorders or obstructive sleep apnea syndrome (OSAS), 
are eligible for surgical intervention according to the international guideline prepared 
by the National Institutes of Health (NIH).22 Surgical techniques focus on restriction of 
dietary intake, reduction of resorption capacity of the intestine (malabsorption), or a 
combination of both. However, most surgical procedures change the normal 
anatomical integrity of the intestine. Therefore, the international guidelines state that 
an operative intervention should be offered only when conventional treatment has 
failed and metabolic surgery is considered as the ‘last resort’ treatment option.22 
Furthermore, patients must be physically and mentally capable to undergo an 
operation. Patients should be motivated to change their lifestyle and eating behavior 
for the rest of their lives. Therefore, medical, physical and psychological screening by 
a specialized multidisciplinary team, including a surgeon, internist/ endocrinologist, 
dietician, physical therapeutic, and psychologist/ psychiatric, is recommended prior to 
their operation.22 When patients met all these criteria an operation can be considered.  
Multiple studies have proven the superiority of bariatric surgery compared to 
non-surgical treatment for the short- and (mid-)long-term period.23-26 Surgery not only 
leads to sustained weight loss, but was associated with a long-term reduction in overall 
mortality, and reduced incidence of T2DM, cardiovascular events (myocardial 
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infarction and stroke) and cancer. Whereas bariatric surgery merely addresses weight 
loss (:’weight loss surgery’), due to these positive effects on metabolic complications 
in morbidly obese patients, ‘metabolic surgery’ is a more appropriate definition and is 
nowadays a commonly used term. Furthermore, surgery is a more cost-effective 
treatment in the mid- and long-term compared to all non-surgical interventions.27,28 
These advantages and the rising prevalence of morbid obesity have led to an increased 
implementation of metabolic surgery. Within a period of 10 years, the total number of 
bariatric procedures has increased from approximately 146 000 in 2003 to 470 000 in 
2013 annually worldwide.29-32 In the same period, the number of bariatric procedures 
in the Netherlands has increased from approximately 800 to 8000 procedures annually. 
Nowadays, the most performed procedures are the Sleeve Gastrectomy (SG), Roux-
en-Y Gastric Bypass (RYGB), and Adjustable Gastric Band (AGB). However, there is 
a huge variation in trends in type of procedures between different countries and 
continents.32  
 
1.4 TREATMENT OUTCOMES 
 
The success of treatment in obesity can be reflected as the amount of weight 
loss, reduction of metabolic co-morbidities such as T2DM, hypertension and 
dyslipidemia, and increasing of quality of life (QOL).  
The main goal in treatment of excess weight should be to achieve sustained 
weight loss.  Different parameters are used in the literature to express the amount of 
weight loss (Table 1). It can be expressed in absolute parameters, such as absolute 
weight loss (kg) or BMI loss (kg/m2). In weight loss surgery, mostly relative outcome 
parameters are used. In the early literature, the most common parameter is percentage 
excess weight loss (%EWL), which defines the amount of weight loss related to the 
patients’ excess weight (above BMI 25 kg/m2) pre-operatively. The amount of excess 
weight is based on the patients’ ideal body weight. In the later articles, percentage total 
body weight loss (%TBWL) is applied, which is considered a more appropriate 
parameter, since it is less effected by the patients’ pre-operative weight and BMI.  
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Table 1. Frequently used weight loss outcome parameters in weight loss surgery 
Parameters Definition (formula) 
Absolute weight loss (kg) Pre-operative weight – Post-operative weight 
BMI loss (kg/m2) Pre-operative BMI – Post-operative BMI 
Percentage excess weight loss (%) ((Pre-operative weight – Post-operative weight) / 
(Pre-operative weight – Ideal body weight based on 
BMI 25 kg/m2)) * 100% 
Percentage total body weight loss (%) ((Pre-operative weight – Post-operative weight) / 
Pre-operative weight) * 100% 
Percentage excess BMI loss (%) ((Pre-operative BMI – Post-operative BMI) /  
(Pre-operative BMI – ideal BMI of 25 kg/m2)) * 100% 
BMI: body mass index 
 
Reduction of metabolic co-morbidities is based on criteria recommended by 
international expert panels.33,34 Remission of T2DM can be divided in complete or 
partial remission, consistent with the definition of the American Diabetes Association 
(ADA) Expert group recommendations.33 Reducing weight has positive effects on 
patients’ QOL, which can be measured by validated questionnaires (such as RAND-
36) during follow-up. However, these questionnaires aren’t specific for bariatric patients. 
The Bariatric Analysis and Reporting Outcome Scale (BAROS) scoring system is used 
in many articles to reflect patients’ well-being after a bariatric operation.35 The 
advantage of this scoring system is that it considers operation related parameters 
(such as weight loss, complications and re-operations) as well as functional outcome 
parameters such as mental status, physical and sexual functioning, social and work 
related activities, and approach to food intake.  
 
1.5 THE ROUX-EN-Y GASTRIC BYPASS 
 
The gastric bypass procedure is first described by Mason et al. in 1966. Griffen 
et al. reported in 1977 for the first time the gastric bypass procedure with the Roux-en-
Y construction (Figure 1). Today, this technique is still performed and known as the 
classic RYGB procedure.36 The RYGB procedure is considered the ‘gold standard’ in 
bariatrics and finds its working mechanism in a restriction and a change in incretin 
pathways. Although it is also still considered by many as a malabsorptive procedure, 
this is only true for micronutrients and not for carbohydrates and fatty acids.37,38 A small 
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gastric pouch of circa 30cc causes restriction in dietary intake, while bypassing the 
distal part of the stomach, duodenum and proximal part of small intestine (varying 
between approximately 50 and 250cm) by creating a Roux-en-Y construction of the 
intestine (theoretically) induces a change in incretin levels, especially after a meal 
intake (Figure 1).  
The RYGB accounts for approximately half of all bariatric operations.31,32 
Sustained weight loss in the (mid-)long-term in combination with excellent reduction of 
obesity related co-morbidities, especially T2DM, made the RYGB a well-accepted 
procedure.26,39-42 Patients achieve an average %EWL of ~60% after a RYGB 
procedure during the first post-operative years.39,40 Patients with T2DM can often 
reduce their medication immediately after operation and many patients have a 
remission of their diabetes within one year after operation.39,40,43,44 Because of this 
metabolic effects, the Diabetes Surgery Summit Consensus Conference (DSSCC) 
promotes bariatric surgery as an alternative therapy for the treatment of obesity-related 
T2DM.45,46 However the beneficial effect on T2DM is not always permanent and as 
diabetes is a chronic progressive disease a risk for relapse of hyperglycemia always 
remains.  
Interestingly, after five decades of experience and a worldwide tremendous 
increase in the number of RYGB procedures, uniformity of the technique is still lacking. 
Many variations in size of the gastric pouch and the length of the limbs are described.36 
Lengthening of the bypass seems a logical step to increase the effect of the procedure, 
however, this is also related to an increased risk of nutritional and vitamin deficiencies, 
such as iron, vitamin B12 and vitamin D. 47-49 Therefore, there is stil a lot of research 
into the ideal configuration of the RYGB procedure. Further optimizing the technique 
and peri-operative care can reduce operation related morbidities. All these issues will 
be discussed in this thesis. 
Surgical technique (Rijnstate Hospital Arnhem): First, a small gastric pouch of 
30–50 cc which is 3 cm wide and 5 cm long is created, over a 40 French gastric tube. 
A biliopancreatic limb of 50 cm distal to the ligament of Treitz was measured using 
hand-over-hand technique. Next, an antecolic antegastric end-to-side 
gastrojejunostomy is created. An alimentary limb of 150 cm is then measured and a 
jejunojejunostomy is created using the same technique as the gastrojejunostomy 
(Figure 1).  
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Figure 1. Roux-en-Y Gastric Bypass (schematic) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.6 THE ADJUSTABLE GASTRIC BAND 
 
The principle of the AGB is based on restriction of the dietary intake by reducing 
the volume of the proximal part of the stomach. Some different non-adjustable 
prostheses were used in the early 1980’s to create restriction.50 The first adjustable 
gastric band was used by Kuzmak et al. in 1986,50,51 which was able to change in 
diameter by an inflatable subcutaneous port (Figure 2).  
Surgical technique (Rijnstate Hospital Arnhem): The described procedure is 
called the pars-flaccida technique. First, the lesser omentum is opened through the 
pars flaccida component, 5 cm distal to the esophagus. Then, the retrogastric pathway 
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Figure 1. Roux-en-Y Gastric Bypass (schematic) 
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and stiching it to the cardia and diaphragm using a total of five stitches. The port is 
positioned subcutaneously on the greater pectoral muscle (Figure 2).  
 
Figure 2. Adjustable Gastric Band (schematic) 
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morbid obese patient, reducing a lot of the morbidity associated with open surgery. The 
first laparoscopically placed AGB is described by Catona et al. in 1993,52 while the first 
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) was introduced in 1994.53 In the 
first years, this minimally invasive evolution made the RYGB a challenging operation 
with a long learning curve while there was still little experience with laparoscopic 
surgery in general. Therefore, appropriate laparoscopic bariatric training of surgeons 
was necessary to reduce post-operative complications and mortality.54,55 Additionally, 
compared to the LRYGB procedure, the Laparoscopic Adjustable Gastric Band (LAGB) 
was considered a less radical operation and was accompanied with low peri-operative 
morbidity and mortality.56 This resulted in an increased popularity of the LAGB among 
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obese patients and surgeons, and led to a significant increase in numbers from 35000 
to 145000 AGB procedures annually worldwide between 2003 and 2008.31 This 
accounted for 42% of all bariatric procedures worldwide. In Europe, the percentage of 
AGB procedures increased exponentially from 9% to 44% of all bariatric operations in 
the same period.32 However, this early enthousiasm was mainly based on the weight 
loss effects on the short-term,56 while long-term results were not yet available. In this 
thesis, a summary of the long-term results and complications of the LAGB will be 
presented in an introductional chapter.  
  
1.7 THE SLEEVE GASTRECTOMY 
 
The SG induces restriction of dietary intake by reducing 2/3 part of the stomach 
through longitudinal resection of the stomach (Figure 3). The SG was introduced as 
the first step of the Duodenal Switch operation in super obese patients (BMI of 60 kg/m2 
or more).57,58 Nowadays, it is a well-accepted stand-alone operation for MO all over the 
world.32 In the last decade, promising results on the mid-long-term were presented in 
the literature,59-62 and SG was therefore appointed by some as the preferred restrictive 
procedure replacing the LAGB.  
Some studies showed similar results, regarding weight loss, co-morbidities and 
complication rates, on the short-term compared to the RYGB operation.63-66 Therefore, 
the SG was also suggested as an equivalent alternative compared to the RYGB 
procedure. This resulted in a huge increase of SG operations, from nihil to 37% of all 
procedures, in a ten years’ period.32 In Europe, the portion of SG procedures is even 
higher compared to the RYGB in 2013.32 However, in the same period, comparative 
studies between these surgeries were scarce regarding effectiveness and safety. 
Therefore, a comparative study of the three most performed operations will be 
presented in this thesis. 
 Surgical technique (Rijnstate Hospital Arnhem): First, the greater omentum is 
dissected from the greater curvature of the stomach starting halfway of the curvature 
in both directions. Then, the stomach and angle of His are mobilized. Next, the stomach 
is lengthwise stapled along a 40F calibration bougie positioned along the lesser 
curvature, starting 4 cm proximal of the pylorus upto the angle of His. The resected 
stomach is retrieved through an enlarged port incision in the left flank (Figure 3). 
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Figure 3. Sleeve Gastrectomy (schematic) 
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o What are the long-term clinical outcomes – weight loss and co-morbidities – of 
the LRYGB?  
o How might the outcome of LRYGB be improved by optimizing the intra- and 
post-operative care? 
o What are the complications (peri-, short- and long-term) of the LRYGB and how 
can we manage them? 
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1.9 THE OUTLINE OF THE THESIS 
 
Part I of this thesis, Chapter 2, summaries the results and experiences of the 
LAGB in Rijnstate Hospital Arnhem (RHA). As mentioned earlier, the LAGB had 
promising results in the short-term (1-3 years), which resulted in an exponential 
increase of LAGB placement worldwide. However, long-term results and thus evidence 
for introducing it on a larger scale were scarce. In this chapter, the disappointing long-
term results of the LAGB regarding weight loss, complications, co-morbidities and 
quality of life are presented. Despite initial good results of the LAGB, removal of the 
band is required in many patients because of band-failure or band-related 
complications. Several patients request a band removal alone, although because of 
the high risk of weight regain the preferred management is to perform a secondary 
bariatric operation. Revision to a LRYGB after a failed LAGB is a commonly performed 
procedure with good results on the mid-long-term.67-71 However, the negative 
experiences with the LAGB formed the basis for searching for more appropriate 
bariatric technique with respect to feasibility and durability. Although the LRYGB wasa 
well-known procedure, the complexity of the procedure restrained many surgeons from 
applying this procedure for many years   
 Part II of the thesis, will discuss the (peri-) operative outcome of the LRYGB 
procedure. The LRYGB is currently one the most performed primary procedures, 
followed currently by the LSG. On the other hand, until recently, the LAGB was still 
performed on a large scale, especially overseas in the United States. However, 
comparative studies are still limited. Therefore, a multicenter matched cohort was 
conducted to study in two high-volume bariatric centers to determine the clinical 
outcome and safety of the LRYGB compared to the LSG and LAGB. The results of this 
study and an overview of the literature are presented in Chapter 3. The RYGB 
procedure underwent several technical modifications over the past five decades to 
improve the outcome of this operation.72 The Roux-en-Y construction consists of two 
small intestinal limbs (Figure 1): the alimentary limb or the ‘Roux’ limb (from the gastro-
jejunostomy to the entero-enterostomy) and the biliopancreatic limb (from Treitz’ 
ligament to the entero-enterostomy). To date, several limb lengths are used, but an 
optimal limb length is not yet determined. Chapter 4 focuses on lengthening of the 
alimentary limb and the peri- and post-operative outcome are reported. Furthermore, 
the LRYGB surgery is still considered a challenging and time consuming operation. To 
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overcome the increasing demand on hospital resources, operative time and personnel, 
a better organization of the peri operative logistics was necessary. Additionally, the 
quality of peri-operative care must be guaranteed in these high risk morbidly obese 
patients. Therefore, a multidisciplinary fast track surgery (FTS) program was 
introduced, to improve both operation logistics and peri-operative care. The outcome 
of this FTS program compared to the conventional peri-operative care is presented in 
Chapter 5. An important item in the treatment of obese patients is the durability of the 
intervention to both weight and the obesity related morbidities. The effect of the LRYGB 
procedure on cardio-metabolic abnormalities on the short-term is well-reported in 
randomized controlled trials,41,42 however, results on the long-term are scarce. 
Chapter 6 describes the effect of the RYGB on remission of T2DM, hypertension and 
dyslipidemia in the long-term.  
 The last two chapters are presented in part III of this thesis. The RYGB 
procedure induces weight loss because of reduction of dietary intake and intestinal 
resorption capacity. The side effect of this mechanism is the risk to develop post-
surgical nutritional deficiencies, such as iron, vitamin B12 and vitamin D, with potential 
health risks.47-49 Therefore, daily use of multivitamin supplements is recommended 
after surgery. Chapter 7 describes the nutritional status and the compliance for 
multivitamin supplements after RYGB on the long term. However, the available 
commercial multivitamin supplements were not adjusted for an altered resorption in the 
altered gastro-intestinal tract, and a RYGB specific multivitamin supplements did not 
exist at the time. Therefore, a customized multivitamin supplement for RYGB patients 
was developed based on data from the available literature and on own research. The 
effect and safety of this supplement compared to a standard multivitamin is studied in 
a double-blind randomized trial. This result of this study is presented in Chapter 8.  
 Finally, a summary and general discussion of all studies, and future 
perspectives are presented in Chapter 9 and Chapter 10 (Dutch) (part IV). 
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PART I
Kemal Doğan
Rise and fall of the Laparoscopic 
Adjustable Gastric Band
  
This chapter is adapted from the following articles: 
 
Long-term results after Laparoscopic Adjustable Gastric Banding: A fourteen year 
follow-up study.  
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ABSTRACT 
Background 
For over a decade, the laparoscopic adjustable gastric band (LAGB) was one of the 
most performed bariatric procedures in Europe. However, several gaps in literature were 
present, especially regarding long-term outcomes and management of failures of the gastric 
band. This will be discussed in this chapter based on the experience in a Dutch high-volume 
bariatric center.  
 
Setting 
In 1995, the LAGB was introduced in the Rijnstate Hospital Arnhem to treat morbid 
obesity. Patients’ data of all LAGB placement up to December 2010 were recorded and 
analyzed. 
 
Conclusions 
The LAGB shows good short term results in excess weight loss (EWL) and co-morbidity 
reduction. In the long-term, however, EWL and co-morbidity reduction are disappointing and 
the LAGB does not live up to expectations. Beside the decrease in EWL over time, the number 
of reoperations is alarming. In total, less than a quarter of patients still had a satisfactory 
functioning band after a mean of fourteen years of follow-up.  
Patients who have their gastric band removed will surely regain their weight, even to 
presurgery levels in most cases. It is inadvisable to just remove the LAGB without performing 
a second bariatric procedure. Converting a gastric band to Roux-en-Y Gastric Bypass (RYGB) 
(as a one-step procedure) is a safe and feasible procedure with acceptable complication rates 
when performed in a specialized institution.  
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INTRODUCTION 
Morbid obesity presents a challenging and important health problem worldwide, 
because it is associated with an increase in co-morbidities and diminished life 
expectancy.1,2  
Conservative treatment is the obvious first treatment for obesity, but often proves to 
have little or no long-term effect. To date, surgical intervention, although rather radical, 
offers the best chance to reach considerable weight loss without an immediate rebound 
effect.3,4 Besides the social advantages of weight loss, there is the prospect of 
resolution of co-morbidities and an increased life expectancy. For the latter, sustained 
weight loss is indispensable.1-4  
The Laparoscopic Adjustable Gastric Band (LAGB) is less radical procedure 
compared to other anatomical changing procedures, such as the Roux-Y gastric 
bypass (RYGB). After the introduction of the adjustable gastric band, it soon acquired 
popularity among patients and surgeons, which led, together with the rising prevalence 
of morbid obesity, to a yearly increase in the number of band implantations.5,6 The 
LAGB can be implanted with low morbidity and mortality with good excess weight loss 
(EWL) and a decrease in co-morbidities in the short-term.1,7 Despite relatively high 
experience in Europe with the LAGB,6 long-term results with sufficient data regarding 
weight loss, complications, and reoperations were scarce. More studies became 
available, who found increased number of complications and weight regain as time 
since LAGB implant progresses.8-16 In many studies, however, the reported results 
were incomplete due to lost to follow-up, which is a general problem in bariatric 
population.13,14,17 Unfortunately, available literature illustrated LAGB failure and 
disappointing EWL in the long-term. Some studies estimate band failure to be as high 
as 66% after ten years.13,14,18 Common reasons for LAGB failure include insufficient 
weight loss or weight regain due to a maladaptive eating pattern and pouch dilation.15,19 
Other often reported band-related complications are pouch formation or slippage, 
heartburn, and band migration.1,14, 20-24  
When an LAGB fails, revisional bariatric surgery is frequently offered. However, 
several patients refuse a second bariatric operation.20,21,25 The limited literature shows 
a modest weight regain after band removal.11,14 Therefore, the preferred treatment for 
many complications is revisional surgery. In most cases, failed LAGB’s have been 
converted to a RYGB.20,25-27 There is evidence in the literature that revisional bariatric 
surgery can be hazardous compared with primary gastric bypass surgery, with a 
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Conservative treatment is the obvious first treatment for obesity, but often proves to 
have little or no long-term effect. To date, surgical intervention, although rather radical, 
offers the best chance to reach considerable weight loss without an immediate rebound 
effect.3,4 Besides the social advantages of weight loss, there is the prospect of 
resolution of co-morbidities and an increased life expectancy. For the latter, sustained 
weight loss is indispensable.1-4  
The Laparoscopic Adjustable Gastric Band (LAGB) is less radical procedure 
compared to other anatomical changing procedures, such as the Roux-Y gastric 
bypass (RYGB). After the introduction of the adjustable gastric band, it soon acquired 
popularity among patients and surgeons, which led, together with the rising prevalence 
of morbid obesity, to a yearly increase in the number of band implantations.5,6 The 
LAGB can be implanted with low morbidity and mortality with good excess weight loss 
(EWL) and a decrease in co-morbidities in the short-term.1,7 Despite relatively high 
experience in Europe with the LAGB,6 long-term results with sufficient data regarding 
weight loss, complications, and reoperations were scarce. More studies became 
available, who found increased number of complications and weight regain as time 
since LAGB implant progresses.8-16 In many studies, however, the reported results 
were incomplete due to lost to follow-up, which is a general problem in bariatric 
population.13,14,17 Unfortunately, available literature illustrated LAGB failure and 
disappointing EWL in the long-term. Some studies estimate band failure to be as high 
as 66% after ten years.13,14,18 Common reasons for LAGB failure include insufficient 
weight loss or weight regain due to a maladaptive eating pattern and pouch dilation.15,19 
Other often reported band-related complications are pouch formation or slippage, 
heartburn, and band migration.1,14, 20-24  
When an LAGB fails, revisional bariatric surgery is frequently offered. However, 
several patients refuse a second bariatric operation.20,21,25 The limited literature shows 
a modest weight regain after band removal.11,14 Therefore, the preferred treatment for 
many complications is revisional surgery. In most cases, failed LAGB’s have been 
converted to a RYGB.20,25-27 There is evidence in the literature that revisional bariatric 
surgery can be hazardous compared with primary gastric bypass surgery, with a 
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reported two-fold mortality and morbidity rate.28-30 For that reason, many surgeons 
advocate a two-step procedure for converting a failed gastric band to a gastric bypass 
procedure, taking the band out during the first procedure and performing a gastric 
bypass some time later. 
Rijnstate Hospital Arnhem (RHA) is a high-volume bariatric center with 
considerable experiences in LAGB placements, LAGB failures, complications and 
revisional operations. Several studies are performed in the RHA to optimize the 
treatment in morbid obesity and fill in the gaps in the literature as described above. In 
this chapter, the following questions will be discussed based on three studies 
performed in RHA.31-33 
o What are the long-term results, in terms of weight loss, weight regain, 
complications and reoperations, of the LAGB procedure? 
o What happens after Gastric Band removal without additional bariatric 
surgery? 
o What is the feasibility, safety and effectivity of RYGB performed as a 
one-stage procedure after failed LAGB? 
 
SETTING 
 In 1995, the LAGB was introduced in the RHA to treat morbid obesity according 
to criteria stated by the National Institute of Health Consensus Development 
Conference Panel for bariatric surgery.34 From 1995 to 1998, patients received 
adjustable gastric band using the perigastric technique.35 Since 1998, the pars-flaccid 
technique is performed.36 Patients’ data of all LAGB placement up to December 2010 
were recorded and analyzed.31-33  
 
RESULTS AND DISCUSSION 
Success of the LAGB? 
Between 1995 and 2003, in total 201 LAGB procedures were performed for 
treatment of morbid obesity. The first 41 patients received a Swedish adjustable gastric 
band using the perigastric technique. The remaining 160 patients received a Lapband 
(Inamed) using the pars flaccid technique. These patients were analyzed after a mean 
follow-up of 164 months (120-216).31 
Mainly, success of bariatric surgery is based on the amount of weight reduction, 
expressed in percentage of excess weight loss (%EWL). Mean %EWL in patients with 
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the band still in place was 49% after 5 years, 41% after 10 years, and 21% after 15 
years. Mean EWL was over 50% after the second year, but then slowly dropped to 
40% and 38% after 10 and 14 years (Figure 1). EWL>50% was almost 50% after 2 
years, but had dropped to 48% and 28% (P<.001) after 5 and 10 years of follow-up, 
respectively. These results are disappointing when treatment of obesity should be 
lifelong. It is very hard to define success in bariatric surgery. A cut-off point of 25% 
EWL is widely accepted in the literature, however, in daily practice, a 25% excess 
weight loss is often synonymous with large disappointment, both with patients and 
surgeons.  
Success of an operation can also be measured by improving the quality of life 
(QOL), using the Bariatric Analysis and Reporting Outcome Scale (BAROS).37 Of the 
193 patients evaluable after fourteen years, 105 (54%) had their band removed (15) or 
converted to a different bariatric procedure (90). Of the 88 patients (46%) who still had 
their band in place, 45 (51%) had a low BAROS score (fail) and can be considered as 
failures. In other words, only 43 patients (23%) still had a functional band and 150 
patients (73%) had failing bands fourteen years after band placement. These numbers 
are far below the initial expectations of the surgeons and patients.  
 
 Figure 1. %EWL in patients with LAGB in situ or converted to RYGB31 
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Reduction of co-morbidities is even more relevant for these patients as it 
influences quality of life and life expectancy.1,2 Although there was a significant 
reduction of type 2 diabetes mellitus (T2DM) during the first years after operation, only 
38% without T2DM medication and had HbA1 c levels under 6.5%. After 10 and 14 
years, the total number of patients with T2DM was higher than at the start, mostly due 
to newly developed disease in other patients. This numbers are flattered, since some 
patients had undergone a RYGB in the meantime. Similar figures can be drawn for 
hypertension and gastroesophageal reflux disease (Figure 2).  
 
Complications and reoperations 
During the fourteen years, many complications and reoperations occurred. 
Pouch dilation or slippage (22%), port or tube leakage (17%), and band migration (6%) 
were among the most frequently diagnosed complications (Table 1). Two hundred four 
reoperations were performed in 133 patients (67%). The most performed reoperations 
were conversions to other bariatric procedures (29%) mainly because of weight 
(re)gain. Other frequent reoperations were correction of the port or a leaking tube 
(18%) and band removal (12%) or repositioning (10%) for pouch dilation or slippage 
(Table 2). The complication rate increased in a linear line over the years. The overall 
complications, excluding weight regain, occurring in 47% of patients is much higher 
than described in the literature.3,10 This is probably explained by the fact that follow-up 
was longer and over half the complications occurred in the last 5 years. 
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Figure 2. (A) Co-morbidities: T2DM, (B) Hypertension, (C) GERD31 
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Table 1. Complications in 14 years after LAGB placement 
 N  (%patients) 
Technical complications   
Leakage PAC 18 (9%) 
Leakage tube 15 (8%) 
Leakage band 9 (5%) 
Lose PAC 5 (3%) 
Patient related   
Pouch formation 27 (14%) 
Slippage 16 (8%) 
Severe reflux 10 (5%) 
Severe esophageal dilatation 7 (4%) 
Band migration 12 (6%) 
Infected band/ PAC 7 (4%) 
Total 126 in 94 patients (47%) 
N: Number of patients 
PAC: Port a Cath 
This table is based on the original table of ref 31.31 
 
 
Table 2. Minor and major reoperations31 
 N  (%patients) 
Port/tube change 37  (18%) 
Band change 13  (6%) 
Repositioning band 20  (10%) 
Conversion to RYGB 90  (44%) 
Conversion to Gastric Sleeve 4    (2%) 
Conversion to Scopinaro 4    (2%) 
Band removal alone 25  (12%) 
Port removal 1    (0.5%) 
Total N of reoperations 204  
N of patients with reoperation(s) 133  (67%) 
N: number 
RYGB: Roux-en-Y gastric bypass 
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Revisional surgery? 
The treatment for many complications is revisional bariatric surgery. A few 
patients, however, request only band removal without secondary bariatric surgery. Up 
to 2010, 38 patients underwent LAGB removal without secondary operations.32 Median 
weight and BMI before LAGB placement were 129 (98–180) kg and 44.3 (37–57) kg/m2, 
respectively, and significantly dropped just before LAGB removal to 104 (62–167) kg 
and 35.5 (23–57.6) kg/m2 (P<.01). The most frequently observed cause for band 
removal (40%) was gastric band migration, while 30% of the patients had persistent 
vomiting. Fear of the complications that occurred with the LAGB (53%) and the fear of 
changing the gut permanently (42%) were the main reasons for patients not choosing 
to have a second bariatric procedure. In Figure 3 and 4, the changes in weight, BMI 
and %EWL before and after removal of the LAGB. It is obvious that patients who had 
no revisional operation could not maintain their weight loss, even when the LAGB was 
highly successful. This trend is also described in other studies.11,38 Although the 
number of patients in these study is limited, the results are uniform. In the present study, 
the difference in %EWL between patients who eventually underwent secondary 
surgery compared with patients who only had their band removed is highly significant, 
with 67% versus –11% (P<.001), respectively. Even with regain of weight after LAGB 
removal, these patients seem to do well after a second bariatric procedure. Therefore, 
a secondary procedure is advised in patients after a failed gastric band, no matter the 
reason of removal.  
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Figure 3. Weight and BMI profile of the patients with or without secondary procedure after 
LAGB removal32 
 
(1A) Pre-and postoperative weight (kg). (1B) Pre-and postoperative BMI (kg/m2) 
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Figure 4. %EWL Pre- and post LAGB removal32 
 
 
 
The aim of a revisional procedure should be to treat complications and achieve 
further weight loss in patients with insufficient %EWL.20 As described above, most 
failed bands are converted to a RYGB procedure. The first revional operation, replacing 
a gastric band to a RYGB, was first perfomed in the RHA in 2000. A total of 195 patients, 
who received a revisional bariatric surgery from January 2000 to December 2010 were 
reviewed.33 The removal of the band en performing the RYGB was during a single 
operation (one-step-procedure). Converting to RYGB was performed after a mean of 
five (±3) years. In total, 175 (90%) patients were operated without any complications. 
There were three conversions to open surgery because of bleeding from the short 
gastric artery and the spleen (two of the patients who underwent LAGB) and firm 
adhesions after open band implantation in the past in the third patient. The other 192 
(98%) operations were performed laparoscopically. Peri-operative outcomes and 
complications are shown in Table 3.  
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Table 3. Perioperative outcomes after revisional RYGB procedure in 195 patients33 
 Mean  (±SD/Range) 
Operative time (min) 111.5  (37.3/50-243) 
Blood loss (ml) 47  (209/0-1800) 
Hospital stay (days) 4.5  (5.1/2-62) 
Uncomplicated  178  (91.3%) 
Complications 17  (8.7%) 
 Stenosis 2  (1%) 
 Cholecystolitiasis <1 year 4  (2%) 
 Wound abscess 2  (1%) 
 Others 2  (1%) 
Re-operation <30 days 8  (4.1%) 
 Active bleeding spleen 1  (0.5%) 
Active bleeding gastric vessel 1  (0.5%) 
Leakage gastro-enterostomie 2  (1%) 
Herniation through Petterson 2  (1%) 
Others 2  (1%) 
SD: Standard Deviation, min: minutes, ml: millilitres 
This table is based on the original table of ref 33.33 
 
The mean weight before RYGB was 122 (±23) kg and 113 (±24) kg after five 
years, which is shown in Figure 5. The results of this study in terms of %EWL are 
excellent, with 150 patients (76%) achieving a %EWL>50% and mean %EWL of 60% 
after a mean 40 months of follow up.  
RYGB seems to be a good solution in this series for many patients requiring a 
LAGB conversion, especially patients which have shown good results in terms 
of %EWL with the LAGB. For patients with only minor %EWL, RYGB in the short term 
also results in adequate results in many patients; however, weight regain is seen in 
over 85% of these patients. Although there are obvious disadvantages like severe 
nutrient deficiencies, more malabsorptive procedures should be considered like the 
biliopancreatic diversion. 
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Figure 5. Pre- and postoperative weight in patients who underwent a revisional RYGB 
operation (kg)33  
 
 
CONCLUSIONS  
Bariatric surgery is introduced to treat chronic morbid obesity. One of the 
treatment options is the LAGB, which, in the short-term, shows good results in terms 
of EWL and co-morbidity reduction. In the long-term, however, EWL and co-morbidity 
reduction are disappointing and the LAGB seems not to live up to expectations. Beside 
the decrease in EWL over time, the number of reoperations is alarming. In total, less 
than a quarter of patients still had a satisfactory functioning band after a mean of 
fourteen years of follow-up.  
Patients who have their gastric band removed will surely regain their weight to 
presurgery levels in most cases. It is inadvisable to remove the LAGB without 
performing a second bariatric procedure. Converting a gastric band to RYGB as a one-
step procedure is a safe and feasible procedure with acceptable complication rates 
when performed in a specialized institution.  
 Overall, it is justifiable to conclude that the LAGB is not suitbale for a durable 
treatment of morbid obesity. Searching for the optimal treatment modality is ongoing. 
At present, the RYGB procedure still remains the golden standard. However, this 
procedure is not yet optimized and additional research is required to define best 
(peri-) operative care in RYGB procedures.  
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ABSTRACT 
Background 
Laparoscopic adjustable gastric band (LAGB), laparoscopic sleeve gastrectomy (LSG), 
and laparoscopic Roux-en-Y gastric bypass (LRYGB) are the most performed procedures 
worldwide (92 %) nowadays. However, comparative clinical trials are scarce in literature. The 
objective of this study was to compare the effectiveness and safety of the three most performed 
bariatric procedures. 
 
Methods 
A multicenter, retrospective, matched cohort study was conducted. Patients were 
eligible for analysis when a primary procedure was performed between 2007 and 2010 in one 
of the two specialized bariatric centers. Primary outcome was weight loss, expressed in the 
percentage excess weight loss (%EWL). Secondary outcome parameters are hospital stay, 
complication rate, and revisional surgery. 
 
Results 
In total, 735 patients, 245 in each group, were included for analysis. The groups were 
comparable for age and gender after matching. Mean postoperative follow-up was 
3.1 ± 1.2 years. LAGB patients showed less %EWL compared to LSG and LRYGB at all 
postoperative follow-up visits. LRYGB showed a %EWL of 71 ± 20 % compared to LSG 
(76 ± 23 %; p = 0.008) after 1-year follow-up; thereafter, no significant difference was observed. 
After 3 years of follow-up, LAGB showed a higher complication rate compared to LSG and 
LRYGB (p < 0.05). Revisional surgery after LAGB was needed in 21 %, while 9 % of the LSG 
underwent conversion to RYGB. 
 
Conclusions 
LRYGB is a safe and effective treatment in morbid obese patients with good long-term 
outcomes. LSG seems to be an appropriate alternative as a definitive procedure, in terms of 
weight reduction and complication rate. LAGB is inferior to both LRYGB and LSG. 
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INTRODUCTION 
Morbid obesity has become a major health care problem, including in The 
Netherlands, which is partly due to increased risk of cardiovascular and metabolic 
diseases.1,2 Currently, bariatric surgery is the most effective long-term treatment of 
obesity and the obesity-related diseases.3 In the past, several bariatric procedures 
were introduced of which laparoscopic Roux-en-Y gastric bypass (LRYGB), 
laparoscopic sleeve gastrectomy (LSG), and laparoscopic adjustable gastric banding 
(LAGB) are currently the most performed surgical techniques worldwide.4 
Literature shows acceptable results of approximately 50 % excess weight loss 
(%EWL) after LAGB on the short and long terms.5-8 However, due to weight regain on 
the long term and high complication and reintervention rates, LAGB has become less 
popular in Europe and decreasingly so in the USA.4,9-11 
The LSG was originally meant to treat superobese patients (BMI >60 kg/m2), as 
a part of the duodenal switch, or high risk patients.12,13 Nowadays, the LSG is a well-
tolerated standalone surgical procedure, even in lower BMI categories, and counted 
for approximately one third of all bariatric procedures worldwide in 2011.4 Promising 
results were reported on the short term of 62–86 % EWL,14-16 which is comparable to 
LRYGB.17,18 However, due to the possibility of regaining weight after 5 years, the 
effectiveness is not yet clarified.19 
The LRYGB, which is considered to be a combination of a restrictive and 
metabolism altering procedure, is a technically more challenging procedure with 
traditionally a higher risk of early complications compared to the LAGB and LSG.20,21 
However, advantages of the LRYGB are approximately 60 % EWL on the long term 
and successful sustained weight loss (EWL > 50 %) in 65 % of the patients.22 Moreover, 
due to positive effects on comorbidities, especially in remission of type 2 diabetes 
mellitus (T2DM),23,24 LRYGB is still considered the “gold standard” in bariatric surgery. 
The LAGB, LSG, and LRYGB account for 92 % of all bariatric procedures 
performed worldwide.4 Surprisingly, only a small number of non-randomized clinical 
trials comparing the effectiveness and safety between these three interventions were 
published25-30 and only a few small numbered randomized controlled trials (RCTs) 
comparing only two of these three interventions are available.17,18,24,31-39 
The aim of this multicenter study is to determine the effectiveness and safety of 
the three most commonly performed bariatric procedures (LSG, LRYGB, and LAGB). 
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METHODS 
After approval of the Local Board of Ethics in both specialized bariatric centers 
(Rijnstate Hospital Arnhem (RHA) and Sint Franciscus Gasthuis Rotterdam (SFG), The 
Netherlands), a retrospective analysis of prospective collected data was performed. All 
adult morbid obese patients (>18 years, BMI >35 kg/m2 with comorbidities or BMI 
>40 kg/m2) who underwent primary bariatric surgery in one of these centers from 2007 
until 2010 were included. Informed consent was obtained from all individual 
participants included in the study. Data collection was carried out prospectively per 
center by specialized morbid obesity nurses in the RHA and bariatric medical team in 
SFG. Patients’ medical chart, including demographic, perioperative, and postoperative 
follow-up data, were reviewed. All LSG procedures were performed in SFG, and 
LRYGB and LAGB procedures in the RHA. 
 
Patient Selection and Outcome 
Patients were eligible when they underwent a primary bariatric procedure to 
treat morbid obesity and had a minimum postoperative follow-up period of 1 year. In 
total, 255 patients received a LSG of which 245 patients had a minimum follow-up of 
1 year. LSG, LRYGB, and LAGB patients were matched for gender and age (±2 years) 
using Matlab version R2010b (the Math-Works Inc., Natick, MA, USA). Figure 1 shows 
the selection procedure. Primary outcome was %EWL defined as the following 
equation: (preoperative weight − current weight) / (preoperative weight − “ideal” 
weight) × 100. Secondary outcome parameters were duration of hospital stay, 
complication rates in the first 30 days, and need for a secondary bariatric procedure. 
 
Follow-Up 
In both centers, a multidisciplinary follow-up program for a minimum duration of 
2 years was offered to all patients. A team consisted of a surgeon, endocrinologist, 
psychologist, dietician, and a specialized obesity nurse. The first year after surgery, 
outpatient clinic consultations were performed after 3, 6, and 12 months, and thereafter 
annually. 
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Figure 1. Flow-chart: selection procedure 
 
LSG: Laparoscopic Sleeve Gastrectomy, LRYGB: Laparoscopic Roux-en-Y Gastric Bypass, LAGB: Laparoscopic 
Adjustable Gastric Banding  
 
Surgical Techniques 
LAGB: In the study period, all patients received the Swedish adjustable gastric 
band (11 cc) (SAGB VC™, Ethicon Endo-Surgery, a Johnson & Johnson company, 
New Brunswick, USA). The procedure was performed by the pars-flaccida technique. 
First, the lesser omentum is opened through the pars flaccida component, 5 cm distal 
to the esophagus. Then, the retrogastric pathway for the band is created by dissecting 
from the right to the left branch of the crus toward the angle of His. The band was 
fixated using a total of five stitches (Vicryl 2.0). The port is positioned on the greater 
pectoral muscle.40 
LSG: First, the greater omentum was dissected from the greater curvature of 
the stomach using an ultrasonic scissor (Harmonic Ace®, Ethicon Endo-Surgery, a 
Johnson & Johnson company, New Brunswick, USA), starting halfway of the curvature 
in both directions. Then, the stomach and angle of His were mobilized, starting by a 
posterior approach and completed by dissection of the anterior part of the angle of His 
and small gastric vessels. Next, the stomach was lengthwise stapled along a 34F 
calibration bougie positioned along the lesser curvature, starting 4 cm proximal of the 
pylorus until the cardia. The remnant of the stomach is retrieved through an enlarged 
port incision in the left flank. A postoperative diagnostic laparoscopy was performed in 
case of high suspicion of leakage. This technique was previously described in detail.41 
LAGB 
n = 622 
 
LSG  
n = 255 
 
Match criteria 
 
1. Gender 
2. Age (± 2 yrs) 
 
LAGB  n = 245 
LSG     n = 245 
LRYGB  n = 245 
 
Total  n =735 
Databases 
LRYGB 
n = 430 
 
Inclusion 
Exclusion 
 
LAGB  n = 377 
LSG  n = 10 
LRYGB n = 185 
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fixated using a total of five stitches (Vicryl 2.0). The port is positioned on the greater 
pectoral muscle.40 
LSG: First, the greater omentum was dissected from the greater curvature of 
the stomach using an ultrasonic scissor (Harmonic Ace®, Ethicon Endo-Surgery, a 
Johnson & Johnson company, New Brunswick, USA), starting halfway of the curvature 
in both directions. Then, the stomach and angle of His were mobilized, starting by a 
posterior approach and completed by dissection of the anterior part of the angle of His 
and small gastric vessels. Next, the stomach was lengthwise stapled along a 34F 
calibration bougie positioned along the lesser curvature, starting 4 cm proximal of the 
pylorus until the cardia. The remnant of the stomach is retrieved through an enlarged 
port incision in the left flank. A postoperative diagnostic laparoscopy was performed in 
case of high suspicion of leakage. This technique was previously described in detail.41 
LAGB 
n = 622 
 
LSG  
n = 255 
 
Match criteria 
 
1. Gender 
2. Age (± 2 yrs) 
 
LAGB  n = 245 
LSG     n = 245 
LRYGB  n = 245 
 
Total  n =735 
Databases 
LRYGB 
n = 430 
 
Inclusion 
Exclusion 
 
LAGB  n = 377 
LSG  n = 10 
LRYGB n = 185 
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LRYGB: First, a small gastric pouch of 30–50 cc is created, which is 3 cm wide 
and 5 cm long over a 40F gastric tube. A biliopancreatic limb of 50 cm distal to the 
ligament of Treitz was measured using hand-over-hand technique along the 
mesenteric border in steps of 5 cm. Next, an antecolic antegastric end-to-side 
gastrojejunostomy is created with a linear blue 4.5 cm stapler combined with a 
continuous suture (Endo Stitch™, Convidien, Mansfield, USA), closing the anterior part. 
An alimentary limb of 100–150 cm was then measured using the same technique. The 
jejunojejunostomy is created using the same technique as gastrojejunostomy besides 
the use of a white 6.0 cm stapler. In all patients, a leak test of the gastrojejunostomy 
was performed. No postoperative gastric swallow tests are performed unless leakage 
is suspected. 
 
Statistics 
Data were analyzed using SPSS 20.0 for Windows. The outcomes were based 
on intention-to-treat analysis. Differences between groups were analyzed using one-
way ANOVA test. When it showed significant differences, the unpaired t test was used 
for continuous data and the chi-squared test was used for dichotomous data. Data 
were reported as the mean (standard deviation) unless otherwise specified. A p value 
<0.05 was considered significant. All figures were created using GraphPad Prism 5.01. 
 
RESULTS 
A total of 735 patients, 245 patients in each group, were finally included for 
analysis. At baseline, age and gender were comparable for all groups (p > 0.05). 
Preoperative BMI was higher for LRYGB (47.2 ± 5.8 kg/m2) compared to LAGB 
(44.8 ± 5.0 kg/m2, p < 0.001) and LSG (45.8 ± 6.0 kg/m2, p = 0.009), and LSG has a 
significantly higher BMI than LAGB (p = 0.047). The number of patients with 
comorbidities was significantly different among groups (p < 0.01), with 59, 36, and 72 % 
of patients experiencing a comorbidity related to morbid obesity in LAGB, LSG, and 
LRYGB, respectively. Table 1 shows the baseline characteristics and comorbidities of 
the study population. 
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Table 1. Patients’ characteristics at baseline 
 LAGB 
(n=245) 
LSG 
(n=245) 
LRYGB 
(n=245) 
P value 
LAGB vs. 
LSG 
P value 
LAGB vs. 
LRYGB 
P value 
LSG vs. 
LRYGB 
Age (years) 39.6 ±10.0 39.7 ±10.0 41.2 ±9.7   0.880  0.075   0.104 
Female (n,%) 201      (82) 201    (82) 201       (82)   1.000  1.000   1.000 
Weight (kg) a 128.1 ±19.4 130.3 ± 22.0 136.9  ±21.6   0.245 <0.001   0.001 
BMI (kg/m2) a 44.8 ±5.0 45.8 ±6.0 47.2  ±5.8   0.047 <0.001   0.009 
Co-morbidities, n (%)      
T2DM 47  (19.2) 4  (1.6) 78  (31.8) <0.001  0.001 <0.001 
Hypertension 70  (28.6) 68  (27.8) 110  (44.9)   0.841 <0.001 <0.001 
Dyslipidemia 21 (8.6) 22  (9.0) 53  (21.6)   0.873 <0.001 <0.001 
Joint pain 102  (41.6) 18  (7.3) 78  (31.8) <0.001  0.025 <0.001 
OSAS 28  (11.4) 8  (3.3) 49  (20.0)   0.001  0.009 <0.001 
Total b 144  (58.8) 89  (36.3) 176  (71.8) <0.001  0.002 <0.001 
Values are mean ± SD, unless otherwise specified 
LSG: laparoscopic sleeve gastrectomy, LRYGB: laparoscopic Roux-en-Y gastric bypass, LAGB: laparoscopic 
adjustable gastric banding, BMI: body mass index, T2DM: type 2 diabetes mellitus, OSAS: obstructive sleep 
apnea syndrome 
aANOVA p < 0.001 
bTotal number of patients with one of the comorbidities described in the table 
 
Mean follow-up was 3.1 ± 1.2 years after surgery. Number of patients in follow-
up after 1, 2, 3, 4, and 5 years were 245 (100 %), 245 (100 %), 204 (83 %), 141 (58 %), 
and 82 (34 %) for LAGB, 245 (100 %), 215 (88 %), 145 (59 %), 71 (29 %), and 27 
(11 %) for LSG, and 245 (100 %), 221 (90 %), 111 (45 %), 50 (20 %), and 19 (8 %) for 
LRYGB, respectively. 
 
Follow-Up 
Among the three groups, a significant difference in %EWL was present during 
all postoperative follow-up moments (ANOVA p < 0.01) which is shown in Table 2 and 
Figure 2a. The LAGB had lower %EWL compared to both LSG and LRYGB during the 
five postoperative years (p < 0.01). %EWL was equal between LSG and LRYGB 
(p > 0.05), except for the first postoperative year (p = 0.008). %EWL between LSG and 
LRYGB were similar at any time during follow-up, when stratified for age (age <40 and 
>40 years) or BMI level (BMI <50 and >50 kg/m2). 
BMI was significantly different between the three groups during the 5-year 
postoperative follow-up period (ANOVA p < 0.05). BMI was higher during all 
postoperative follow-up moments for LAGB compared to LSG and LRYGB (p < 0.001), 
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LRYGB: First, a small gastric pouch of 30–50 cc is created, which is 3 cm wide 
and 5 cm long over a 40F gastric tube. A biliopancreatic limb of 50 cm distal to the 
ligament of Treitz was measured using hand-over-hand technique along the 
mesenteric border in steps of 5 cm. Next, an antecolic antegastric end-to-side 
gastrojejunostomy is created with a linear blue 4.5 cm stapler combined with a 
continuous suture (Endo Stitch™, Convidien, Mansfield, USA), closing the anterior part. 
An alimentary limb of 100–150 cm was then measured using the same technique. The 
jejunojejunostomy is created using the same technique as gastrojejunostomy besides 
the use of a white 6.0 cm stapler. In all patients, a leak test of the gastrojejunostomy 
was performed. No postoperative gastric swallow tests are performed unless leakage 
is suspected. 
 
Statistics 
Data were analyzed using SPSS 20.0 for Windows. The outcomes were based 
on intention-to-treat analysis. Differences between groups were analyzed using one-
way ANOVA test. When it showed significant differences, the unpaired t test was used 
for continuous data and the chi-squared test was used for dichotomous data. Data 
were reported as the mean (standard deviation) unless otherwise specified. A p value 
<0.05 was considered significant. All figures were created using GraphPad Prism 5.01. 
 
RESULTS 
A total of 735 patients, 245 patients in each group, were finally included for 
analysis. At baseline, age and gender were comparable for all groups (p > 0.05). 
Preoperative BMI was higher for LRYGB (47.2 ± 5.8 kg/m2) compared to LAGB 
(44.8 ± 5.0 kg/m2, p < 0.001) and LSG (45.8 ± 6.0 kg/m2, p = 0.009), and LSG has a 
significantly higher BMI than LAGB (p = 0.047). The number of patients with 
comorbidities was significantly different among groups (p < 0.01), with 59, 36, and 72 % 
of patients experiencing a comorbidity related to morbid obesity in LAGB, LSG, and 
LRYGB, respectively. Table 1 shows the baseline characteristics and comorbidities of 
the study population. 
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Table 1. Patients’ characteristics at baseline 
 LAGB 
(n=245) 
LSG 
(n=245) 
LRYGB 
(n=245) 
P value 
LAGB vs. 
LSG 
P value 
LAGB vs. 
LRYGB 
P value 
LSG vs. 
LRYGB 
Age (years) 39.6 ±10.0 39.7 ±10.0 41.2 ±9.7   0.880  0.075   0.104 
Female (n,%) 201      (82) 201    (82) 201       (82)   1.000  1.000   1.000 
Weight (kg) a 128.1 ±19.4 130.3 ± 22.0 136.9  ±21.6   0.245 <0.001   0.001 
BMI (kg/m2) a 44.8 ±5.0 45.8 ±6.0 47.2  ±5.8   0.047 <0.001   0.009 
Co-morbidities, n (%)      
T2DM 47  (19.2) 4  (1.6) 78  (31.8) <0.001  0.001 <0.001 
Hypertension 70  (28.6) 68  (27.8) 110  (44.9)   0.841 <0.001 <0.001 
Dyslipidemia 21 (8.6) 22  (9.0) 53  (21.6)   0.873 <0.001 <0.001 
Joint pain 102  (41.6) 18  (7.3) 78  (31.8) <0.001  0.025 <0.001 
OSAS 28  (11.4) 8  (3.3) 49  (20.0)   0.001  0.009 <0.001 
Total b 144  (58.8) 89  (36.3) 176  (71.8) <0.001  0.002 <0.001 
Values are mean ± SD, unless otherwise specified 
LSG: laparoscopic sleeve gastrectomy, LRYGB: laparoscopic Roux-en-Y gastric bypass, LAGB: laparoscopic 
adjustable gastric banding, BMI: body mass index, T2DM: type 2 diabetes mellitus, OSAS: obstructive sleep 
apnea syndrome 
aANOVA p < 0.001 
bTotal number of patients with one of the comorbidities described in the table 
 
Mean follow-up was 3.1 ± 1.2 years after surgery. Number of patients in follow-
up after 1, 2, 3, 4, and 5 years were 245 (100 %), 245 (100 %), 204 (83 %), 141 (58 %), 
and 82 (34 %) for LAGB, 245 (100 %), 215 (88 %), 145 (59 %), 71 (29 %), and 27 
(11 %) for LSG, and 245 (100 %), 221 (90 %), 111 (45 %), 50 (20 %), and 19 (8 %) for 
LRYGB, respectively. 
 
Follow-Up 
Among the three groups, a significant difference in %EWL was present during 
all postoperative follow-up moments (ANOVA p < 0.01) which is shown in Table 2 and 
Figure 2a. The LAGB had lower %EWL compared to both LSG and LRYGB during the 
five postoperative years (p < 0.01). %EWL was equal between LSG and LRYGB 
(p > 0.05), except for the first postoperative year (p = 0.008). %EWL between LSG and 
LRYGB were similar at any time during follow-up, when stratified for age (age <40 and 
>40 years) or BMI level (BMI <50 and >50 kg/m2). 
BMI was significantly different between the three groups during the 5-year 
postoperative follow-up period (ANOVA p < 0.05). BMI was higher during all 
postoperative follow-up moments for LAGB compared to LSG and LRYGB (p < 0.001), 
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except for BMI between LAGB versus LRYGB at 5 years postoperatively (p = 0.056). 
LSG had, compared to LRYGB, similar BMI levels (p > 0.05) during the first five 
postoperative years, except for the first year (p = 0.005). BMI levels are shown in Table 
2, and the trend during follow-up is demonstrated in Figure 2b. 
 
Table 2. Body mass index and excess weight loss at baseline, 1-5 year follow-up 
 LAGB 
(n=245) 
LSG 
(n=245) 
LRYGB 
(n=245) 
ANOVA 
P value 
 
LAGB vs. 
LSG 
P value 
LAGB vs. 
LRYGB 
P value 
LSG vs. 
LRYGB 
P value 
BMI 
0  44.8±5.0 45.8±6.0 47.2±5.8 P<0.001   0.047 <0.001 0.009 
1 year 37.8±5.3 30.6±5.8 32.1±5.2 P<0.001 <0.001 <0.001 0.005 
2 years 36.3±5.4 30.8±6.0 31.7±5.8 P<0.001 <0.001 <0.001 0.108 
3 years 36.5±5.7 31.8±6.1 32.4±6.5 P<0.001 <0.001 <0.001 0.506 
4 years 37.2±6.0 31.7±4.9 33.6±5.3 P<0.001 <0.001  0.001 0.054 
5 years 36.7±7.9 32.6±5.5 32.9±5.9 P=0.016   0.005  0.056 0.859 
%EWL 
1 year 36.6±17.1 76.5±23.4 70.8±19.8 P<0.001 <0.001 <0.001 0.008 
2 years 44.2±19.8 75.4±24.7 72.3±23.6 P<0.001 <0.001 <0.001 0.179 
3 years 42.7±22.1 69.7±25.1 69.7±25.5 P<0.001 <0.001 <0.001 0.985 
4 years 37.7±24.0 67.1±24.3 67.1±23.0 P<0.001 <0.001 <0.001 0.400 
5 years 44.6±30.0 62.5±23.8 65.1±23.2 P=0.002 <0.001  0.006 0.684 
Values are mean ± SD 
LSG: laparoscopic sleeve gastrectomy, LRYGB: laparoscopic Roux-en-Y gastric bypass, LAGB: laparoscopic 
adjustable gastric banding, BMI: body mass index (kg/m2), %EWL: percentage excess weight loss 
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Figure 2. Follow-up weight 
A. Excess weight loss at 1–5-year follow-up 
 
Mean excess weight loss (EWL) in percentages over time for laparoscopic sleeve gastrectomy (LSG), 
laparoscopic adjustable gastric banding (LAGB), and laparoscopic Roux-en-Y gastric bypass 
(LRYGB). Whiskers are standard deviation. 
 
B. Body mass index at baseline, 1–5-year follow-up 
 
Mean body mass index (BMI) over time for LSG, LAGB, and LRYGB. Whiskers are standard deviation 
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except for BMI between LAGB versus LRYGB at 5 years postoperatively (p = 0.056). 
LSG had, compared to LRYGB, similar BMI levels (p > 0.05) during the first five 
postoperative years, except for the first year (p = 0.005). BMI levels are shown in Table 
2, and the trend during follow-up is demonstrated in Figure 2b. 
 
Table 2. Body mass index and excess weight loss at baseline, 1-5 year follow-up 
 LAGB 
(n=245) 
LSG 
(n=245) 
LRYGB 
(n=245) 
ANOVA 
P value 
 
LAGB vs. 
LSG 
P value 
LAGB vs. 
LRYGB 
P value 
LSG vs. 
LRYGB 
P value 
BMI 
0  44.8±5.0 45.8±6.0 47.2±5.8 P<0.001   0.047 <0.001 0.009 
1 year 37.8±5.3 30.6±5.8 32.1±5.2 P<0.001 <0.001 <0.001 0.005 
2 years 36.3±5.4 30.8±6.0 31.7±5.8 P<0.001 <0.001 <0.001 0.108 
3 years 36.5±5.7 31.8±6.1 32.4±6.5 P<0.001 <0.001 <0.001 0.506 
4 years 37.2±6.0 31.7±4.9 33.6±5.3 P<0.001 <0.001  0.001 0.054 
5 years 36.7±7.9 32.6±5.5 32.9±5.9 P=0.016   0.005  0.056 0.859 
%EWL 
1 year 36.6±17.1 76.5±23.4 70.8±19.8 P<0.001 <0.001 <0.001 0.008 
2 years 44.2±19.8 75.4±24.7 72.3±23.6 P<0.001 <0.001 <0.001 0.179 
3 years 42.7±22.1 69.7±25.1 69.7±25.5 P<0.001 <0.001 <0.001 0.985 
4 years 37.7±24.0 67.1±24.3 67.1±23.0 P<0.001 <0.001 <0.001 0.400 
5 years 44.6±30.0 62.5±23.8 65.1±23.2 P=0.002 <0.001  0.006 0.684 
Values are mean ± SD 
LSG: laparoscopic sleeve gastrectomy, LRYGB: laparoscopic Roux-en-Y gastric bypass, LAGB: laparoscopic 
adjustable gastric banding, BMI: body mass index (kg/m2), %EWL: percentage excess weight loss 
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Figure 2. Follow-up weight 
A. Excess weight loss at 1–5-year follow-up 
 
Mean excess weight loss (EWL) in percentages over time for laparoscopic sleeve gastrectomy (LSG), 
laparoscopic adjustable gastric banding (LAGB), and laparoscopic Roux-en-Y gastric bypass 
(LRYGB). Whiskers are standard deviation. 
 
B. Body mass index at baseline, 1–5-year follow-up 
 
Mean body mass index (BMI) over time for LSG, LAGB, and LRYGB. Whiskers are standard deviation 
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Postoperative hospital admission is significantly lower for LAGB (1.2 ± 1.2 days) 
compared to LSG (3.3 ± 5.6 days, p < 0.001) and LRYGB (2.9 ± 1.4 days, p < 0.001). 
Readmission rate within 30 days was significantly higher for LSG (4.5 %) compared to 
LAGB (0 %, p = 0.001) and LRYGB (0.4 %, p = 0.003). 
Twenty-three (9.4 %) patients in the LSG group received a conversion to 
LRYGB after a mean period of 2.2 years. Reason for revision were dysphagia (n = 2), 
weight regain (n = 5), and insufficient weight loss (n = 16). 
In 51 (21 %) patients, a revisional procedure (49 LRYGB and 2 biliopancreatic 
diversion) was performed in the LAGB group after a mean period of 3.5 years. These 
were performed because of weight regain (n = 16), recurrent vomiting (n = 16), slippage 
of the band (n = 6), insufficient weight loss (n = 4), band migration (n = 2), reflux (n = 2), 
pouch (n = 2), pain (n = 2), and dislocation of the band (n = 1). This was significantly 
higher compared to LSG (p < 0.001). No revisional procedures were performed after a 
LRYGB. 
 
Intra-operative and Postoperative Complications 
An overview of the intra-operative and postoperative complications is shown in 
Table 3. Most intra-operative complications occurred performing the LSG (4 %) 
compared to LAGB (1 %, p = 0.033) and LRYGB (2 %, p = 0.260). Postoperatively, 
patients with LSG had more complications within 30 days after surgery compared to 
LAGB and LRYGB (p > 0.05). In total, nine (4 %) patients required a reoperation within 
30 days after LSG, compared to two (1 %) patients after LAGB (p = 0.033) and seven 
(3 %) patients after LRYGB (p = 0.611). 
Postoperative complications on the long term were significantly higher for 
LAGB compared to both LSG and LRYGB (p < 0.001), while the long-term 
complication rate after LRYGB was higher compared to LSG, but no significance was 
reached (p = 0.054). In 66 (27 %) patients, a reoperation was performed after LAGB, 
followed by 25 (10 %) patients after LSG and 10 (4 %) after LRYGB (p < 0.01). In 
total, 55 (22 %) patients had their LAGB removed for reasons of a complication. 
Table 4 shows the LAGB-specific complications. A laparoscopic cholecystectomy for 
symptomatic cholecystolithiasis during the initial procedure was performed in five 
patients (2.0 %) in both the LSG and the LRYGB group. During follow-up, a number 
of patients underwent a laparoscopic cholecystectomy, 7 % after LAGB, 4 % after 
LSG, and 5 % after LRYGB (p > 0.05). 
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Table 3. Intra-operative and postoperative complications 
 LAGB 
N=245 
LSG 
N=245 
LRYGB 
N=245 
LAGB vs. 
LSG 
P value 
LAGB vs. 
LRYGB 
P value 
LSG vs. 
LRYGB 
P value 
Intra-operative       
Spleen laceration 1 (0.4) 3 (1.2) 1 (0.4) NS NS NS 
Liver laceration 1 (0.4) 1 (0.4) 1 (0.4) NS NS NS 
CBD laceration - - 1 (0.4) NS NS NS 
Intestinal perforation  - - 1 (0.4) NS NS NS 
Drain stapling - 3 (1.2) - NS NS NS 
Bleeding - 2 (0.8) - NS NS NS 
No. of patients 2 (0.8) 9 (3.7) 4 (1.6) 0.033 0.686 0.260 
Short term (< 30 
days) 
      
Leakage - 4 (1.6) 1 (0.4) NS NS NS 
Bleeding/ hematoma - 7 (2.9) 5 (2.0) 0.015 NS NS 
Intra-abdominal abscess - 4 (1.6) - NS NS NS 
Passage complaints 7 (2.9) - - 0.015 0.015 NS 
Pulmonary Embolism - 2 (0.8) 1 (0.4) NS NS NS 
Pneumonia 2 (0.8) 1 (0.4) 1 (0.4) NS NS NS 
Wound infection - 1 (0.4) 2 (0.8) NS NS NS 
Others - 3 (1.2) 5 (2.0) NS NS NS 
Re-admission -  11 (4.5) 1 (0.4) 0.001 NS 0.003 
No. of patients 9 (3.7) 19 (7.6) 14 (5.7) 0.052 0.286 0.367 
Long term (>30 days)       
Laparoscopic 
cholecystectomy  
16 (6.5) 9 (3.7) 12 (4.9) NS NS NS 
Pancreatitis 1 (0.4) - 2 (0.8) NS NS NS 
Ileus - - 1 (0.4) NS NS NS 
Stenosis - - 1 (0.4) NS NS NS 
Mesenteric internal 
hernia 
- - 4 (1.6) NS NS NS 
Passage complaints 3 (1.2) 2 (0.8) - NS NS NS 
Reflux  5 (2.0) - - NS NS NS 
Recurrent vomiting 19 (7.6) - 1 (0.4) <0.001 <0.001 NS 
Marginal ulcer - - 3 (1.2) NS NS NS 
Unexplained abdominal 
pain  
- - 8 (3.3) NS 0.007 0.007 
Bleeding - - 1 (0.4) NS NS NS 
Hernia cicatricalis - 2 (0.8) - NS NS NS 
Others - 8 (3.3) 3 (1.2) 0.007 NS NS 
No.  of patientsa 68 (28)b 12 (5) 23 (9) <0.001 <0.001 0.054 
No. of re-operations       
Short term (< 30 days) 2 (0.8) 9 (3.7) 7 (2.9) 0.033 NS NS 
Long term (> 30 days)a  66 (26.9) 25 (10.2) 10 (4.1) <0.001 <0.001 0.009 
Revisional procedure 51 (20.8) 23 (9.4) - <0.001 <0.001 <0.001 
Mean period (year) 3.5 ±1.2 2.2 ±1.3 - <0.001 - - 
RYGB 49 23 - - - - 
Biliopancreatic diversion  2 - - - - - 
Values are numbers (%), unless otherwise stated 
 - no complication; LSG: Laparoscopic Sleeve Gastrectomy, LRYGB: Laparoscopic Roux-en-Y Gastric Bypass, 
LAGB: Laparoscopic Adjustable Gastric Banding, CBD:  Common Bile Duct; NS: not significant 
a Exclusive laparoscopic cholecystectomy 
b Including band-related complications, presented in table 4 
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Postoperative hospital admission is significantly lower for LAGB (1.2 ± 1.2 days) 
compared to LSG (3.3 ± 5.6 days, p < 0.001) and LRYGB (2.9 ± 1.4 days, p < 0.001). 
Readmission rate within 30 days was significantly higher for LSG (4.5 %) compared to 
LAGB (0 %, p = 0.001) and LRYGB (0.4 %, p = 0.003). 
Twenty-three (9.4 %) patients in the LSG group received a conversion to 
LRYGB after a mean period of 2.2 years. Reason for revision were dysphagia (n = 2), 
weight regain (n = 5), and insufficient weight loss (n = 16). 
In 51 (21 %) patients, a revisional procedure (49 LRYGB and 2 biliopancreatic 
diversion) was performed in the LAGB group after a mean period of 3.5 years. These 
were performed because of weight regain (n = 16), recurrent vomiting (n = 16), slippage 
of the band (n = 6), insufficient weight loss (n = 4), band migration (n = 2), reflux (n = 2), 
pouch (n = 2), pain (n = 2), and dislocation of the band (n = 1). This was significantly 
higher compared to LSG (p < 0.001). No revisional procedures were performed after a 
LRYGB. 
 
Intra-operative and Postoperative Complications 
An overview of the intra-operative and postoperative complications is shown in 
Table 3. Most intra-operative complications occurred performing the LSG (4 %) 
compared to LAGB (1 %, p = 0.033) and LRYGB (2 %, p = 0.260). Postoperatively, 
patients with LSG had more complications within 30 days after surgery compared to 
LAGB and LRYGB (p > 0.05). In total, nine (4 %) patients required a reoperation within 
30 days after LSG, compared to two (1 %) patients after LAGB (p = 0.033) and seven 
(3 %) patients after LRYGB (p = 0.611). 
Postoperative complications on the long term were significantly higher for 
LAGB compared to both LSG and LRYGB (p < 0.001), while the long-term 
complication rate after LRYGB was higher compared to LSG, but no significance was 
reached (p = 0.054). In 66 (27 %) patients, a reoperation was performed after LAGB, 
followed by 25 (10 %) patients after LSG and 10 (4 %) after LRYGB (p < 0.01). In 
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Table 3. Intra-operative and postoperative complications 
 LAGB 
N=245 
LSG 
N=245 
LRYGB 
N=245 
LAGB vs. 
LSG 
P value 
LAGB vs. 
LRYGB 
P value 
LSG vs. 
LRYGB 
P value 
Intra-operative       
Spleen laceration 1 (0.4) 3 (1.2) 1 (0.4) NS NS NS 
Liver laceration 1 (0.4) 1 (0.4) 1 (0.4) NS NS NS 
CBD laceration - - 1 (0.4) NS NS NS 
Intestinal perforation  - - 1 (0.4) NS NS NS 
Drain stapling - 3 (1.2) - NS NS NS 
Bleeding - 2 (0.8) - NS NS NS 
No. of patients 2 (0.8) 9 (3.7) 4 (1.6) 0.033 0.686 0.260 
Short term (< 30 
days) 
      
Leakage - 4 (1.6) 1 (0.4) NS NS NS 
Bleeding/ hematoma - 7 (2.9) 5 (2.0) 0.015 NS NS 
Intra-abdominal abscess - 4 (1.6) - NS NS NS 
Passage complaints 7 (2.9) - - 0.015 0.015 NS 
Pulmonary Embolism - 2 (0.8) 1 (0.4) NS NS NS 
Pneumonia 2 (0.8) 1 (0.4) 1 (0.4) NS NS NS 
Wound infection - 1 (0.4) 2 (0.8) NS NS NS 
Others - 3 (1.2) 5 (2.0) NS NS NS 
Re-admission -  11 (4.5) 1 (0.4) 0.001 NS 0.003 
No. of patients 9 (3.7) 19 (7.6) 14 (5.7) 0.052 0.286 0.367 
Long term (>30 days)       
Laparoscopic 
cholecystectomy  
16 (6.5) 9 (3.7) 12 (4.9) NS NS NS 
Pancreatitis 1 (0.4) - 2 (0.8) NS NS NS 
Ileus - - 1 (0.4) NS NS NS 
Stenosis - - 1 (0.4) NS NS NS 
Mesenteric internal 
hernia 
- - 4 (1.6) NS NS NS 
Passage complaints 3 (1.2) 2 (0.8) - NS NS NS 
Reflux  5 (2.0) - - NS NS NS 
Recurrent vomiting 19 (7.6) - 1 (0.4) <0.001 <0.001 NS 
Marginal ulcer - - 3 (1.2) NS NS NS 
Unexplained abdominal 
pain  
- - 8 (3.3) NS 0.007 0.007 
Bleeding - - 1 (0.4) NS NS NS 
Hernia cicatricalis - 2 (0.8) - NS NS NS 
Others - 8 (3.3) 3 (1.2) 0.007 NS NS 
No.  of patientsa 68 (28)b 12 (5) 23 (9) <0.001 <0.001 0.054 
No. of re-operations       
Short term (< 30 days) 2 (0.8) 9 (3.7) 7 (2.9) 0.033 NS NS 
Long term (> 30 days)a  66 (26.9) 25 (10.2) 10 (4.1) <0.001 <0.001 0.009 
Revisional procedure 51 (20.8) 23 (9.4) - <0.001 <0.001 <0.001 
Mean period (year) 3.5 ±1.2 2.2 ±1.3 - <0.001 - - 
RYGB 49 23 - - - - 
Biliopancreatic diversion  2 - - - - - 
Values are numbers (%), unless otherwise stated 
 - no complication; LSG: Laparoscopic Sleeve Gastrectomy, LRYGB: Laparoscopic Roux-en-Y Gastric Bypass, 
LAGB: Laparoscopic Adjustable Gastric Banding, CBD:  Common Bile Duct; NS: not significant 
a Exclusive laparoscopic cholecystectomy 
b Including band-related complications, presented in table 4 
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Table 4. LAGB-related complications 
Total no. of patients 245  
Band Related   
Band Slippage 10  (4.1) 
Band Migration 4  (1.6) 
Pouch formation 4  (1.6) 
Esophagus dilatation 2 (0.8) 
Leakage 3  (1.2) 
Removal 55 (22.4) 
Port-à-cath related   
Chronic pain  13 (5.3) 
Infection  4  (1.6) 
Dislocation 1 (0.4) 
Reposition 9 (3.7) 
Values are numbers (%) 
LAGB: Laparoscopic Adjustable Gastric Banding 
 
DISCUSSION 
  The present study shows that the LAGB is inferior to the LSG and the LRYGB 
in terms of weight reduction, number of long-term complications, and need for a 
revisional surgery. The LSG is comparable to the LRYGB regarding weight loss and 
complication rate. However, 9 % required a conversion to a LRYGB after a LSG, mostly 
because of insufficient weight loss.  
 The number of LSG operations as a definitive restrictive procedure is increasing 
rapidly from nil in 2003 to 28 % in 2011 of all bariatric procedures worldwide.4 In 
contrast, a sharp decrease is observed in the number of LAGB procedures. Only 
5 years ago LAGB was the most performed restrictive procedure in Europe, but 
nowadays are there less LAGB procedures performed than LSG.4 Surprisingly, only 
one RCT comparing the LAGB and LSG is available in the literature.33 The authors 
found a marked decrease in BMI in both groups after 36 months, although it was 
significantly higher after the LSG than after LAGB. Several non-randomized 
comparative studies had similar outcomes in favor of the LSG.25-30 In line with the 
present study, several RCTs31,32,35 and non-randomized comparative trials25-30 
demonstrate also greater weight loss after the LRYGB compared to the LAGB during 
a short- and long-term follow-up. Additionally, an important fact which probably 
contributed to the decline of the LAGB procedure is the high long-term complication 
rate. The LAGB operation used to be considered as a safe procedure with low short-
term morbidity and mortality.9-11 Previous studies with long-term follow-up reported 
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high conversion or removal rate of 17–41 % after 5 to 10 years.11,31 In line with these 
reports, the present study shows a high incidence of band-related complications which 
led to band removal in 22% of the patients and revisional bariatric procedure in 21%. 
This is the main cause of the higher long-term complication rate compared to both the 
LSG and the LRYGB procedure. One would expect that improved operative techniques 
in combination with the last generation adjustable bands could have a better outcome 
than previous reports indicate. Indeed, an Australian study showed a good reduction 
of complications and revisional procedures after changes were made to the LAGB 
technique and claimed durable weight loss of 47 % EWL after 15 years.42 
 Nowadays, the LSG is the preferred restrictive procedure and some authors 
demonstrated even greater weight reduction than a LRYGB during the first 
postoperative year.17,18 However, other RCTs had conflicting results.24,36,37,39 It must 
be noted that the outcomes of these studies must be interpreted with caution and 
probably not generalizable for the bariatric population because of several limitations. 
Most studies have a limited follow-up of only 12 months (5 out of 6 RCTs) and a small 
study population of less than 30 patients (4 out of 6 RCTs), while some studied only a 
selected study population such as uncontrolled T2DM or non-diabetics, female patients, 
or BMI <50 kg/m2. Therefore, the available level of evidence regarding the 
effectiveness of these two techniques is limited, while more than three quarter of all 
bariatric procedures worldwide are LSG or LRYGB procedures.4 The present large 
matched cohort study of 735 patients is to our knowledge, the second largest study 
available in the literature. The largest non-randomized study (n = 2949 each group) had 
a follow-up to 36 months.26 During the first three postoperative years, LRYGB had 
significantly higher %EWL at annual follow-up than a LSG. Unfortunately, this study 
struggled with incomplete follow-up data due to lost to follow-up and incomplete 
questionnaires. This resulted in a low follow-up rate of 28 % after 3 years. In the 
present study, a higher %EWL after LSG was found in the first postoperative year. It 
must be noted, however, that a higher preoperative BMI level in LRYGB group can also 
explain this difference, since %EWL is significantly influenced by initial BMI level.43 
Nevertheless, thereafter, no differences were observed due to slightly drop of %EWL 
in the LSG group which indicates regaining weight. The study of Braghetto et al. had 
similar findings and reported their concerns about regaining weight after a LSG 
procedure.19 Conversion to another bariatric procedure is advised if this occurs. In this 
study, a conversion rate of 9 % after LSG to a LRYGB is performed, mostly for reasons 
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of insufficient weight loss or weight regain, compared to none after a LRYGB. In 
contrast, a large study of a total of 2199 patients by Fridman et al.44 showed a revision 
rate of <1 % for LSG into a LRYGB procedure. However, the follow-up rate for LSG 
procedures after 3 years was only 13 %. In the present study, revisional surgery after 
a LRYGB because of insufficient weight loss or weight regain is not exceptional. 
Himpens et al. demonstrated 54 % additional %EWL after a revision, such as 
distalization of the bypass, banded bypass, or resizing of the pouch.45 However, 
optimal treatment option in case of insufficient weight loss or weight regain after either 
a LSG or LRYGB is not yet clarified. 
 In the present study, no significant differences between LSG and LRYGB 
concerning overall short- and long-term complications are observed. Most importantly, 
short-term complications after the LSG procedure were bleeding (3 %), staple-line 
leakage (2 %), and intra-abdominal abscess (2 %). Staple-line leakage after a LSG is 
of great concern among surgeons and is associated with longer hospitalization or 
readmissions.46 However, Fridman et al.44 reported a leakage rate of 0.3 % in 619 LSG 
procedures, and readmission rate was lowest compared to the LRYGB and LAGB. 
Several studies showed an early overall complication rate after LSG that varied 
between 2 and 14 %.14,16-19,24,47-49  
 The present study shows an early complication rate of 6 % after the LRYGB, 
which is similar to earlier reported randomized trials.17,18,24 One (0.4 %) patient had a 
leakage of the gastrojejunostomy, and five (2 %) patients had a bleeding. In contrast, 
up to 32 % early complications after LRYGB have been reported in non-randomized 
trials.19,48,50,51 However, definitions and recording strategies varied among these 
articles, making them difficult to compare. 
 Important long-term complications to state are patients with unexplained 
abdominal pain (3 %), mesenteric internal hernia (2 %), and marginal ulcer (1 %) after 
a LRYGB. Open spaces in the mesentery due to the antecolic Roux-en-Y construction 
can cause (intermittent) abdominal pain because of a slippage of small intestine 
through the mesenteric defect. This is coupled with a high risk for small bowel 
obstruction (SBO), which could be reduced by closing these defects during the 
procedure.52,53 Schauer et al.24 reported an incidence of 8 % marginal ulcers after a 
LRYGB within the first postoperative year. Therefore, use of proton pump inhibitors 
after a LRYGB is advised. 
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 Next to weight reduction and complications, the effectiveness regarding the 
obesity-related comorbidities is an important issue in bariatric patients, which is not 
outlined in the present study. Previous studies showed in both LSG and LRYGB 
markedly remission of T2DM and reduction cardiovascular medication during the first 
postoperative year.24,34,54,55 On the other hand, bariatric surgery procedures can lead 
to comorbidities, such as gastroesophageal reflux disease (GERD) or nutritional 
deficiencies.56,57 Furthermore, subjective outcome parameters such as food tolerance 
and quality of life after surgery are probably underestimated objectives. A prospective 
cross-sectional study showed best food tolerance and gastrointestinal quality of life 
after LSG, followed closely by the LRYGB and worst after LAGB.28 Due to these 
advantages and disadvantages of bariatric surgery, patients’ comorbidities and 
potential risks must be included in the decision which type of bariatric procedure will 
be offered to the patient. In case of a patient with a metabolic complication, the LRYGB 
may be preferred; otherwise, the LSG procedure may be an appropriate alternative, 
unless manifestation of GERD is present. 
 Certain limitations of this study must be pointed out. The retrospective aspect of 
this study may have resulted in a low follow-up rate of 8–34 % after 5 years. 
Furthermore, the different operations were performed in two different hospitals, i.e., the 
LSG in SFG, and LRYGB and LAGB in RHA. Both centers are qualified bariatric 
centers in The Netherlands; however, the study cohorts could not be matched for 
hospital performance which may have influenced the outcomes. Additionally, the LSG 
group was a relative new technique which might be resulted in an increased number 
of readmissions. Finally, the cohorts were matched for age and gender to create “equal” 
patient groups; nevertheless, more preoperative comorbidities were recorded in the 
RYGB patients. 
 In conclusion, this large matched cohort study demonstrates the long-term 
effectiveness and safety of the LRYGB for treatment of morbid obesity. LSG seems to 
be an appropriate alternative. LAGB is inferior to the previous two procedures, 
especially due to high revisional rate after 2 years. However, considering the level of 
evidence obtained, as well as available in literature, additional evidence is needed by 
RCTs or meta-analysis with long-term follow-up. 
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ABSTRACT 
Background 
The Roux-en-Y gastric bypass (RYGB) still remains the gold standard in bariatric 
surgery. However, no consensus exists on the optimal limb lengths to induce maximum weight 
reduction. The aim of the present study was to assess the effect of a longer alimentary limb 
(AL) length on weight reduction after RYGB. 
 
Methods 
A retrospective analysis of a prospectively collected database of patients who 
underwent a primary laparoscopic RYGB between January 2001 and March 2011 was 
performed. Patients received a short AL (SAL; 100 cm) or a long AL (LAL; 150 cm). Primary 
outcome was weight loss, and secondary outcomes were short- and long-term complication 
rates. 
 
Results 
A total of 768 patients received a RYGB during the study period. Of these, 730 
consecutive patients were included for long-term analysis and had a mean follow-up (FU) of 
37 ± 26 [range 0–120] months; 360 (47 %) patients received a SAL RYGB. Overall %TBWL 
was 33 ± 9 % after 2 years (FU 74 %) and 28 ± 12 % after 5 years (FU 20 %). No significant 
differences in %TBWL were found between SAL RYGB and LAL RYGB during the study period. 
The 30-day mortality rate was 0.13, 9 % overall short-term complication rate and 19 % 
cumulative long-term complication rate. No differences in complications were found between 
SAL and LAL RYGB patients. 
 
Conclusion 
Lengthening of the alimentary limb from 100 to 150 cm did not affect post-RYGB weight 
loss. Overall complication rates were low and comparable in this series of RYGB patients. 
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INTRODUCTION 
The Roux-en-Y gastric bypass (RYGB) is currently still the most performed 
surgical intervention to treat morbid obesity and its related co-morbidities. The total 
number of bariatric procedures was approximately 470.000 annually worldwide in 2013 
of which 45 % were RYGB procedures.1 Sustained adequate weight reduction in the 
short and long term has made the RYGB a well-accepted treatment modality for morbid 
obesity.2 
Several technical modifications of the RYGB procedure have been introduced 
over the past decades, such as variations in pouch size and limb length. Currently, no 
consensus exists for the optimal limb length required to induce maximum weight 
reduction. Studies in the early 1990s suggested that the amount of post-RYGB weight 
loss depended on the length of the alimentary limb (AL or Roux limb).3,4 Since then, 
conflicting reports have been published regarding the effect of the AL length (varying 
between 40 and 250 cm).5-19 
The purpose of the present study was to assess the effect of a longer AL length 
on weight reduction in patients undergoing a primary laparoscopic RYGB procedure. 
In addition, we reviewed the short- and long-term complication rates. 
 
MATERIALS AND METHODS 
Patient selection 
Consecutive morbidly obese patients who underwent a primary laparoscopic 
RYGB surgery in accordance with international guidelines20 were included for analysis. 
Patients were operated in the Rijnstate Hospital Arnhem (RHA), the Netherlands 
between January 2001 and March 2011. The study protocol was approved by the local 
board of ethics of the RHA. 
Inclusion criteria were age >18 years, BMI above 40 kg/m2, or BMI above 
35 kg/m2 with an obesity-related co-morbidity, and minimal follow-up of 12 months. 
Exclusion criteria were other primary bariatric procedures or a revisional RYGB 
procedure. Patients were selected from our prospectively collected computerized 
database which is filled out since 2000. Pre-, intra- and postoperative data were 
collected by specialized nurses. Postoperative follow-up visits were offered to all 
patients after 3, 6, 9, 12, 18, and 24 months, and annually thereafter. 
The primary end point was weight reduction expressed as percentage Total 
Body Weight Loss (%TBWL; defined as weight loss divided by preoperative body 
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INTRODUCTION 
The Roux-en-Y gastric bypass (RYGB) is currently still the most performed 
surgical intervention to treat morbid obesity and its related co-morbidities. The total 
number of bariatric procedures was approximately 470.000 annually worldwide in 2013 
of which 45 % were RYGB procedures.1 Sustained adequate weight reduction in the 
short and long term has made the RYGB a well-accepted treatment modality for morbid 
obesity.2 
Several technical modifications of the RYGB procedure have been introduced 
over the past decades, such as variations in pouch size and limb length. Currently, no 
consensus exists for the optimal limb length required to induce maximum weight 
reduction. Studies in the early 1990s suggested that the amount of post-RYGB weight 
loss depended on the length of the alimentary limb (AL or Roux limb).3,4 Since then, 
conflicting reports have been published regarding the effect of the AL length (varying 
between 40 and 250 cm).5-19 
The purpose of the present study was to assess the effect of a longer AL length 
on weight reduction in patients undergoing a primary laparoscopic RYGB procedure. 
In addition, we reviewed the short- and long-term complication rates. 
 
MATERIALS AND METHODS 
Patient selection 
Consecutive morbidly obese patients who underwent a primary laparoscopic 
RYGB surgery in accordance with international guidelines20 were included for analysis. 
Patients were operated in the Rijnstate Hospital Arnhem (RHA), the Netherlands 
between January 2001 and March 2011. The study protocol was approved by the local 
board of ethics of the RHA. 
Inclusion criteria were age >18 years, BMI above 40 kg/m2, or BMI above 
35 kg/m2 with an obesity-related co-morbidity, and minimal follow-up of 12 months. 
Exclusion criteria were other primary bariatric procedures or a revisional RYGB 
procedure. Patients were selected from our prospectively collected computerized 
database which is filled out since 2000. Pre-, intra- and postoperative data were 
collected by specialized nurses. Postoperative follow-up visits were offered to all 
patients after 3, 6, 9, 12, 18, and 24 months, and annually thereafter. 
The primary end point was weight reduction expressed as percentage Total 
Body Weight Loss (%TBWL; defined as weight loss divided by preoperative body 
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weight), and percentage Excess Weight Loss (%EWL; defined as weight loss divided 
by excess weight based on BMI 25 kg/m2). Secondary end points were short- 
(≤30 days) and long-term (>30 days) complications, and perioperative mortality rate. 
 
Surgical procedure 
All patients underwent a laparoscopic antecolic antegastric RYGB procedure. A 
small gastric pouch of approximately 40 ml was constructed using a linear stapler 
(Echelon, Ethicon, Johnson & Johnson, New Brunswick, NJ, USA), and a fixed 
biliopancreatic limb (BPL) of approximately 50 cm was measured using the hand-over-
hand technique without stretch along the mesenteric border. Until 2010, patients with 
BMI < 50 kg/m2 received a short AL of 100 cm (SAL) and patients with 
BMI > 50 kg/m2 received a long AL of 150 cm (LAL) using the same technique. From 
2010, all patients received a LAL RYGB. In all patients, the gastro-jejunostomy and 
entero-enterostomy were performed using a linear stapler combined with a running 
Vicryl suture (Endo Stitch™, Covidien, Dublin, Ireland). The integrity of the gastro-
jejunostomy and gastric pouch staple-line was tested intra-operatively for anastomotic 
leak via a burst test. Intraluminal air is insufflated via nasogastric tube while the 
anastomosis is holded in an intra-abdominal introduced water.  
 
Multidisciplinary treatment program 
Prior to the operation, a screening by a multidisciplinary team, including a 
surgeon, endocrinologist, obesity coach, dietitian, physiotherapist, and 
psychologist/psychiatrist, was performed. Patients who were eligible for a surgery 
according to the international guidelines20 were enrolled in a multidisciplinary coaching 
program. Preoperatively, patients followed multiple sessions at the Dutch Obesity 
Clinic, Velp, the Netherlands. During these sessions, patients received nutritional, 
psychological, and fitness training. Postoperatively, these sessions continued during 
the first 2 years, with a total frequency of 15 follow-up moments. 
 
Statistical analysis 
Patients with a follow-up of less than 12 months were excluded from long-term 
analysis for %EWL and %TBWL. The short- and long-term complication rate is based 
on the total study population. The results are presented as mean values ± standard 
deviation (SD), unless otherwise specified. Variance between groups was analyzed 
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using the Mann–Whitney test for continuous data and χ2 test for categorical data. Data 
were analyzed using IBM® SPSS® (version 20.0 for Windows) statistical software, and 
all figures were created using Graph Path Prism® (version 5.01). A p value <0.05 was 
considered significant. 
 
RESULTS 
In total, 768 patients underwent a primary RYGB in the studied period, of which 
360 (46.9 %) patients received a SAL RYGB. Baseline patient characteristics are 
shown in Table 1.  
 
Table 1. Baseline characteristics for overall study population (n=768) 
Demographic data   
Female gender 533 69.4% 
Age (years) 44.2 ±10.6 
BMI (kg/m2) 47.3 ±6.1 
Weight (kg) 139.6 ±22.3 
Excess weight (kg) 65.7 ±18.5 
Perioperative data   
Roux limb of 100 cm 360 46.9% 
Surgery time (min) 98.0 ±39.7 
Hospitalization (days) 5.6 ±8.9 
Co-morbidities   
T2DM 302 39.3% 
Hypertension 380 49.5% 
Dyslipidemia 191 24.9% 
OSAS 142 18.5% 
Joint pain 266 34.6% 
Values are mean ± standard deviation or numbers (%) 
T2DM: Type 2 Diabetes Mellitus; OSAS: Obstructive Sleep Apnea Syndrome 
 
Thirty-eight patients were excluded from analysis because they were lost to follow-up; 
they completed their follow-up in another hospital (n = 32) or died within one year after 
surgery (n = 6). The mean follow-up period of the remaining 730 patients was 37 ± 26 
[range 0–120] months. The number of patients followed-up during the postoperative 
period was 708 (97 %) at 6 months, 687 (94 %) at 1 year, 620 (85 %) at 18 months, 
541 (74 %) at 2 years, 327 (45 %) at 3 years, 203 (28 %) at 4 years, and 147 (20 %) 
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at 5 years. There was a significant difference in follow-up between the SAL 
(43.3 ± 31.2 [range 0–120] months) and LAL (26.8 ± 17.5 [range 0–120] months) 
groups (p < 0.0001). 
 
Weight loss 
Overall %EWL was 69.6 ± 19.7 % at one year, 72.9 ± 22.6 % at 2 years, 
69.1 ± 25.4 % at 3 years, and 60.8 ± 27.2 % at 5 years. Overall %TBWL was 
31.5 ± 7.6 % at 1 year, 33.1 ± 9.3 % at 2 years, 31.4 ± 10.8 % at 3 years, and 
27.8 ± 12.3 % at 5 years. 
Baseline weight and BMI were significantly lower for the SAL group compared 
to the LAL group, as expected given that a long limb was chosen for patients with a 
BMI > 50 kg/m2. %EWL for the first 18 months postoperatively was significantly higher 
for the SAL compared to the LAL group; however, after 24 months, no significant 
differences were found. %TBWL was similar during each follow-up visit in the two 
groups. Weight, %EWL, and %TBWL during follow-up are presented in Table 2 and 
Figure 1. 
 
Figure 1. Percentage excess weight loss (%EWL) and total body weight loss (%TBWL) for 
short and long alimentary limb (AL) during follow-up 
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Table 2. Follow-up of weight, BMI, %EWL and %TBWL up to 5 postoperative years 
 SAL RYGB  LAL RYGB  P 
Weight (kg)      
Baseline (T0) 135.6 ±22.8 143.0 ±21.2 <0.0001 
12 months (T1) 92.2 ±18.7 97.5 ±18.7 0.001 
18 months (T2) 89.8 ±17.8 95.2 ±17.8 0.003 
24 months (T3) 89.5 ±17.4 94.8 ±19.3 0.006 
36 months (T4) 93.3 ±19.9 99.1 ±24.5 0.160 
60 months (T5) 102.5 ±22.6 101.9 ±26.1 0.819 
      
BMI (kg/m2)      
Baseline (T0) 45.8 ±5.9 48.6 ±5.8 <0.0001 
12 months (T1) 31.3 ±5.1 33.3 ±5.4 <0.0001 
18 months (T2) 26.1 ±4.5 27.8 ±4.7 <0.0001 
24 months (T3) 30.6 ±5.3 32.3 ±5.8 0.001 
36 months (T4) 32.1 ±6.2 33.3 ±7.3 0.315 
60 months (T5) 34.1 ±6.8 34.9 ±8.5 0.662 
      
%EWL      
12 months (T1) 72.7 ±20.2 66.8 ±18.8 0.001 
18 months (T2) 76.5 ±22.0 70.8 ±19.6 0.012 
24 months (T3) 75.0 ±24.3 71.2 ±21.0 0.123 
36 months (T4) 69.5 ±25.2 68.3 ±25.8 0.939 
60 months (T5) 59.3 ±27.4 63.1 ±27.6 0.826 
      
%TBWL      
12 months (T1) 31.8 ±7.4 31.3 ±7.7 0.509 
18 months (T2) 33.3 ±8.3 33.7 ±8.5 0.569 
24 months (T3) 32.4 ±9.4 33.6 ±9.2 0.187 
36 months (T4) 30.4 ±9.7 32.9 ±12.2 0.071 
60 months (T5) 26.6 ±12.1 30.8 ±13.1 0.400 
Bold values indicate statistical significance (p < 0.05) 
Values are mean ± standard deviation 
No. of patients in follow-up (%) at T0 = 730 (100), T1 = 687 (94), T2 = 620 (85), T3 = 541 (74), T4 = 327 (45), 
T5 = 147 (20) 
SAL: short alimentary limb; LAL: long alimentary limb; RYGB: Roux-en-Y gastric bypass; BMI: body mass 
index; %EWL: percentage excess weight loss; %TBWL: percentage total body weight loss 
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Complications 
In total, six (0.8 %) patients died within the first year after surgery. Only one 
(0.13 %) patient died within 30 days, because of abdominal sepsis after an 
anastomotic leak. The other five (0.65 %) patients died after 30 days, of which only one 
might have been related to surgery. This patient suffered from a pulmonary embolism 
6 weeks after surgery. 
The short-term complication rate (<30 days) was similar in the SAL group 
(n = 32; 8.9 %) and LAL group (n = 33; 8.3 %; p = 0.745). Overall short- and long-term 
complications are presented in Table 3. In addition, one patient underwent with a LAL 
an undo-operation (restoration of the gastrointestinal tract) because of persistent 
abdominal pain and dysphagia. 
 
Table 3. Overall short- (< 30 days) and long-term (> 30 days) complications 
< 30 days N % > 30 days N % 
Bleeding 17 2.2% Cholecystolithiasis (symptomatic) 57 7.4% 
Pneumonia 11 1.4% Unexplained abdominal complaints 44 5.7% 
Wound infection 6 0.8% Marginal ulcer 20 2.6% 
Iatrogenic* 6 0.8% Internal hernia 17 2.2% 
Anastomotic leakage 4 0.5% Incisional hernia 18 2.3% 
Intra-abdominal abscess 5 0.7% Constipation 6 0.8% 
Thrombo-embolism 1 0.1% Anastomotic stricture 4 0.5% 
Anastomotic stricture 1 0.1% Anastomotic leakage 4 0.5% 
Small bowel obstruction 1 0.1% Small bowel obstruction 3 0.4% 
Re-operation 31 4.0% Pulmonary embolism 4 0.5% 
Readmission 5 0.7% Bleeding 1 0.1% 
   Re-operation** 92 12.0% 
Total N of complications 65 8.5% Total N of complications 145 18.9% 
Values are numbers (%) 
* Specified: anastomotic lesion due to nasogastric tube (n = 1), small/large bowel lesion (n = 4), spleen lesion (n = 1) 
** Re-operation (definition): operation due to a complication 
 
DISCUSSION 
Weight loss 
Laparoscopic RYGB surgery still remains the gold standard in bariatric surgery, 
with an %EWL of 63–80 % during the first 5 years, and an %EWL of 57–75 % in the 
long-term (5–10 years).2,12,15,21,22 RYGB surgery induces weight loss by reducing the 
gastric volume (restriction) and inducing metabolic changes through adaptations in 
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gastrointestinal anatomy (bypass of the majority of the stomach, duodenum and 
proximal part of the small intestine). Given the lack of uniformity regarding the length 
of the bypassed small intestine, clinical heterogeneity exists in the published data. An 
overview of the studies comparing short versus long Roux limb Roux-en-Y gastric 
bypass is presented in Table 4. Orci et al.23 reviewed eight studies, including five 
randomized controlled trials (RCTs) and three prospective cohort studies, and found 
much variation in design and outcome, making the results difficult to interpret. 
Additionally, most studies of limb length had a limited follow-up of only 3 years. 
Furthermore, %EWL is widely used as an outcome parameter, whereas it is a relative 
measure that varies with initial BMI. The %TBWL allows for better comparison, but is 
only used in the literature in recent years.24 In the present study, the long-term effects 
of the primary laparoscopic RYGB were analyzed. Additionally, a comparative study 
with a study population group of 768 patients is the largest available in the literature. 
No difference in %TBWL was found between SAL and LAL RYGB in the follow-up 
period of 5 years. After 10-year follow-up, mean %TBWL was at least 24 % (data not 
shown). 
Some studies claim significantly more weight loss after lengthening of the AL in 
super obese patients and a BMI of ≥50 kg/m2, while patients with BMI < 50 kg/m2 may 
not demonstrate a benefit of a longer AL.3,6,7,9,10,12,25 The first published RCT comparing 
LAL RYGB (150 cm) with SAL RYGB (75 cm), in patients with a BMI > 50 kg/m2, 
reported a difference in %EWL after 24 months of 64 and 50 %, respectively 
(p < 0.01).3 Another RCT also showed higher weight loss for LAL (250 cm) compared 
to SAL (150 cm) in RYGB patients after 18 months.6 This suggests that patients with a 
BMI > 50 kg/m2 might benefit from lengthening of the AL. However, an RCT conducted 
by Pinheiro et al. reported no difference in outcome for SAL (150 cm) and LAL (250 cm) 
RYGB in super obese patients after 4 years.14 This is consistent with the present study, 
in which no difference was found between the groups of super obese patients (data 
not shown). Reports comparing the effect of AL lengths in patients with a BMI lower 
than 50 kg/m2 also showed nonsignificant differences.6,9,10  
Inabnet et al.10 randomized 48 patients with a BMI < 50 kg/m2 between SAL 
(100 cm) and LAL (150 cm), and found no difference during 24 months of follow-up. 
Choban and Flancbaum6 randomized 67 patients with a BMI < 50 kg/m2 between SAL 
(75 cm) and LAL (150 cm), and reported similar weight loss in the two groups during a 
follow-up of 36 months. The most recent RCT by Valezi et al.19 reported no significant 
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not shown). Reports comparing the effect of AL lengths in patients with a BMI lower 
than 50 kg/m2 also showed nonsignificant differences.6,9,10  
Inabnet et al.10 randomized 48 patients with a BMI < 50 kg/m2 between SAL 
(100 cm) and LAL (150 cm), and found no difference during 24 months of follow-up. 
Choban and Flancbaum6 randomized 67 patients with a BMI < 50 kg/m2 between SAL 
(75 cm) and LAL (150 cm), and reported similar weight loss in the two groups during a 
follow-up of 36 months. The most recent RCT by Valezi et al.19 reported no significant 
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difference in percentage weight loss among four groups with different AL (100 and 
150 cm) en BPL (50 and 100 cm) lengths after a limited follow-up of 12 months. These 
findings are comparable to those of the current study, which implies that the length of 
AL does not influence weight reduction in morbidly obese patients with a BMI up to 
50 kg/m2. In line with these previous studies, Mahawar et al.25 propose a bypass with 
a total length of 100–200 cm (BPL and AL combined), since minor alterations in AL 
and BPL lengths showed no differences in outcome based on their review of the 
available literature. 
Besides reduction in gastric volume and inducing metabolic changes by 
adapting the gastrointestinal anatomy, there is a third component that can be added to 
achieve weight loss. This component is true malabsorption for macronutrients and 
might be added in specific patients. In our opinion, these malabsorptive procedures 
should not be the first choice due to their side-effects, such as malnutrition for 
micronutrients and severe diarrhea.26,27 However, in patients with a BMI over 60 kg/m2, 
a two-step procedure toward a duodenal switch might be an excellent technique to 
induce long-term weight loss.28 Another group of patients that might benefit from 
malabsorption are patients who have in terms of weight loss a failed a primary RYGB.29 
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much variation in design and outcome, making the results difficult to interpret. 
Additionally, most studies of limb length had a limited follow-up of only 3 years. 
Furthermore, %EWL is widely used as an outcome parameter, whereas it is a relative 
measure that varies with initial BMI. The %TBWL allows for better comparison, but is 
only used in the literature in recent years.24 In the present study, the long-term effects 
of the primary laparoscopic RYGB were analyzed. Additionally, a comparative study 
with a study population group of 768 patients is the largest available in the literature. 
No difference in %TBWL was found between SAL and LAL RYGB in the follow-up 
period of 5 years. After 10-year follow-up, mean %TBWL was at least 24 % (data not 
shown). 
Some studies claim significantly more weight loss after lengthening of the AL in 
super obese patients and a BMI of ≥50 kg/m2, while patients with BMI < 50 kg/m2 may 
not demonstrate a benefit of a longer AL.3,6,7,9,10,12,25 The first published RCT comparing 
LAL RYGB (150 cm) with SAL RYGB (75 cm), in patients with a BMI > 50 kg/m2, 
reported a difference in %EWL after 24 months of 64 and 50 %, respectively 
(p < 0.01).3 Another RCT also showed higher weight loss for LAL (250 cm) compared 
to SAL (150 cm) in RYGB patients after 18 months.6 This suggests that patients with a 
BMI > 50 kg/m2 might benefit from lengthening of the AL. However, an RCT conducted 
by Pinheiro et al. reported no difference in outcome for SAL (150 cm) and LAL (250 cm) 
RYGB in super obese patients after 4 years.14 This is consistent with the present study, 
in which no difference was found between the groups of super obese patients (data 
not shown). Reports comparing the effect of AL lengths in patients with a BMI lower 
than 50 kg/m2 also showed nonsignificant differences.6,9,10  
Inabnet et al.10 randomized 48 patients with a BMI < 50 kg/m2 between SAL 
(100 cm) and LAL (150 cm), and found no difference during 24 months of follow-up. 
Choban and Flancbaum6 randomized 67 patients with a BMI < 50 kg/m2 between SAL 
(75 cm) and LAL (150 cm), and reported similar weight loss in the two groups during a 
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AL does not influence weight reduction in morbidly obese patients with a BMI up to 
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a total length of 100–200 cm (BPL and AL combined), since minor alterations in AL 
and BPL lengths showed no differences in outcome based on their review of the 
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Besides reduction in gastric volume and inducing metabolic changes by 
adapting the gastrointestinal anatomy, there is a third component that can be added to 
achieve weight loss. This component is true malabsorption for macronutrients and 
might be added in specific patients. In our opinion, these malabsorptive procedures 
should not be the first choice due to their side-effects, such as malnutrition for 
micronutrients and severe diarrhea.26,27 However, in patients with a BMI over 60 kg/m2, 
a two-step procedure toward a duodenal switch might be an excellent technique to 
induce long-term weight loss.28 Another group of patients that might benefit from 
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gastrointestinal anat my (bypass of the majority of the stomach, duodenum and 
proximal part of the small intestine). Given the lack of uniformity regarding the length 
of the bypassed small intestine, clinical heterogeneity exists in the published data. An 
overview of the studies comparing short versus long Roux limb Roux-en-Y gastric 
bypass is presented in Table 4. Orci et al.23 reviewed eight studies, including five 
randomized controlled trials (RCTs) and three prospective coho t studies, and found 
much variation in design and outcome, making the results difficult to interpret. 
Additionally, most studies of limb length had a limited follow-up of only 3 years. 
Furthermore, %EWL is widely used as an outcome parameter, whereas it is a relative 
measure that varies with initial BMI. The %TBWL allows for better comparison, but is 
only used in the literature in recent years.24 In the present study, the long-term effects 
of the primary laparoscopic RYGB were analyzed. Additionally, a comparative study 
with a study population group of 768 patients is the largest available in the literature. 
No difference in %TBWL was found between SAL and LAL RYGB in the follow-up 
period of 5 years. After 10-year follow-up, mean %TBWL was at least 24 % (data not 
shown). 
Some studies claim significantly more weight loss after lengthening of the AL in 
super obese patients and a BMI of ≥50 kg/m2, while patients with BMI < 50 kg/m2 may 
not demonstrate a benefit of a longer AL.3,6,7,9,10,12,25 The first published RCT comparing 
LAL RYGB (150 cm) with SAL RYGB (75 cm), in patients with a BMI > 50 kg/m2, 
reported a difference in %EWL after 24 months of 64 and 50 %, respectively 
(p < 0.01).3 Another RCT also showed higher weight loss for LAL (250 cm) compared 
to SAL (150 cm) in RYGB patients after 18 months.6 This suggests that patients with a 
BMI > 50 kg/m2 might benefit from lengthening of the AL. However, an RCT conducted 
by Pinheiro et al. reported no difference in outcome for SAL (150 cm) and LAL (250 cm) 
RYGB in super obese patients after 4 years.14 This is consistent with the present study, 
in which no difference was found between the groups of super obese patients (data 
not shown). Reports comparing the effect of AL lengths in patients with a BMI lower 
han 50 kg/m2 also showed nonsignificant differences.6,9,10  
Inabnet et al.10 randomized 48 patients with a BMI < 50 kg/m2 between SAL 
(100 cm) and LAL (150 cm), and found no difference during 24 months of follow-up. 
Choban and Flancbaum6 randomized 67 patients with a BMI < 50 kg/m2 between SAL 
(75 cm) and LAL (150 cm), a d reported similar weight los  in the two groups during a 
follow-up of 36 months. The most recent RCT by Valezi et al.19 reported no significant 
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Next to the technical aspects of the operation, changes in dietary habits and 
lifestyle are important in treating obesity. This part of the treatment should be a 
multidisciplinary approach, including surgeon, endocrinologist, dietitian, 
physiotherapist, and psychologist, with an intensive coaching program (before and 
after the operation). Patients with a lifestyle program may have better sustained weight 
loss, less weight regain, and improved metabolic outcomes.
30-32 
 
Hormonal changes 
Previous studies focused their attention on the length of the AL and may 
underestimated the effect of the BPL, probably due to the significant advantage of a 
longer AL reported in the first published RCT by Brolin et al..
3
 Several gastrointestinal 
hormonal changes have been proposed as mediators of weight loss after RYGB 
surgery. Alterations in the blood serum levels of upper gastrointestinal peptides (ghrelin 
and glucose-dependent insulinotropic polypeptide (GIP)) may contribute to this effect 
by bypassing the stomach, duodenum and proximal part of the jejunum (foregut 
theory).
33-36
 However, it is plausible that other mechanisms are more crucial since 
patients with longer BPL had more weight loss compared to patients with standard 
gastric bypass.
12,14,37
 Rapid exposure of nutrients to distal small intestine as a result of 
the Roux-en-Y construction induce enlarged secretion of L-cell derived hormones 
glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) (hindgut theory).
38
 A study 
group in Iceland demonstrated a significantly higher weight loss with a long BPL of two 
meters and a short AL of 50 cm compared to short BPL and long AL.
37,39
 Additionally, 
the mini-gastric bypass operation is another example with a long BPL (without Roux 
limb), which resulted in similar or even greater weight loss than a standard RYGB 
operation.
34
 Therefore, the BPL may be the essential component for weight loss (and 
metabolic effects) in RYGB surgery. RYGB technique is evolving; this could be one of 
the future changes. 
 
Complications 
It is known that the outcome of bariatric surgery is correlated with the experience 
of the bariatric surgeon/team. The learning curve for laparoscopic RYGB surgery is 
considered to be 75–150 cases.
40
 In the present study, with increasing experience and 
refinement of the technique, the operative 30-day complication rate decreased over 
time to approximately 6 % in 2011, with a mean overall complication rate of 8.5 % over 
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all study years. This is similar to large series in the literature, which reported an overall 
early complication rate of 5–19 % and a mortality rate up to 0.2 %.
15,41,42
 The early 
complication rate was similar in SAL and LAL RYGB. Frequently reported 
complications in the literature are marginal (anastomotic) ulcer and internal hernias.
15
 
In the present study, these complications were diagnosed in 3 and 2 % of patients, 
respectively. Elongation of the limb length may be accompanied by higher complication 
rates. Internal hernias are a result of the Roux-en-Y construction associated with newly 
created mesenteric defects. A previous study reported a higher internal hernia rate in 
patients with a longer limb length.
10
 Nowadays, the mesenteric defects in our hospital 
are closed with staples (Endopath
®
 EMS Endoscopic Multifeed Stapler, Johnson and 
Johnson Medical Ltd.), by only clipping the peritoneum, to prevent these hernias.
43
 
Leifsson et al. reported a high anastomotic ulcer rate of 17 % in patients after a long 
BPL RYGB.
39
 Postoperative prescription of proton pump inhibitor (PPI) is advised to 
prevent these ulcers; however, this was only the case during the first postoperative 
period in this study. In our hospital, PPIs are prescribed for 6 months. 
 
Limitations 
Certain limitations of this study must be pointed out. In this study, we observed 
the effects of a 100 and 150 cm AL RYGB; however, this relative minor change in 
bypassed small intestine may had limited contribution to weight loss. On the other hand, 
we assume that other mechanisms, like additional changes in incretins may have more 
effects than the length of the alimentary limb. Additionally, follow-up after 5 years was 
limited. Therefore, difference between the groups on the long term could not be pointed 
out. Furthermore, the observational aspect of the study had some restrictions, such as 
difference in baseline weight and BMI between the groups. In addition, data regarding 
pre- and post-operative nutritional and vitamin status were not generally available. 
 
CONCLUSION 
Primary laparoscopic RYGB surgery is an effective treatment modality in 
morbidly obese patients in the long term. Outcomes were not affected by lengthening 
of the alimentary limb from 100 to 150 cm. Overall complication rates were low and 
decreased over time. 
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ABSTRACT 
Background 
 Due to the increased incidence of morbid obesity, the demand for bariatric surgery is 
increasing. Therefore, the methods for optimising perioperative care for the improvement of 
surgical outcome and to increase efficacy are necessary. The aim of this prospective matched 
cohort study is to objectify the effect of the fast-track surgery (FTS) programme in patients 
undergoing primary Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) surgery compared to 
conventional perioperative care (CPC). 
 
Methods 
 This study compared the perioperative outcome data of two groups of 75 consecutive 
morbid obese patients who underwent a primary LRYGB according to international guidelines 
in the periods January 2011–April 2011 (CPC group) and April 2012–June 2012 (FTS group). 
The two groups were matched for age and sex. Primary endpoints were surgery and 
hospitalisation time, while secondary endpoints were intraoperative medication use and 
complication rates. 
 
Results 
Baseline patient characteristics for age, sex, weight and ASA classification were similar 
(p > 0.05) for CPC and FTS patients. BMI and waist circumference were significantly lower 
(p < 0.05) in the FTS compared to CPC. The total time from arrival at the operating room to the 
arrival at the recovery was reduced from 119 to 82 min (p < 0.001). Surgery time was reduced 
from 80 to 56 min (p < 0.001); mean hospital stay was reduced from 65 to 43 h (p < 0.001). 
Major complications occurred in 3 versus 4 % in the FTS and CPC, respectively. 
 
Conclusions 
 The introduction of a fast-track programme after primary LRYGB improves short-term 
recovery and may reduces direct hospital-related resources. 
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INTRODUCTION 
In the Netherlands, approximately 42 % of the adult population is overweight, of 
which 10 % are obese,
1
 defined as a BMI > 30 kg/m
2
.
2
 Due to the increased risk of 
obesity-related diseases like Type 2 diabetes mellitus (T2DM), hypertension, 
dyslipidemia, coronary artery disease, sleep apnoea syndrome, infertility and certain 
types of cancers,
2
 obesity has become a heavy burden on our healthcare system.
3
 The 
only proven effective long-term treatment for morbid obesity still remains bariatric 
surgery.
4
 In addition, bariatric surgery is a cost-effective treatment compared to non-
surgical treatment.
5,6
 The rising prevalence of morbid obesity (defined as 
BMI > 40 kg/m2 or BMI >35 kg/m2 and a comorbidity) has led to an increasing demand 
for bariatric surgery worldwide. In the Netherlands, the number of bariatric procedures 
has increased from 800 in 2003 to an estimated 8,000 in 2013.
7,8
 Furthermore, 
worldwide, there has been a shift in bariatric surgery type from restrictive procedures, 
such as laparoscopic adjustable gastric banding (LAGB), to more challenging and time-
consuming procedures, such as the Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) 
surgery.
8 
This combination of increased demand and more lengthy procedures creates a 
dilemma for operation planning and logistics. Operation time and staff is costly and 
scarce, and cannot be issued indefinitely. Ideally, better logistics and use of resources 
could increase both production and quality of care. Fast-track surgery (FTS), also 
known as the Enhanced Recovery after Surgery (ERAS) programme, is a well-
documented logistic programme in colorectal and gastric surgery.
9-11
 It demonstrates 
how an ‘evidence-based’ approach of perioperative care leads to faster recovery and 
shorter hospital admission, with improved patient well-being. However, the fast-track 
programmes do not involve optimisation of logistics in the operating room itself. The 
essence of these programmes is the multimodal approach, and many authors have 
demonstrated safety and feasibility in fast-track bariatric surgery.
12-17
 According to this 
approach, a multidisciplinary FTS programme for bariatric surgery, to improve both 
operation logistics and perioperative care, was implemented in our clinic. We 
hypothesised that through such a multidisciplinary FTS programme for morbid obese 
patients, an improvement in both hospital logistics and length of patient hospital stay 
could be achieved. Therefore, a prospective case-matched cohort study was 
conducted comparing two consecutive cohorts of LRYGB groups. 
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MATERIALS AND METHODS 
Prior to the start of an FTS programme within the Bariatric Unit setup of the 
Rijnstate Hospital Arnhem, an implementation and evaluation process was set up. 
According to the research protocol for the matched cohort study on FTS versus CPC, 
prospective data collection was carried out for the first cohort of LRYGB patients with 
CPC (January–April 2011), at that time being the standard care for the last 8 years. 
After this, implementation of the FTS programme, from May 2011 to April 2012, was 
conducted according to the Scandinavian programme (Dr H. Gislason, Aleris Hospital, 
Oslo, Norway). After evidence that the programme had been implemented completely 
and successfully (Internal audit by the hospital Quality Council), prospective data 
collection for the second cohort of LRYGB patients with FTS was started in April–June 
2012. All patients met the international criteria for bariatric surgery.
18
 The ethical board 
of the Rijnstate Hospital approved this study protocol. Informed consent was obtained 
from all individual participants included in the study. 
In this study, 75 morbidly obese patients with a primary LRYGB who underwent 
FTS were prospectively selected for inclusion (FTS group) and were compared with 
LRYGB patients treated with the conventional care programme (CPC group). 
These patients were matched for gender and age (±3 years), which resulted in 
the exclusion of 24 patients in the CPC group and 20 patients in the FTS group.  
Figure 1 shows the selection procedure. 
 
Figure 1. Selection procedure 
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The primary endpoints of this study were operating time and length of hospital 
stay. Secondary endpoints were the amount of perioperative medication use and 
complications, including reoperations, bleedings, anastomotic leakages, 30-day 
readmission and 30-day mortality rate. 
 
CPC programme 
The characteristics of the CPC programme are shown in Table 1. All patients 
underwent a multidisciplinary screening preoperatively by a physician, a dietician, an 
exercise expert and a psychologist.  
Patients were admitted to the hospital a few hours before their surgery, or on 
the night before surgery, if the patient was on insulin. During hospitalisation, all patients 
received pneumatic stockings and nadroparin 5,700 IU daily to prevent 
thromboembolic complications. 
In the conventional programme, there was no standardised anaesthesia 
protocol. The anaesthesia administration depended on the anaesthesiologist’s choice. 
All patients received a controlled analgesia pump (PCA-pump) with morphine for 
postoperative pain control. Epidural analgesia was not part of the protocol. Only after 
the patient was sent to sleep and intubated could the surgical team start the positioning 
and sterile draping of the patient. 
 
Surgical procedure: The surgical technique was adapted from the technique 
described by Lönroth.
19
 The patient is placed in a split leg reversed Trendelenburg 
position with the legs in stirrups. The procedure was performed using a 5-trocard 
technique and a 30° angled laparoscope. A gastric-pouch of 30–50 ml was created 
using an endoscopic linear stapler (Echelon, Ethicon, Johnson & Johnson, New 
Brunswick, New Jersey, USA), over a 40 Fr gastric tube. The biliopancreatic limb was 
measured up to 50 cm and brought up antecolically and antegastric to create an end-
to-side stapled gastroenterostomy with a 35 mm stapler. The remaining opening was 
closed with a running suture, using the Endostitch™ device (Covidien, Dublin, Ireland). 
An alimentary limb of 150 cm was then measured, and a side-to-side 
enteroenterostomy was created with a 60 mm linear stapler. Again, the remaining 
opening was closed using the Endostitch™. To complete the Roux-en-Y configuration, 
the loop was divided on the left side of the gastroenterostomy. Tissucol, a fibrin sealant, 
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was used to cover all anastomoses. Finally, a leak test of the gastroenterostomy was 
performed. 
Postoperatively, all patients were planned for admission on the medium care. 
The start of mobilisation depended on patient choice. Oral liquid diet on the first day 
was allowed; thereafter, thick liquid was prescribed for the first week, followed by a 
normal diet. 
 
FTS programme 
A summary of the FTS programme is shown in Table 1. The screening and 
preoperative work-up programme was identical to the conventional care programme. 
The patients were admitted to the hospital on the day of their surgery or the 
evening before if the patient was on insulin. The patients were prepared for planned 
discharge the next day at 18.00 h. Criteria for discharge were no fever 
(temperature < 38°°C), no tachycardia (rate < 100 per minute), normal blood pressure 
(<160/90 mmHg), adequate pain control and adequate oral intake. No standard 
pneumatic stockings were used. 
In all patients, a standardised anaesthesia protocol for bariatric surgery was 
used (see Table 2).12,16 The anaesthesia protocol was based on short working agents, 
enabling fast recovery and postoperative mobilisation. 
Positioning and draping of the patients started directly after the induction of 
general anaesthesia, but before intubation, enabling simultaneous preparation by both 
the operating team and the anaesthesia team. The LRYGB procedure slightly differs 
from the conventional group: the Angle of His was not freed, the greater omentum was 
not divided, Tissucol was no longer administered and internal herniation ports 
(Peterson’s space and enteroenterostomy space) were closed with staples (EMS 
stapler, Johnson & Johnson, New Brunswick, New Jersey, USA). 
Additional local anaesthesia in the skin and peritoneum with Bupivacaine 0.5 % 
with adrenaline 1:200 k (maximum of 40 ml (8 ml/port)) was infiltrated into all wounds 
to reduce postoperative pain. Epidural analgesia or PCA pump were not part of the 
standard postoperative care. All patients received oral analgesia only or subcutaneous 
injection of morphine on demand. 
All patients received standardised postoperative care. The patients were 
monitored and observed for a maximum of 2 h in the recovery room before they were 
sent to the ward, where monitoring of vital parameters (e.g. pulse oximetry) has been 
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available since 2011. Admission to the medium care unit was only considered if ASA 
classification was three or higher. Patients were mobilised within 2 h after their 
operation and were encouraged to walk around. They had no restrictions on oral fluid 
intake. Four hours after surgery, the patients were allowed to eat thick liquid food and 
the day after the surgery to eat a pureed diner. 
 
Data Collection and Statistics 
Perioperative data of all patients were prospectively collected and registered in 
a computerised database. Data were analysed using SPSS® version 18.0 for Windows. 
Data are shown as means (standard deviation), unless stated otherwise. Comparisons 
between both groups for continuous data were performed using Student’s t test, with a 
p value <0.05 being regarded as statistically significant. 
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Table 1. Summary of conventional perioperative care and fast track surgery protocol 
CPC protocol FTS protocol 
Screening by physician, dietician, exercise 
expert and psychologist 
Screening by physician, dietician, exercise expert 
and psychologist 
Pre-operative work-up day at hospital Pre-operative work-up day at hospital 
Hospitalisation 
- Admission a couple hours before 
surgery/night before* 
- Information about ward and exercises 
separately 
- Received pneumatic stockings 
- Urine catheter 
- Mobilisation based on patient 
preference 
- Care provided by the nurses 
- Planned discharge 1 days after surgery 
Hospitalisation 
- Admission on 07:15h on morning day of 
surgery/night before* 
- Information about ward and exercises in 
a group session 
- Pneumatic stockings, only on indication**  
- No urine catheter 
- Mobilisation within 2 hours after surgery 
 
- Patients stimulated to provide self-care 
- Planned discharge 1 day after surgery 
Surgery 
- Transport by bed 
- Operation (LRYGB) 
- Four drapes for sterile draping 
- Skin closure with intracutaneous 
stitches 
- Patient is transferred to the bed by OR 
staff 
- Positioning and sterile draping after 
intubation 
- Sometimes local anaesthesia skin and 
pre-peritoneum 
- Tissuecol 
Surgery 
- Patient walks into the OR 
- Operation (LRYGB) 
- One combined drape for sterile draping 
- Skin closure with staples 
 
- Patient is able to change from operating 
table to bed after surgery 
- Positioning, sterile draping and intubation 
at the same time 
- Local anaesthesia skin and pre-
peritoneum 
- No Tissuecol 
Anaesthesia 
- No standard protocol 
- PCA-pump with morphine 
- Admission on recovery as long as 
necessary  
Anaesthesia 
- Drug administration following protocol 
- Only oral analgesia 
- Planned recovery time maximum of 2 
hours 
*Admission night before surgery if patient has insulin-dependent diabetes mellitus (IDDM) or is the first on the 
operation room list (OR list)  
**Patients with thrombo-embolic event, such as deep venous thrombosis or pulmonary embolism 
FTS: fast track surgery; OR: operation room; LRYGB: laparoscopic Roux-en-Y gastric bypass; PCA-pump: patient 
controlled analgesia pump 
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Table 2. Enhanced recovery anaesthesia protocol during surgery 
Monitoring: non-invasive blood pressure, ECG, pulse oximetry and train-of-four stimulation (TOF). 
Pre-medication on ward 
- 40mg Pantoprazol  
- 10mg Metoclopramid 
- First dose nadroparin 0.6cc s.c. 
On holding 
- Cefazoline 2000 mg i.v. 
- Metronidazol 500 mg i.v. 
- Ringer lactate 1000 ml 
Induction 
- Semi-sitting position 
- Pre-oxygenation until EtO2 >90% with PEEP 10 cm H20 
- Starch colloid (Voluven) 500ml 
- Phenylephrine and norepinephrine standby 
- Propofol 200 mg i.v. 
- Sufentanil 10 µg i.v. 
- Rocuronium i.v. on Ideal Weight dosage 
- Remifentanilpump i.v. 
o 2mg/40ml NaCl; Ideal Weight dosage (in ml/hour) for 3 min 
- Oral tracheal intubation with standard Macintosh laryngoscope 
- Prevention postoperative nausea 
o Droperidol 1.25 mg i.v. 
o Dexamethasone 5 mg i.v. 
Continuation of anaesthesia 
- Positive pressure ventilation with continuation of PEEP 10 cm H20 
- Sevoflurane 0.8–1.0 MAC 
- Remifentanyl pump i.v. 
o After 3 min to a quarter of Ideal Weight dosage (in ml/hour) and further on patients’ 
necessity 
- Start surgery 
o Local anaesthesia 
§ Bupivacaine 0.5% with epinephrine 1:200.000, maximum of 40ml (8ml/port) 
- Whilst making the enteroenterostomy 
o Morphine 5 mg i.v. 
o Paracetamol 1000 mg i.v. 
- After making the entero-entero anastomosis 
o Remifentanil pump i.v. 
§ Dosage to half of current dosage 
o Sevoflurane to 1.0% (about 0.6 MAC) 
o Ondansetron 4 mg i.v. 
Termination of anaesthesia (begin: stapling Peterson’s and enteroenterostomy space) 
- Stop Sevoflurane 
- Stop Remifentanilpump 
- Reversal of relaxants when TOF<90% with Sugammadex. Extubation when patient has 
restored spontaneous respiration and is awake, mostly during stapling 
EtO2: end tidal O2; PEEP: positive end expiratory pressure; TCI: target controlled infusion target; MAC: minimal 
alveolair concentration, TOF: train of four stimulation 
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RESULTS 
A total of 150 patients, 75 in each group, were included in this study for analysis. 
The two groups are comparable, except for the waist circumference and BMI. BMI and 
waist circumference were 46.8 ± 5.6 kg/m
2
 and 137.7 ± 10.3 cm, compared to 
44.9 ± 5.5 kg/m
2
 and 132.9 ± 17 cm, for the CPC group and FTS group, respectively. 
Patient characteristics are shown in Table 3. 
 
Table 3. Baseline patients’ characteristics 
 Total group CPC group  FTS group P value 
Male/female  46/104 
(30.7/69.3) 
23/52 
(30.7/69.3)  
 23/52  
(30.7/69.3) 
1.00 
Age (years) 47.3 ±9.5 46.2 ±10.1 48.4 ±8.9 0.16 
Weight (kg) 134.9 ±19.8 136.2 ±19.4 133.6 ±20.3 0.41 
BMI (kg/m
2
)  45.9 ±5.6 46.8 ±5.6 44.9 ±5.5 0.04 
EW (kg) 61.2 ± 16.6 63.2 ±16.1 59.2 ±17.0 0.15 
Waist circumference (cm) 135.3 ±12.1 137.7 ±10.3 132.9 ±13.4 0.02 
ASA classification 2.15 ±0.6 2.08 ±0.6 2.23 ±0.6 0.14 
Neck size (cm) 45.15 ±4.8 45.3 ±4.7 45.0 ±4.8  0.74 
Mallampati score 1.90 ±0.8  1.99 ±0.9  1.82 ±0.8 0.24 
Comorbidity (n) 
T2DM (%) 
    Insulin dependent (%) 
Hypertension (%) 
Hypercholesterolemia (%) 
Sleep apnoea syndrome (%) 
Osteoarthritis (%) 
Hypothyroidism (%) 
Reflux (%) 
 
61  
25  
65  
38  
22  
33  
2  
31  
  
31  
10  
35  
20  
13 
18  
1  
14  
 
(41.3) 
(13.3) 
(46.7) 
(26.7) 
(17.3) 
(24.0) 
(1.3) 
(18.7) 
 
30  
15  
30  
18  
9  
15  
1  
17  
 
(40.0) 
(20.0) 
(40.0) 
(24.0) 
(12.0) 
(20.0) 
(1.3) 
(22.7) 
 
0.87 
0.27 
0.41 
0.71 
0.36 
0.55 
1.00 
0.55 
Data are mean (±SD) or numbers (n, %) 
T2DM: Type 2 diabetes mellitus; BMI: body mass index (kg/m2); EW: excess weight (kg); ASA: American society of 
anaesthesiologists 
 
Perioperative Time and Hospitalisation 
The perioperative times are shown in Table 4. Overall time in the OR was 
reduced from 119 to 82 min (p < 0.001). Time needed for anaesthesia and surgery was 
reduced significantly (p < 0.05). The time needed for transporting patients between 
holding or recovery and the OR and time between arrival at OR and the start of 
induction did not change significantly. 
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Table 4. Perioperative time 
Duration between CPC group FTS group P value 
Holding – arrival OR (min) 
 
Total time at OR (min) 
Arrival OR – Induction (min) 
Start induction – End induction (min) 
End induction – Start surgeon (min) 
Start surgery – End surgery (min) 
End surgery – Leaving OR (min) 
Leaving OR – To recovery (min) 
 
Arrival Recovery – To ward (min) 
Time to next patient on OR (min) 
43 ±22 
 
119 ±21 
6 ±4 
9 ±4 
10 ±4 
80 ±20 
11 ±5 
3 ±1 
 
104 ±36 
17 ±17, n=51 
39 ±20 
 
82 ±21 
5 ±2 
7 ±3 
4 ±6 
56 ±19 
7 ±8 
3 ±2 
 
95 ±33 
16 ±22, n=56 
0.31 
 
<0.001 
0.12 
<0.001 
<0.001 
<0.001 
0.01 
0.81 
 
0.11 
0.69 
Patients admitted to medium care unit (%) 
      Duration (hh:mm) 
14 (18.7) 
21:25 ±03:15 
4 (5.3) 
18:38 ±05:27 
0.01 
0.21 
Total hospital stay (hh:mm) 65:27 ±09:49 42:41 ±08:58 <0.001 
Data are mean (±SD), unless stated otherwise 
OR: operating room 
 
Overall hospital stay was reduced by almost 1 day from 65 to 43 h (p < 0.001). 
The amount of medium care admissions was significantly reduced from 19 to 5 % 
(p < 0.05). The length of stay on the medium care unit remained unchanged. 
 
Complications 
In the CPC group, there were eight patients with a complication, including four 
major complications (one patient with intra-abdominal bleeding, one patient with intra-
luminal bleeding, one asthma cardiale in a patient with pre-existing cardiac disease 
and one patient with an asystole during induction corrected with medication) and four 
minor complications (all port site bleeding). One re-laparoscopy was necessary for 
intra-abdominal bleeding; in addition, one diagnostic re-laparoscopy was performed. 
In the FTS group, a total of six patients experienced a complication, including three 
major complications (two re-laparoscopies for intra-abdominal bleeding and one 
gastroscopy for intra-luminal bleeding) and three minor complications with a port site 
bleeding. In the CPC, one patient had a readmission within 30 days with acute 
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Perioperative Time and Hospitalisation 
The perioperative times are shown in Table 4. Overall time in the OR was 
reduced from 119 to 82 min (p < 0.001). Time needed for anaesthesia and surgery was 
reduced significantly (p < 0.05). The time needed for transporting patients between 
holding or recovery and the OR and time between arrival at OR and the start of 
induction did not change significantly. 
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Table 4. Perioperative time 
Duration between CPC group FTS group P value 
Holding – arrival OR (min) 
 
Total time at OR (min) 
Arrival OR – Induction (min) 
Start induction – End induction (min) 
End induction – Start surgeon (min) 
Start surgery – End surgery (min) 
End surgery – Leaving OR (min) 
Leaving OR – To recovery (min) 
 
Arrival Recovery – To ward (min) 
Time to next patient on OR (min) 
43 ±22 
 
119 ±21 
6 ±4 
9 ±4 
10 ±4 
80 ±20 
11 ±5 
3 ±1 
 
104 ±36 
17 ±17, n=51 
39 ±20 
 
82 ±21 
5 ±2 
7 ±3 
4 ±6 
56 ±19 
7 ±8 
3 ±2 
 
95 ±33 
16 ±22, n=56 
0.31 
 
<0.001 
0.12 
<0.001 
<0.001 
<0.001 
0.01 
0.81 
 
0.11 
0.69 
Patients admitted to medium care unit (%) 
      Duration (hh:mm) 
14 (18.7) 
21:25 ±03:15 
4 (5.3) 
18:38 ±05:27 
0.01 
0.21 
Total hospital stay (hh:mm) 65:27 ±09:49 42:41 ±08:58 <0.001 
Data are mean (±SD), unless stated otherwise 
OR: operating room 
 
Overall hospital stay was reduced by almost 1 day from 65 to 43 h (p < 0.001). 
The amount of medium care admissions was significantly reduced from 19 to 5 % 
(p < 0.05). The length of stay on the medium care unit remained unchanged. 
 
Complications 
In the CPC group, there were eight patients with a complication, including four 
major complications (one patient with intra-abdominal bleeding, one patient with intra-
luminal bleeding, one asthma cardiale in a patient with pre-existing cardiac disease 
and one patient with an asystole during induction corrected with medication) and four 
minor complications (all port site bleeding). One re-laparoscopy was necessary for 
intra-abdominal bleeding; in addition, one diagnostic re-laparoscopy was performed. 
In the FTS group, a total of six patients experienced a complication, including three 
major complications (two re-laparoscopies for intra-abdominal bleeding and one 
gastroscopy for intra-luminal bleeding) and three minor complications with a port site 
bleeding. In the CPC, one patient had a readmission within 30 days with acute 
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appendicitis. In the FTS group, one patient had a readmission with biliary pancreatitis 
followed by a laparoscopic cholecystectomy. 
 
Anaesthesia and Medication Use 
Table 5 shows the drugs administration during surgery. The mean amount of 
propofol given in the CPC group was 276 mg and was reduced to 222 mg in the FTS 
group (p < 0.001). The amount of sufentanil used was also reduced from 31 to 10 mg 
(p < 0.001). In the FTS group, less relaxants were given, especially rocuronium 
(p < 0.001). Loco-regional analgesics were used in 11 patients in the CPC and in all 
patients in the FTS group. The amount of morphine use was reduced by 50 % from 10 
to 5 mg. 
 
Table 5. Intraoperative medication administration 
 CPC group FTS group P value 
Propofol (mg) 276.2 ±63.1 222.0 ±84.5  <0.001 
Sufentanil (µg) 31.1 ±10.6 10.1 ±2.6 <0.001 
Relaxants 
Rocuronium (mg) 
Sugammadex (mg) 
Suxamethonium (mg) 
 
49.3 ±10.8, n=75 
207.4 ±38.5, n =27 
122.9 ±27.4, n=7 
 
24.9 ±4.4, n=72 
207.9 ±78.6, n=19 
50.0, n=1 
 
<0.001 
0.98 
0.05 
Antiemetics 
Dexamethason (mg) 
Ondansetron (mg) 
Droperidol (mg) 
 
5.0 ±0.0, n=4 
4.0 ±0.0, n=12 
3.3 ±1.4, n=3 
 
4.0 ±0.0, n =71 
4.1 ±0.5, n=68 
1.4 ±0.4, n=73 
 
<0.001 
0.68 
0.15 
Analgesics 
Morphine (mg) 
Acetaminophen (mg) 
 
10.2 ±1.6, n=75 
1000 ±0.0, n=75 
 
5.3 ±1.2, n=70 
1000 ±0.0, n=75 
 
<0.001 
0.65 
Pumps 
Fenylephrine 0.1mg/ml (ml) 
Remifentanil 2000µg (ml) 
 
6.8 ±8.0, n=18 
- 
 
9.7 ±5.7, n=65 
22.7 ±7.1, n=74 
 
0.09 
 
Crystalloid/Colloid  
Ringer lactate (ml) 
Voluven (ml) 
 
1108.1 ±353.8, n=74 
518.9 ±96.2, n=53 
 
1000 ±0.0, n=72 
507.0 ±59.3, n=71 
 
0.01 
0.40 
Data are mean (±SD), unless stated otherwise 
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DISCUSSION 
The study shows that fast-track surgery is feasible and results in faster recovery 
compared to conventional perioperative care in morbidly obese patients who 
underwent a primary LRYGB. In addition, FTS decreased the length of hospitalisation, 
increased efficacy and may reduce the number of hospital resources required. These 
results confirm the findings of the previous studies.
12-16,20
 Furthermore, there are no 
differences in complication rate. However, the safety of the FTS programme should be 
assessed in larger studies, given the small study population of this study. 
The basis of FTS is a multidisciplinary approach of patients using a specialised 
team, including surgical, anaesthetic and nursing teams and paramedics (dietician and 
physiotherapist).
17
 Encouraging patient self-reliance is essential in this concept. 
Preoperative information and preparation for surgery and hospital admission induce 
more adaptability for postoperative instructions and create realistic expectations about 
hospitalisation, analgesia, mobilisation and discharge.
21
 All disciplines strive to 
approach the patients in the same way, treating them not as being sick and needy, but 
instead encouraging them to contribute to their recovery. 
Obese patients have a higher risk for postoperative pulmonary and venous 
thromboembolic (VTE) complications,
22
 which increases postoperative morbidity and 
delays postoperative recovery. Early mobilisation is an important modality to prevent 
these complications.
23-26
 These can be achieved by optimal perioperative analgesia 
regimens. A multimodal analgesic approach is recommended for adequate pain control, 
when minimal opiate administration is required.
17,26,27
 Local-regional anaesthesia 
(LRA)
17,28
 before visceral dissection at the trocar sites during laparoscopic surgery can 
help to reduce postoperative abdominal pain by blocking visceral afferent pathways.
29
 
By introducing LRA in the FTS protocol, the intraoperative use of morphine could be 
reduced by 50 %. Short-working relaxants and sedatives during anaesthesia provide 
faster recovery after surgery and the potential for early mobilisation.
16
  
Promoting mobility by reducing attributes like pneumatic sleeves and urinary 
catheters, and stimulating self-support of the patient makes a planned discharge on 
the day after surgery possible.
12
 The most common reasons for the failure of discharge 
were abdominal pain, nausea, vomiting and atelectasis.
21
 Therefore, fast-track 
programmes include adequate pain management, aggressive antiemetic prophylaxis 
during surgery and early mobilisation protocols. In accordance with the literature, the 
hospital stay in the FTS group was reduced by 35 % to 43 h compared to conventional 
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care.
12,14,16,20
 Jacobsen et al. reported a reduction in hospital stay from 3 to 2 days in 
large cohort of 2,000 consecutive patients.
12
 McCarty et al. demonstrated, in 1,669 
patients, that even early discharge within 23 h after LRYGB was feasible, provided 
there was sufficient surgeon experience and careful patient selection.
20
 Despite these 
large series, in a recent published systematic review by Elliot et al., the authors were 
reluctant to advocate routine adoption of fast-track protocols for LRYGB, because of a 
lack of sufficient data.
21
 However, given the recent improvements in perioperative care 
of bariatric patients which resulted in decreased morbidity and mortality, it is feasible 
that day case LRYGB procedures will be standard of care for the future. Indeed, a 
drawback of early discharge is to overlook early complications. However, the literature 
shows that most of the complications occur within the first 24 h after the surgery.
13,14
 
The readmission rate in our study did not increase after the implementation of the FTS 
programme.
17
 In both groups, only one readmission within 30 days occurred. It must 
be noted, however, that these readmissions could not have been avoided by longer 
hospitalisation. The number of complications after the implementation of FTS was 
comparable to earlier reports of bariatric surgery and did not increase despite shorter 
operative times.
12,14
  
Standardising surgery and anaesthesia protocols was essential in the FTS 
programme. Working with the help of protocols improves the reproducibility of the 
operative procedure and leads to less room for failure or mistakes and increased 
speed.
12,16
 Our study confirms these findings. The surgery time and total OR time in 
the FTS group were reduced significantly by 30 and 31 %, respectively. This enabled 
us to increase the number of procedures from four to five in a single OR in 1 day (from 
8.00 to 16.00 h), and we performed over 1,000 bariatric operations in 2012 with the 
same number of staff and hospital beds. Although it was not a subject of this study, 
increased efficiency has proven to reduce costs.
12
  
Our study shows the value of an enhanced recovery programme in bariatric 
surgery; however, it should be noted that although weight was similar in both groups, 
the CPC group had higher BMI and waist circumference compared to FTS group. This 
may flatter the results in favour of the FTS, but the enormous differences will probably 
hold ground. On the other hand, the patients in both groups were similar for age, weight, 
comorbidities and ASA classification. More experience could be another factor for the 
time difference between the two groups, since the FTS group was operated on a year 
after the CPC group. However, bariatric surgery has been conducted at our clinic since 
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1996 and LRYGB procedures since 2000. Hence, the team is far above the 
recommended learning curve of 100 cases, as before the start of this study, over 3,000 
procedures had already been performed.
14,30
 The present study shows the effect of the 
total package of FTS programme compared to the conventional programme. Despite 
the significant reduction of operative time, this may not fully explain the earlier 
discharge of the patients in FTS group. The impact of postoperative care actually plays 
an important role in the FTS surgery concept. However, the aim of this study was to 
show the improvement of clinical turnover in bariatric surgery patients. Therefore, the 
effect of the individual changes is not monitored and was outside the outline of this 
study. Furthermore, we compared primary LRYGB, which is currently one of the most 
performed bariatric procedures. Lemanu et al. demonstrated in a randomised 
controlled trial that the advantages of FTS also apply to sleeve gastrectomy (SG) 
surgery.
31
 Nowadays, all bariatric procedures in our hospital, including SG, Duodenal 
Switch and revisional surgery, are performed according to the fast-track protocol.  
 
CONCLUSION 
The introduction of fast-track bariatric surgery improves short-term recovery 
after primary LRYGB. Further research is required to investigate the safety of this 
protocol. In addition, it can be assumed that fast track surgery may reduce the amount 
of hospital resources required as it shortens the OR time and hospitalisation, and may 
increase production volumes. This kind of approach and experience can be 
implemented in all bariatric procedures in specialised high volume centres and may be 
able to be translated to other types of surgery. 
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Long-term effects of 
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Bypass on diabetes mellitus, 
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ABSTRACT 
Background 
Severely obese patients have an increased risk for developing metabolic complications 
such as type 2 diabetes mellitus (T2DM), dyslipidaemia (DL) and hypertension (HT). The aim 
of the present study is to research the effect of a primary laparoscopic Roux-en-Y gastric 
bypass (LRYGB) on T2DM, HT and DL in the long-term. 
 
Methods 
Fifty-two out of 89 (58 %) adult severely obese patients with T2DM who had received 
a LRYGB between January 2000 and December 2008 were evaluated. Primary outcome of 
evaluation was remission of T2DM according to the definition of 2009 consensus statement. 
Complete remission was defined as achievement fasting plasma glucose (FPG) of <5.6 mmol/l 
(<100.8 mg/dL) and HbA1c <42 mmol/mol (<6.0 %)) without glucose-lowering medication for 
at least 1 year. Partial remission was defined as a FPG of 5.6–6.9 mmol/l (100.8–124.2 mg/dL) 
and HbA1c 42–48 mmol/mol (6.0–6.5 %), without glucose-lowering medication for at least 
1 year. Remission of T2DM was considered if the patient met the criteria for complete or partial 
remission. Secondary outcomes were remission of HT, DL and changes in medication use. 
 
Results 
Patients had a mean age of 47.5 ± 9.6 years, body mass index of 46.6 ± 6.4 kg/m2 and 
a mean duration of T2DM of 6.1 ± 5.4 years at the time of surgery. The mean post-operative 
follow-up period was 6.9 ± 2.3 years. At the end of the follow-up, mean weight loss was 
60 ± 24 % excess weight loss (EWL) and 26 ± 10 % total body weight loss (TBWL). Mean 
HbA1c level had significantly decreased from 64.8 ± 19.7 mmol/mol to 46.4 ± 12.9 mmol/l 
(p < 0.0001). Overall medication use was reduced from 85 % to 37 % of the patients 
(p < 0.0001), while the number of insulin users was reduced from 40 % to 6 % (p < 0.0001). 
Nineteen percent of the patients had a relapse of T2DM during follow-up. Pre-operative 
HbA1ac level (odds ratio 0.911, p = 0.020) and duration of T2DM (odds ratio 0.637, p = 0.010) 
were independent risk factors for failed remission of T2DM. The number of patients with HT 
was significantly reduced from 73 % to 54 % (p = 0.042), and number of patients with DL was 
non-significantly decreased from 71 % to 54 % (p = 0.068). 
 
Conclusions 
The laparoscopic RYGB operation results in a sustained EWL of 60 % (26 % TBWL) 
with 52 % long-term remission of T2DM. However, 19 % of the patients had a relapse of their 
T2DM. Furthermore, HT and DL improved markedly. 
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INTRODUCTION 
Type 2 diabetes mellitus (T2DM) is an epidemic disease with an estimated 285 
million people affected worldwide and closely related to obesity.
1,2
 In addition to T2DM 
and elevated glucose levels, obese patients often have dyslipidaemia (DL) and 
hypertension (HT) which further adds to an increased risk for micro- and macrovascular 
long-term complications that significantly decrease the quality of life and life 
expectancy of these patients.
3 
Weight loss is the most important therapeutic intervention in obese patients with 
T2DM because it restores insulin sensitivity and improves β-cell function.
4-8
 Weight-
reducing surgery, i.e. bariatric surgery, is far more effective in achieving sustained 
weight loss than conventional (non-surgical) treatment.
9,10
 The Roux-en-Y gastric 
bypass (RYGB) procedure is currently the most performed bariatric procedure and has 
been shown to reduce the metabolic abnormalities of severely obese T2DM patients 
with a body mass index (BMI) >35 kg/m
2
.
9,11-14
 Therefore, the Diabetes Surgery 
Summit Consensus Conference promotes bariatric surgery as an alternative therapy 
for the treatment of obesity-related (BMI > 35 kg/m
2
) T2DM.
15,16 
However, long-term post-operative data on severely obese T2DM patients are 
limited. The aim of the present study was to evaluate the long-term effectiveness of 
laparoscopic RYGB (LRYGB) on the remission of T2DM, DL and HT.  
 
PATIENTS AND METHODS 
Patient Selection and Outcome 
All adult obese patients (age > 18 years, BMI > 35 kg/m
2
) with T2DM who 
underwent a primary LRYGB between January 2000 and December 2008 were invited 
to our outpatient clinic for a long-term follow-up visit. First invitations were sent by letter, 
followed by contact by phone if the patient had not responded. The local board of ethics 
of the Rijnstate hospital waved the necessity for informed consent since the follow-up 
of patients after surgery is already part of the postoperative protocol. All patients gave 
their permission for conducting this study. 
Patients were excluded when they had type 1 diabetes mellitus or if the LRYGB 
had been a revisional bariatric procedure. All patients underwent a pre-operative 
multidisciplinary screening by a multidisciplinary team, including a surgeon, 
endocrinologist, dietician, psychologist and physiotherapist. All patients met the criteria 
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for bariatric surgery according to the National Institutes of Health Consensus 
Conference.
17 
The patients were selected from our prospective collected (since 2000) 
database. Operation type and date, medical history, weight (kilograms), height 
(centimetres), co-morbidities, medication use and follow-up were registered in this 
database. The following parameters were documented at the follow-up: medical history, 
height (centimetres), weight (kilograms), BMI (kilograms per square meter), weight loss 
expressed in percentage excess weight loss (percent EWL) and percentage total body 
weight loss (percent TBWL), presence of co-morbidities, medication use and laboratory 
tests after an overnight fasting, including fasting plasma glucose (FPG), HbA1c, insulin, 
C-peptide, total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C) 
and triglycerides (TG). 
Primary endpoint was remission of T2DM according to the definition of 2009 
consensus statement.
18
 Patients were classified into three groups according to their 
remission rate. Complete remission was defined as achievement of ‘normal’ glucose 
parameters (FPG of <5.6 mmol/l (<100.8 mg/dL) and HbA1c <42 mmol/mol (<6.0 %)) 
without glucose-lowering medication for at least 1 year.
19
 Partial remission was defined 
as a FPG of 5.6–6.9 mmol/l (100.8–124.2 mg/dL) and HbA1c 42-48 mmol/mol (6.0–
6.5 %), without glucose-lowering medication for at least 1 year. Remission of T2DM 
was considered if the patient met the criteria for complete or partial remission. 
Secondary outcome measures were remission of other metabolic co-morbidities 
such as HT and DL. Patients were considered to have hypertensive control if they had 
an acceptable blood pressure (systolic of <160 mmHg and diastolic of <90 mmHg 
measured on the left arm) without antihypertensive medication. The DL treatment goal 
in patients with T2DM is to lower LDL-C level (<2.6 mmol/l (<100.5 mg/dL)), raise HDL-
C level (>1.02 mmol/l (>39.4 mg/dL)) and lower TG level (<1.7 mmol/l 
(<150.7 mg/dL)).
20
 Dosage of medication use was expressed in daily defined dose 
(DDD) as recommended by the World Health Organization (WHO).
21
 The DDD is the 
assumed average maintenance dose per day for a drug used for its main indication in 
adults. DDDs provide a fixed unit of measurement independent of price, currencies, 
package size and strength enabling to assess trends in drug consumption and to 
perform comparisons between population groups. For example, 150 mg of metoprolol 
(beta-blocker) is equal to 1 DDD, while 75 mg of atenolol (beta-blocker) is equal to 1 
DDD. 
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Surgical Procedure 
 All patients underwent a LRYGB procedure in a single bariatric centre. Antecolic 
antegastric bypass was performed with a small gastric pouch of 30–50 mL and fixed 
biliopancreatic limb (BPL) of 50 cm. Patients with BMI < 50 kg/m
2
 had a Roux limb of 
approximately 100 cm (range, 75–125 cm) and patients with BMI > 50 kg/m
2
 a Roux 
limb of 150 cm (range, 125–175 cm).
22 
 
Statistical Analysis 
Results are presented as mean values ± standard deviation (SD), unless 
otherwise specified. Variance between groups was analysed using unpaired t test or 
Mann–Whitney U test (in cases of not normally distributed data) for continuous data 
and Chi-square test or Fisher exact test for categorical data. Paired t test was used for 
variance within the group. Parameters were selected for multivariate regression 
analysis for detection of independent risk factors for remission of T2DM if there was a 
difference of p < 0.05 for individual parameters. Data were analysed using IBM® 
SPSS® (version 20.0 for Windows) statistical software, and all figures were created 
using Graph Path Prism® (version 5.01). A p < 0.05 was considered significant.  
 
RESULTS 
Eighty-nine patients with T2DM out of a total of 310 severely obese patients 
underwent a primary LRYGB and were eligible for long-term follow-up. Two patients 
died post-operatively after 1 (alcohol intoxication) and 7 years (sudden death, known 
with M. non-Hodgkin, splenectomy, myocardial infarction and nephropathy). Twenty-
five patients were lost to follow-up, and 12 patients refused follow-up for personal 
reasons. In total, 52 (58.4 %) patients completed the long-term follow-up and were 
included in the analysis. Their mean age at the time of operation was 47.5 ± 9.6 years, 
with a BMI of 46.6 ± 6.4 kg/m
2
. Mean T2DM duration at surgery was 6.1 ± 5.4 years, 
and 21 (40 %) patients were on insulin therapy. Table 1 shows the baseline 
characteristics. 
Mean post-operative follow-up period was 82.2 ± 27.6 months (6.9 ± 2.3 years). 
At the end of the follow-up, mean weight and BMI were 103.7 ± 21.1 kg 
(−36.9 ± 15.6 kg) and 34.3 ± 6.6 kg/m
2
 (−12.3 ± 5.0 kg/m
2
), respectively, with an 
overall %EWL of 59.5 ± 24.4 % and %TBWL of 26.3 ± 10.1 %. 
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Table 1. Baseline characteristics 
 Total group (n=52) 
Age (years) 47.5 ±9.6 
Female gender 31 (59.6%) 
Weight (kg) 140.6 ±21.8 
BMI (kg/m
2
) 46.6 ±6.4 
EW (kg) 64.8 ±18.9 
T2DM   
Duration (years) 6.1 ±5.4 
Medication use (n, %) 44  (84.6%) 
Insulin treatment (n, %) 21  (40.4%) 
Data are mean (± standard deviation), unless otherwise specified 
BMI: Body Mass Index; EW: Excess Weight; T2DM: Type 2 Diabetes Mellitus 
 
Glucose Metabolism 
The changes in parameters of glucose metabolism and that of glucose-lowering 
medication are summarised in Table 2. In total, 27 (51.9 %) patients had remission of 
their T2DM at their last follow-up visit (p < 0.0001). In the overall population, both mean 
FPG and HBA1c levels had decreased significantly from 9.3 ± 3.7 mmol/l to 
7.2 ± 2.8 mmol/l and from 64.8 ± 19.7 mmol/mol to 46.4 ± 12.9 mmol/l, respectively 
(p < 0.0001). Medication use was reduced from 44 (85 %) patients to 19 (37 %) 
(p < 0.0001). All types of diabetes medication were reduced in numbers and dosages 
compared with baseline. The number of insulin users was reduced from 21 (40 %) to 
3 (6 %) (p < 0.0001), and the mean insulin dose was reduced from 2.85 ± 2.24 DDD to 
0.20 ± 0.51 DDD (p < 0.0001). In all three groups (remission, temporary remission and 
no remission), metabolic improvement was observed. In the group with long-term 
remission, FPG and HbA1c levels had decreased significantly from 7.7 ± 2.4 to 
5.5 ± 0.8 (p < 0.0001) and 51.8 ± 12.8 to 38.6 ± 4 mmol/mol (p < 0.0001), respectively. 
In patients who had a temporary remission, FPG and HbA1c levels had decreased by 
−2.2 ± 4.0 mmol/l to 8.7 ± 3.1 mmol/l (p = 0.137) and by −27.4 ± 21 mmol/mol to 
53.6 ± 9.2 mmol/mol (p = 0.004), respectively. Even patients without remission had a 
lowering of FPG and HbA1c levels at their last follow-up visit; FPG had decreased from 
11.1 ± 4.2 to 8.8 ± 3.3 mmol/l (p = 0.028) and HbA1c level from 79.5 ± 15.6 to 
54.5 ± to13.6 mmol/mol (p < 0.001). 
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Table 2. Follow-up glucose metabolism 
 Before surgery 
(n=52) 
After surgery 
(n=52) 
P value 
T2DM (n, %) 52 (100) 25  (48) <0.0001 
Medication use (n, %) 44 (85) 19 (37) <0.0001 
Biguanide (n, %) 39 (75) 19 (37) <0.0001 
DDD 0.76 ±0.41 0.37 ±0.47 <0.0001 
SU-derivate (n, %) 16 (31) 6 (12) 0.016 
DDD 1.85 ±1.34 0.56 ±0.97 0.002 
Thiazolidinedione (n, %) 1 (2) 0  (0) 1.000 
DDD 0.67  0.00  - 
Insulin (total) (n, %) 21 (40) 3 (6) <0.0001 
DDD 2.85 ±2.24 0.20 ±0.51 <0.0001 
Insulin (mix) (n, %) 8 (15) 3 (6) 0.201 
DDD 1.70 ±1.33 0.44 ±0.61 0.004 
Insulin (long-acting) (n, %) 12 (23) 1 (2) 0.002 
DDD 1.75 ±1.19 0.046 ±1.16 <0.0001 
Insulin (fast-acting) (n, %) 11 (21) 0 (0) 0.001 
DDD 2.21 ±1.28 0.00  <0.0001 
Fasting glucose (mmol/l) 9.3 ±3.7 7.2 ±2.8 <0.0001 
HbA1c (mmol/mol) 64.8 ±19.7 46.4 ±12.9 <0.0001 
Fasting C-peptide (nmol/l) 1.89 ±1.38 0.92 ±0.39 0.001 
Data were mean (±SD), unless otherwise specified 
T2DM: Type 2 Diabetes Mellitus; DDD: Daily Defined Dose  
 
Baseline characteristics of patients reaching remission of T2DM were compared 
with those who failed to reach remission (Table 3). Patients with remission of T2DM 
were younger (44.1 vs. 51.3 years, p = 0.006), had a shorter duration of T2DM (2.4 vs. 
10.1 years, p < 0.0001), less users of insulin (22 % vs. 60 %, p = 0.006) and had lower 
glucose (7.7 vs. 11.1 mmol/l, p = 0.001) and HbA1c levels (51.7 vs. 79.5 mmol/mol, 
p < 0.0001) compared with patients who had no remission. Logistic regression analysis 
showed that pre-operative HbA1c level (odd ratio 0.911, p = 0.020) and duration of 
T2DM (odds ratio 0.637, p = 0.010) were independent risk factors for the persistence 
of T2DM after LRYGB. Age (p = 0.937), insulin usage (p = 0.905) and glucose level 
(p = 0.632) were not identified as risk factors (Table 4). 
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Table 3. Difference between remission and no remission (long-term follow-up) 
 Remission  
(n=27) 
No remission  
(n=25) 
P value 
Demographic      
Age (years) 44.1 ±9.3 51.3 ±8.7 0.004 
Female (n, %) 17 (63) 14  (56) 0.609 
Long Roux limb (n, %) 8 (30) 4 (16) 0.329 
Weight       
Weight pre-operative (kg) 144.9 ±20.9 136.0 ±22.1 0.141 
Weight loss (kg) -39.4 ±17.1 -34.3 ±13.6 0.238 
BMI (kg/m
2
) 47.5 ±6.6 45.5 ±6.1 0.274 
BMI loss (kg/m
2
) -13.0 ±5.6 -11.4 ±4.3 0.259 
EW (kg) 61.1 ±17.9 68.3 ±19.4 0.166 
%EWL 60.7 ±28.1 58.2 ±20.2 0.712 
Glucose metabolism      
Diabetes Duration (years) 2.4 ±2.8 10.1 ±4.7 <0.0001 
Medication use (n, %) 20 (74) 24 (96) 0.051 
Insulin treatment (n, %) 6 (22) 15 (60) 0.006 
Glucose preoperative (mmol/l) 7.7 ±2.4 11.1 ±4.2 0.003 
HbA1c preoperative (mmol/mol) 51.7 ±12.6 79.5 ±15.6 <0.0001 
C-peptide preoperative (nmol/l) 2.24 ±1.7 1.57 ±0.9 0.207 
Data were mean (±SD), unless otherwise specified 
BMI: Body Mass Index; EW: Excess Weight; %EWL: percentage Excess Weight Loss 
 
Table 4. Multiple regression analysis for remission of T2DM 
Individual variable P value Odds Ratio (95% CI) 
Age (years) 0.937 1.005 (0.879 – 1.150) 
Pre-operative FPG 0.632 0.909 (0.616 – 1.343) 
Pre-operative HbA1c 0.020 0.911 (0.841 – 0.985) 
Duration of T2DM 0.010 0.637 (0.452 – 0.898) 
Insulin usage 0.905 0.851 (0.061 – 11.958) 
T2DM: Type 2 Diabetes Mellitus; FPG: Fasting Plasma Glucose 
 
Ten out of 25 patients (40 %) who had no remission at their last follow-up had 
temporarily met the criteria for remission during the preceding period (within 2 years 
after surgery), but later experienced a relapse of T2DM. Compared with patients in 
sustained remission, these patients with relapse had a longer duration of T2DM 
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(8.9 ± 4.7 vs. 2.4 ± 2.8 years; p < 0.0001), higher pre-operative FPG levels (10.9 ± 3.8 
vs. 7.7 ± 2.4 mmol/l; p = 0.034) and higher HbA1c levels (81 ± 16.6 vs. 
51.7 ± 12.6 mmol/mol; p < 0.0001). Table 5 demonstrates the parameters for patients 
who had relapse, no remission and remission of T2DM during follow-up. 
 
Table 5. Comparison of patients with no remission, relapse and sustained remission of T2DM 
during long-term follow-up 
 No Remission 
(n=15) 
Relapse 
(n=10) 
Sustained 
Remission  
(n=27) 
Pa 
value 
 
Pb 
value 
Demographic         
Age (years) 51.9 ±8.5 50.3 ±9.5 44.1 ±9.3 0.723 0.108 
Female (n, %) 10 (67) 4 (40) 17 (63) 0.241 0.274 
Long Roux limb (n, %) 3 (20) 1 (10) 8 (30) 0.626 0.393 
Weight         
Weight preoperative (kg) 130.8 ±13.6 143.8 ±30.0 144.9 ±20.9 0.233 0.901 
BMI preoperative (kg/m
2
) 45.1 ±5.4 46.3 ±7.2 47.5 ±6.6 0.641 0.623 
EW (kg) 57.6 ±12.2 66.3 ±23.9 68.3 ±19.4 0.309 0.789 
%EWL 58.6 ±21.7 57.6 ±18.8 60.7 ±28.1 0.911 0.749 
Glucose metabolism         
Diabetes duration (years) 10.9 ±4.7 8.9 ±4.7 2.4 ±2.8 0.297 <0.0001 
Medication use (n, %) 14 (93) 10 (100) 20 (74) 1.000 0.155 
Insulin treatment (n, %) 10 (67) 5 (50) 6 (22) 0.442 0.101 
Pre-op Glucose (mmol/l) 11.2 ±4.5 10.9 ±3.8 7.7 ±2.4 0.861 0.034 
Pre-op HbA1c (mmol/mol) 78.5 ±15.5 81.0 ±16.6 51.7 ±12.6 0.688 <0.0001 
Pre-op C-peptide (nmol/l) 1.12 ±0.41 2.16 ±1.0 2.2 ±1.7 0.017 0.913 
Data were mean (±SD), unless otherwise specified  
BMI: Body Mass Index; EW: Excess Weight; %EWL: percentage Excess Weight Loss; IDDM: Insulin Dependent 
Diabetes Mellitus 
aRelapse versus No remission 
bRelapse versus Remission 
 
Hypertension and Dyslipidaemia 
 The number of patients with HT was significantly reduced from 38 (73 %) to 28 
(54 %) (p = 0.042). The total number of medication users was non-significantly reduced 
from 34 (65 %) to 25 (48 %) patients (p = 0.075). Nearly all types of anti-hypertensive 
medication were reduced in both the number of users and dosages compared with 
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Hypertension and Dyslipidaemia 
 The number of patients with HT was significantly reduced from 38 (73 %) to 28 
(54 %) (p = 0.042). The total number of medication users was non-significantly reduced 
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baseline; however, statistical significance for single medication types was not reached 
(Table 6). 
Overall lipid profile improved after surgery compared with baseline. Mean serum 
TC and TG decreased, while HDL-C increased significantly compared with baseline. 
Number of patients with DL decreased non-significantly from 37 (71.2 %) to 28 
(53.8 %) (p = 0.068). Medication use was slightly decreased after surgery, from 18 
(35 %) patients to 16 (31 %) (p = 0.676).  
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Table 6. Prevalence, medication use and laboratory tests of hypertension and dyslipidaemia  
 Before surgery 
(n=52) 
After surgery 
(n=52) 
P value 
Hypertension (n, %) 38 (73) 28 (54) 0.042 
Medication use (n, %) 34 (65) 25 (48) 0.075 
Ace – inhibitor (n, %) 16 (31) 11 (21) 0.263 
DDD 1.31 ±1.09 0.71 ±0.85 0.077 
Angiotensin - II – inhibitor (n, %) 16 (31) 9 (17) 0.108 
DDD 1.33 ±0.80 0.74 ±0.87 0.064 
Dihydropyridin derivate (n, %) 9 (17) 7 (13) 0.587 
DDD 1.63 ±1.06 1.13 ±1.20 0.273 
β – Blocker (n, %) 9 (17) 8 (15) 0.791 
DDD 0.60 ±0.56 0.39 ±0.41 0.329 
Sulphonamides (n, %) 6 (12) 3 (6) 0.488 
DDD 1.67 ±0.41 0.67 ±0.82 0.076 
Potassium-sparing agent (n, %) 2 (4) 2 (4) 1.000 
DDD 0.58 ±0.69 0.25 ±0.32 0.546 
Thiazide (n, %) 10 (27) 7 (13) 0.426 
DDD 0.71 ±0.69 0.33 ±0.39 0.222 
Anti-adrenergic agent (n, %) 1 (2) 1 (2) 1.000 
DDD 1.00 ±1.41 0.50 ±0.71 0.795 
Calcium antagonist (n, %) 0 (0) 1 (2) 1.000 
DDD 0.00  0.83  - 
Dyslipidaemia (n, %) 37 (71) 28 (54) 0.068 
Medication use (n, %) 18 (35) 16 (31) 0.676 
HMG CoA reductase inhibitor (n, %) 16 (31) 16 (31) 1.000 
DDD 1.17 ±1.01 0.78 ±0.57 0.147 
Fibrate (n, %) 2 (4) 0 (0) 0.495 
DDD 1.0 ±0.00 0.00  - 
Total cholesterol (mmol/l) 4.78 ±0.92 4.35 ±0.81 0.028 
HDL-cholesterol (mmol/l) 1.17 ±0.31 1.42 ±0.40 <0.0001 
LDL-cholesterol (mmol/l) 2.47 ±0.83 2.31 ±0.55 0.307 
Triglycerides (mmol/l) 2.79 ±2.22 1.42 ±0.82 <0.0001 
Data were mean (±SD), unless otherwise specified 
DDD: Daily Defined Dose 
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DISCUSSION 
In the present study, the long-term metabolic effects of LRYGB were analysed 
in severely obese patients with T2DM. After a mean post-operative follow-up period of 
82 months, there was a reduction in T2DM (52 %), HT (26 %) and DL (24 %). 
Furthermore, there was a marked reduction of medication use for T2DM and HT. 
Although the LRYGB is a proven effective treatment for T2DM and other 
cardiovascular risk factors in the short-term (<2 years), in patients with obesity 
(BMI < 35 kg/m
2
)
14,23
 and severe obesity (BMI > 35 kg/m
2
),
13,14,24,25
 with remission rates 
of T2DM of 64–81 % after RYGB in the mid-long-term (3–5 years),
26-29
 some 
professionals argue the durability of these positive effects in the long-term and 
advocate for better predictors for success.
30
 In a long-term follow-up of 10 years after 
primary LRYGB, Higa et al.
31
 showed that T2DM had resolved or improved in 67 % of 
patients; however, this study was based on questionnaires which are prone to 
misdiagnosis. In contrast, a large non-randomised, prospective Swedish Obese 
Subjects (SOS) study showed a low recovery rate of T2DM of only 36 % 10 years after 
bariatric surgery. It must be mentioned that only 5 % of patients in the SOS had 
undergone an RYGB procedure.
32
 In our experience, 52 % of the patients had 
sustained remission of T2DM after a mean period of approximately 7 years. This is 
slightly lower compared with other studies within the same timeline.
33,34
 Nevertheless, 
the published remission rates in the long-term are still lower compared with data on the 
short- and mid-long-term, probably due to the recurrence of T2DM over time. In this 
study, 71 % of the patients reached remission of T2DM during follow-up; however, 
19 % had a relapse of their diabetes over time. 
Predictors for remission and/or recurrence of T2DM after bariatric surgery, i.e., 
RYGB, can help to estimate the success rate in the long-term. Furthermore, it could be 
helpful in the selection of pre-operative patients and could provide more realistic 
expectations on the chance of diabetes resolution for the patients. In the present study, 
pre-operative HbA1c level (OR 0.911) and duration of T2DM prior to surgery (OR 
0.637) were independent predictors for remission of T2DM. Previous studies 
postulated different independent predictors for glycaemic control after RYGB, including 
age,
29,35
 female gender,
34
 BMI,
36,37
 C-peptide level,
37-39
 oral medication and/ or insulin 
use,
29,34
 duration of T2DM prior to surgery
37,40
 and post-operative weight loss and/or 
weight regain.
29,35,36 
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Previous studies, including one of our own study group, demonstrated that pre-
operative fasting C-peptide, a marker for beta-cell function of the pancreas, lower than 
1.0 nmol/l is associated with a reduced chance of complete remission of T2DM after 
RYGB surgery.
37-39
 In the present study, a non-significant difference was found for pre-
operative C-peptide levels between patients who had remission (2.24 ± 1.7 nmol/l) and 
no-remission (1.57 ± 0.9 nmol/l) of their T2DM at the last follow-up visit. Relapse of 
T2DM has not been described in earlier studies with a short-term follow-up.
37-39
 When 
eliminating patients who had a relapse of their T2DM, the C-peptide level was 
significantly lower for patients who did not have remission (1.12 ± 0.4 nmol/l) during the 
follow-up compared with patients who remained in remission (2.2 ± 1.7 nmol/l; 
p = 0.030). Patients who had a relapse of T2DM had similar pre-operative C-peptide 
levels (p = 0.913) compared with patients who remained in remission. These findings 
implicate that a low pre-operative C-peptide level is associated with no remission of 
T2DM in the short- and long-term; however, high C-peptide levels do not predict the 
chance of sustained remission of T2DM in the long-term. 
Low C-peptide level, use of insulin and longer duration of T2DM prior to 
operation are determinants of severity of disease. It can be stated that higher severity 
of T2DM prior to surgery results in less remission of T2DM after RYGB. Due to the 
progressive nature of T2DM, long-term remission after surgery is hard to achieve in 
many patients; however, almost all patients profit from surgery in the long-term. 
Several studies have also demonstrated a long-term reduction of other obesity 
related co-morbidities, such as HT (42–73 %)
31,33,41-43
 and DL (62–80 %)
41,42
 after 
RYGB. In the present study, there was a significant reduction in the prevalence of 
hypertension and a reduction of anti-hypertensive medication use after surgery. 
Furthermore, lipid profile significantly improved and prevalence of DL decreased. 
However, the reduction of HT (26 %) and DL (24 %) were lower compared with these 
previous studies. 
Before interpreting the findings of the present study, the limitations of this study 
should be considered. Eighty-five percent of the eligible population had completed the 
long-term follow-up visits. This fact could result in over- or underestimation of the 
metabolic effects, since patients with good results following their operation could deem 
a control visit unnecessary, while patients with disappointing results may reject visits 
due to a loss of motivation. Therefore, we had a relatively small study population; 
however, all patients were seen in the outpatient clinics, which provided us with reliable 
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data. In contrast, some other published long-term studies were based on telephone 
contact. Additionally, this study corroborates the data which is available from long-term 
cohort studies, such as the SOS study, with biochemical data. 
 
CONCLUSION 
The results of this study showed that LRYGB, in addition to the short- and mid-
term follow-up data from the literature, affords long-term remission of T2DM as well as 
a decrease in HT and DL. All patients seem to benefit in terms of better glucose 
regulation and lower medication use. Individual predictors for the remission of T2DM 
were lower pre-operative HbA1c level and shorter duration of T2DM in the medical 
history. The limited rate of follow-up in this study may be responsible for either an over- 
or underestimation of this long-term effect and needs to be researched further.  
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ABSTRACT 
Background & aims 
Roux-en-Y gastric bypass (RYGB) is an effective treatment for obesity. However, it also 
leads to multiple nutritional deficiencies. Much is known about the short term prevalence, but 
hardly any long term data is available on deficiencies. The aim of this study was to assess the 
long term outcome of nutritional status after RYGB. 
 
Methods 
We performed a retrospective analysis of prospectively collected data obtained from 51 
morbidly obese patients who underwent a primary laparoscopic RYGB. Primary outcomes 
were iron, vitamin B12 and vitamin D deficiencies. Secondary outcomes were deficiencies of 
other vitamins and minerals and compliance of the patients to multivitamin use. 
 
Results 
The mean follow-up was 81 ± 27 months. A total of 35%, 16% and 55% of the patients 
had deficiencies for iron, vitamin B12 and vitamin D respectively. Sixty-nine percent of patients 
used a (nonspecific) multivitamin supplement on a daily basis. Patients with multivitamin usage 
had a lower rate of iron deficiency (26% vs. 56%, p = 0.034), vitamin B12 (11% vs. 25%, 
p = 0.46) and vitamin D (46% vs. 75%, p = 0.07), compared to non-compliant patients. 
 
Conclusions 
Nutritional deficiencies are common after a RYGB operation. Therefore, strict follow-up 
by a bariatric surgeon, endocrinologist or general practitioner is required, both short and long 
term. 
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INTRODUCTION 
The Roux-en-Y gastric bypass (RYGB) is one of the most frequently performed 
surgical procedures to induce sustained weight loss in morbidly obese patients.
1
 In 
addition, it is an effective treatment to reduce obesity-related co-morbidities such as 
Type 2 Diabetes Mellitus (T2DM), hypertension and obstructive sleep apnoea 
syndrome.
2-5
 However, due to alterations in the gastrointestinal tract after a RYGB 
procedure, patients are prone to develop nutritional deficiencies. These deficiencies 
can lead to serious hematological (i.e. anemia, leucopenia, thrombocytopenia), 
neurological (i.e. myeloneuropathy, Wernicke encephalopathy, paresthesia), and 
musculoskeletal (i.e. osteoporosis, bone pain, fractures) complications.
6
 Most reported 
vitamin and mineral deficiencies are for iron (47–66%), vitamin B12 (37–50%), folate 
(15–38%), vitamin D (20–51%) and calcium (±10%).
7-17
 Although there are numerous 
reports on deficiencies after RYGB, most only have a limited follow-up period and long-
term follow-up studies are scarce.
18-21
 Daily use of multivitamin and mineral 
supplements is generally recommended to prevent post-surgical deficiencies.
22
 
Nevertheless it is often observed that patients' compliance to chronic use of 
medications drops over time. Additionally, patients lost to follow up most often not only 
have worse weight loss compared to other patients, but also experience more 
deficiencies. 
The aim of this study was to assess the long-term nutritional status of morbidly 
obese patients who were initially lost to follow-up after laparoscopic RYGB (LRYGB), 
and also to evaluate the prevalence of deficiencies in patients who were compliant to 
multivitamin use compared to non-compliant patients. 
 
MATERIALS AND METHODS 
Patient selection and outcome 
Adult patients (age > 18 years) who underwent a primary LRYGB between 
January 2000 and December 2008 for severe obesity (BMI > 35 kg/m
2
) or morbid 
obesity (BMI > 40 kg/m2) according to international guidelines
23
 with T2DM were 
invited to our outpatient clinic for a long-term follow-up visit. Patients were invited by a 
letter, followed by a reminder letter after no response. Finally, when patients still had 
not shown, they were contacted by phone and invited for the additional visit. 
Patients with T2DM enroll a strict follow-up program by the endocrinologist, 
including extensive laboratory tests. The invited (study) patients followed this regular 
CHAPTER 7 
 
126 
ABSTRACT 
Background & aims 
Roux-en-Y gastric bypass (RYGB) is an effective treatment for obesity. However, it also 
leads to multiple nutritional deficiencies. Much is known about the short term prevalence, but 
hardly any long term data is available on deficiencies. The aim of this study was to assess the 
long term outcome of nutritional status after RYGB. 
 
Methods 
We performed a retrospective analysis of prospectively collected data obtained from 51 
morbidly obese patients who underwent a primary laparoscopic RYGB. Primary outcomes 
were iron, vitamin B12 and vitamin D deficiencies. Secondary outcomes were deficiencies of 
other vitamins and minerals and compliance of the patients to multivitamin use. 
 
Results 
The mean follow-up was 81 ± 27 months. A total of 35%, 16% and 55% of the patients 
had deficiencies for iron, vitamin B12 and vitamin D respectively. Sixty-nine percent of patients 
used a (nonspecific) multivitamin supplement on a daily basis. Patients with multivitamin usage 
had a lower rate of iron deficiency (26% vs. 56%, p = 0.034), vitamin B12 (11% vs. 25%, 
p = 0.46) and vitamin D (46% vs. 75%, p = 0.07), compared to non-compliant patients. 
 
Conclusions 
Nutritional deficiencies are common after a RYGB operation. Therefore, strict follow-up 
by a bariatric surgeon, endocrinologist or general practitioner is required, both short and long 
term. 
  
LONG-TERM NUTRITIONAL STATUS 
  127 
INTRODUCTION 
The Roux-en-Y gastric bypass (RYGB) is one of the most frequently performed 
surgical procedures to induce sustained weight loss in morbidly obese patients.
1
 In 
addition, it is an effective treatment to reduce obesity-related co-morbidities such as 
Type 2 Diabetes Mellitus (T2DM), hypertension and obstructive sleep apnoea 
syndrome.
2-5
 However, due to alterations in the gastrointestinal tract after a RYGB 
procedure, patients are prone to develop nutritional deficiencies. These deficiencies 
can lead to serious hematological (i.e. anemia, leucopenia, thrombocytopenia), 
neurological (i.e. myeloneuropathy, Wernicke encephalopathy, paresthesia), and 
musculoskeletal (i.e. osteoporosis, bone pain, fractures) complications.
6
 Most reported 
vitamin and mineral deficiencies are for iron (47–66%), vitamin B12 (37–50%), folate 
(15–38%), vitamin D (20–51%) and calcium (±10%).
7-17
 Although there are numerous 
reports on deficiencies after RYGB, most only have a limited follow-up period and long-
term follow-up studies are scarce.
18-21
 Daily use of multivitamin and mineral 
supplements is generally recommended to prevent post-surgical deficiencies.
22
 
Nevertheless it is often observed that patients' compliance to chronic use of 
medications drops over time. Additionally, patients lost to follow up most often not only 
have worse weight loss compared to other patients, but also experience more 
deficiencies. 
The aim of this study was to assess the long-term nutritional status of morbidly 
obese patients who were initially lost to follow-up after laparoscopic RYGB (LRYGB), 
and also to evaluate the prevalence of deficiencies in patients who were compliant to 
multivitamin use compared to non-compliant patients. 
 
MATERIALS AND METHODS 
Patient selection and outcome 
Adult patients (age > 18 years) who underwent a primary LRYGB between 
January 2000 and December 2008 for severe obesity (BMI > 35 kg/m
2
) or morbid 
obesity (BMI > 40 kg/m2) according to international guidelines
23
 with T2DM were 
invited to our outpatient clinic for a long-term follow-up visit. Patients were invited by a 
letter, followed by a reminder letter after no response. Finally, when patients still had 
not shown, they were contacted by phone and invited for the additional visit. 
Patients with T2DM enroll a strict follow-up program by the endocrinologist, 
including extensive laboratory tests. The invited (study) patients followed this regular 
C
ha
pt
er
 7
CHAPTER 7 
 
128 
follow-up schedule. We obtained approval of the local board of ethics, although the 
study was a part of a regular follow-up protocol. The procedures followed were in 
accordance with the ethical standards the Helsinki Declaration of 1975 as revised in 
1983. 
Surgical procedure: An antecolic antegastric bypass was performed using a 
small gastric pouch of 30–50 ml and a fixed biliopancreatic limb (BPL) of 50 cm. 
Patients with a BMI <50 kg/m
2
 received a Roux limb of approximately 100 cm and 
patients with a BMI >50 kg/m
2
 received a Roux limb of 150 cm. All procedures were 
performed by two experienced bariatric surgeons. 
The patients were selected from our prospectively collected database (Windows 
Excess 2000). Operation type and date, medical history, height (cm), weight (kg), BMI 
(kg/m
2
), weight loss expressed in percentage Excess Weight Loss (% EWL; defined 
as weight loss divided by excess weight based on BMI 25 kg/m
2
; formula: ((pre-
operative body weight − post-operative body weight)/(pre-operative body weight − ideal 
body weight)) × 100%) and percentage Total Body Weight Loss (% TWBL; defined as 
weight loss divided by pre-operative body weight; formula: ((pre-operative body weight 
− post-operative body weight)/(pre-operative body weight) × 100%)), medication and 
multivitamin use, and laboratory tests were recorded at regular follow-up appointments.  
Regular follow-up was performed at 2, 3, 6, 9, 12, 18 and 24 months 
postoperatively. After 24 months, follow-up was conducted annually. Standard 
laboratory blood testing was performed preoperatively consisting of a complete blood 
count (XN-10 and XN-20, Sysmex Nederland B.V., The Netherlands), a mean cell 
volume (MCV) measured by hydrodynamic focusing (XN-10 and XN-20, Sysmex 
Nederland B.V., The Netherlands). Post-operative laboratory blood testing included 
hemoglobin (Hb) measured by colorimetric test (XN-10 and XN-20, Sysmex Nederland 
B.V., The Netherlands); MCV measured by hydrodynamic focusing (XN-10 and XN-20, 
Sysmex Nederland B.V., The Netherlands); iron, albumin, phosphate and magnesium 
measured by colorimetric test (Modular P800, Roche, Almere, The Netherlands); total-
iron-binding-capacity (TIBC) is calculated via transferrin and measured by 
immunometric method (Modular P800, Roche, Almere, The Netherlands), ferritin, 
folate, vitamin B12, 25-hydroxyvitamin D (25-OHD) measured by 
electrochemiluminescence method (Modular E170, Roche, Almere, The Netherlands); 
parathyroid hormone (PTH) measured by chemiluminescence method (Immulite 2000 
XPi, Siemens, The Netherlands); calcium measured by colorimetric test (BAPTA buffer, 
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Modular P800, Roche, Almere, The Netherlands); vitamin A analyzed on an HPLC with 
UV–vis detector (Shimadzu Corporation, Japan); vitamin B1 analyzed on a HPLC with 
fluorescence detector (Shimadzu Corporation, Japan); vitamin B6 analyzed on a HPLC 
with fluorescence detector (Shimadzu Corporation, Japan); zinc analyzed by 
inductively coupled plasma mass spectrometry (Shimadzu Corporation, Japan). 
The primary endpoint was the long-term nutritional status (deficiencies). The 
lower limit of normal was used to define deficiencies (normal ranges are presented in 
Table 1). Anemia was defined using Hb level, and ferritin levels for iron deficiency (ID). 
Patients were subdivided into two groups: those who were still using multivitamin 
supplements at the follow-up visit (compliant) and those who did not (non-compliant). 
Type of multivitamin and amount of daily use were recorded based on questionnaires. 
Compliance was defined as reported use of multivitamin supplements on a daily basis, 
for at least 6 days a week. 
 
Statistical analysis 
Data were analyzed using IBM® SPSS® (version 20.0 for Windows). Results 
are presented as mean values ± standard deviation (SD) and range for normally 
distributed continuous data and median and inter-quartile range for skewed continuous 
data. Data normality was verified by both visual inspection and Shapiro Wilk testing. 
Differences between groups were tested using the unpaired t-test or the Mann–
Whitney U test, as appropriate. The paired t-test or Wilcoxon signed ranks test was 
used to assess differences within groups. Categorical data are presented as 
frequencies and percentages and differences between groups are tested using the Chi 
square test or Fisher exact test. A p < 0.05 was considered significant. 
 
RESULTS 
Eighty-nine patients were invited for a long-term regular outpatient follow-up visit. 
Twenty-five patients did not respond and 13 patients refused renewed follow-up for 
personal reasons. Fifty-one out of 89 (57.3%) patients agreed to participate and all 
were eligible for analysis. Thirty patients were female (58.8%). Patients had a mean 
age of 47.6 ± 9.7 years, a baseline weight of 140.1 ± 21.7 kg and a BMI of 46.3 ± 6.2 
kg/m
2
. The mean post-operative follow-up period was 81.4 ± 27.1 months. 
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Nutritional status and patients' compliance 
Forty-one (80.4%) patients used a supplement at least occasionally for the 
prevention and treatment of nutritional deficiencies, including multivitamin, iron, vitamin 
B12, cholecalciferol and/or calcium. Thirty-five (68.6%) patients were still using their 
multivitamin supplements at the last follow-up visit and were categorized as compliant 
patients. Sixteen (31.4%) patients were categorized as non-compliant. 
Compliant patients used eight different commercially available multivitamin 
supplements. Only one of them was an optimized multivitamin supplement for bariatric 
surgery used by four patients. This supplement contained vitamin B12 of 350 mcg (14 
000% recommended daily allowance [RDA]), folate of 600 mcg (300% RDA), iron of 
70 mg (500% RDA), vitamin B1 of 2.75 mg (250% RDA) and vitamin B6 of 2.8 mg 
(150% RDA) per tablet for usage of one tablet daily. All other (standard) multivitamin 
supplements contained vitamin B12 of 1–3 mcg (40%–120% RDA), folate of 100–200 
mcg (50%–100% RDA), iron of 2.5–14 mg (18%–100% RDA), vitamin B1 of 0.6–3.3 
mg (50%–300% RDA) and vitamin B6 of 0.7–2.1 mg (50%–150% RDA) per tablet. Half 
of the patients used one tablet per day, the other half used the multivitamin twice daily. 
The laboratory results at the last follow-up are summarized in Table 1, Table 2a 
and 2b. Five (9.6%) patients had normocytic anemia preoperatively. At the last follow-
up visit, anemia was present in 12 (23.5%) patients, in six (17.1%) compliant patients 
and in six (37.5%) non-compliant patients (p = 0.11). None of the patients had used 
additional iron supplements. In seven patients, anemia was attributed to an iron 
deficiency (ID). Eleven additional patients had ID without anemia, meaning that 
eighteen patients had ID in total (35.3%). ID was more frequent in non-compliant than 
in compliant patients (56.3% vs. 25.7%, p = 0.034). 
The median serum vitamin B12 level was 348 [IQR 230–525] pmol/L. Eight 
(15.7%) patients had vitamin B12 deficiency, i.e. four (11.4%) in the compliant group 
and four (25%%) in the non-compliant group (p = 0.46). One of these patients used 
additional vitamin B12 medication (orally) at the moment of laboratory test. Additionally, 
nineteen (37.3%) patients had started additional vitamin B12 supplementation after 
being diagnosed with a deficiency in the years after RYGB (commonly vitamin B12 
injections for intra-muscular use). Thus in total 27 (52.9%) patients had developed 
vitamin B12 deficiency after the RYGB. Patients taking additional vitamin B12 
medication had a significantly higher serum vitamin B12 level compared to patients 
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without additional medication (median 533.5 [IQR 339.3–1063.8] pmol/vs. median 
260.0 [IQR 213–378] pmol/L; p < 0.0001). 
 
Table 1. Laboratory blood tests and number of deficiencies at the end of follow-up in total study 
group 
 Normal 
range 
No. of 
patients 
Blood 
levels 
SD/ IQR Range No. of 
def. 
% 
deficiencies 
Haemoglobin 
(mmol/L) 
F: 7.4-9.9 
M: 8.4-10.8 
51 8.4 ±0.96 6.4 - 10.7 12 23.5 
Ferritin (μg/L) 20-200 51 47
a 
13 - 81 5.0 -350.0 18 35.3 
Folate (nmol/L) 9.0-36.0 49 24.6 ±10.0 8.0 - 45.3 1 2.0 
Vitamin B12 
(pmol/L) 
200-640 51 348
a 
230 - 525 83 – 1476 8 15.7 
Vitamin D 
(nmol/L) 
>50 51 47.2 ±26.1 5 - 115 28 54.9 
Parathyroid 
hormone 
(pmol/L) 
1.3-6.8 51 7.6 ±10.1 1.6 – 74.9 0 0 
Calcium 
(mmol/L) 
2.10-2.55 50 2.32 ±0.09 2.11 – 2.57 0 0 
Albumin (g/l) 35-50 50 38
a 
36.8 - 40 28 – 43 4 8.0 
Magnesium 
(mmol/L) 
0.71-0.93 49 0.79 ±0.07 0.60 – 0.92 6 12.2 
Phosphate 
(mmol/L) 
0.87-1.45 49 1.00 ±0.19 0.60 – 1.60 10 20.4 
Zinc (μmol/L) 9.2-18.4 43 12.4 ±1.4 9.3 – 14.8 0 0 
Vitamin A 
(μmol/L) 
1.05-2.80 38 1.98 ±0.85 0.46 – 3.71 6 15.8 
Vitamin B1 
(nmol/L) 
95-175 48 164.1 ±44.5 91.0 - 291.0 1 2.1 
Vitamin B6 
(nmol/L) 
25-100 47 78* 57.0 – 
114.0 
31.0 – 
1561.0 
0 0 
aValues are numbers (%), mean ± standard deviation (SD) for normal distributed variable, otherwise reflected as 
median (inter-quartile ranges (IQR) p25–p75) 
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vitamin B12 deficiency after the RYGB. Patients taking additional vitamin B12 
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without additional medication (median 533.5 [IQR 339.3–1063.8] pmol/vs. median 
260.0 [IQR 213–378] pmol/L; p < 0.0001). 
 
Table 1. Laboratory blood tests and number of deficiencies at the end of follow-up in total study 
group 
 Normal 
range 
No. of 
patients 
Blood 
levels 
SD/ IQR Range No. of 
def. 
% 
deficiencies 
Haemoglobin 
(mmol/L) 
F: 7.4-9.9 
M: 8.4-10.8 
51 8.4 ±0.96 6.4 - 10.7 12 23.5 
Ferritin (μg/L) 20-200 51 47
a 
13 - 81 5.0 -350.0 18 35.3 
Folate (nmol/L) 9.0-36.0 49 24.6 ±10.0 8.0 - 45.3 1 2.0 
Vitamin B12 
(pmol/L) 
200-640 51 348
a 
230 - 525 83 – 1476 8 15.7 
Vitamin D 
(nmol/L) 
>50 51 47.2 ±26.1 5 - 115 28 54.9 
Parathyroid 
hormone 
(pmol/L) 
1.3-6.8 51 7.6 ±10.1 1.6 – 74.9 0 0 
Calcium 
(mmol/L) 
2.10-2.55 50 2.32 ±0.09 2.11 – 2.57 0 0 
Albumin (g/l) 35-50 50 38
a 
36.8 - 40 28 – 43 4 8.0 
Magnesium 
(mmol/L) 
0.71-0.93 49 0.79 ±0.07 0.60 – 0.92 6 12.2 
Phosphate 
(mmol/L) 
0.87-1.45 49 1.00 ±0.19 0.60 – 1.60 10 20.4 
Zinc (μmol/L) 9.2-18.4 43 12.4 ±1.4 9.3 – 14.8 0 0 
Vitamin A 
(μmol/L) 
1.05-2.80 38 1.98 ±0.85 0.46 – 3.71 6 15.8 
Vitamin B1 
(nmol/L) 
95-175 48 164.1 ±44.5 91.0 - 291.0 1 2.1 
Vitamin B6 
(nmol/L) 
25-100 47 78* 57.0 – 
114.0 
31.0 – 
1561.0 
0 0 
aValues are numbers (%), mean ± standard deviation (SD) for normal distributed variable, otherwise reflected as 
median (inter-quartile ranges (IQR) p25–p75) 
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Table 2a. Laboratory results in compliant and non-compliant patients for multivitamin 
supplements  
 Compliant 
patients 
SD/IQR Range Non-
compliant 
patients 
SD/IQR Range p-value 
Haemoglobin 
(mmol/L) 
8.5 ±0.85 6.6 – 10.7 8.1 ±1.17 6.4 – 9.6 0.28 
MCV (fL) 89.9 ±5.23 78 – 99  88.2 ±6.07 77 – 100 0.30 
Iron (μmol/L) 14.1 ±5.40 3.1 – 28.2  12.7 ±4.62 4.0 – 22.0 0.38 
Ferritin (μg/L)
a 
55 15 -95  10 – 350 17.5 12.3 – 66.8  5 – 142 0.161 
TIBC (μmol/L, 
45-81) 
65.5 ±11.28 39 – 87 73.2 ±11.39 55 – 100 0.03 
Folate 
(nmol/L) 
27.6 ±9.5 12.0 – 45.3 17.1 ±6.57 8.0 – 29.5 <0.0001 
Vitamin B12 
(pmol/L)
a 
412.0 276 – 542  142 – 1476 239.5 198.8 – 
371.3 
83 – 1401 0.016 
Vitamin D 
(nmol/L) 
54.9 ±23.8 17 – 115 30.3 ±23.3 5 – 90  0.001 
PTH (pmol/L) 5.9 ±2.86 1.6 – 13.9 11.5 ±17.2 2.0 – 74.9 0.22 
Calcium 
(mmol/L) 
2.32 ±0.09 2.11 – 2.51 2.33 ±0.09 2.20 – 2.57 0.921 
Albumin (g/l)
a 
38 37 – 40  29 – 43 38 36 – 40  28 – 42  0.881 
Vitamin A 
(μmol/L) 
1.9 ±0.89 0.46 – 3.64 2.3 ±0.72 1.16 – 3.71 0.185 
Vitamin B1 
(nmol/L) 
175.5 ±44.7 103 – 291 133.5 ±26.50 91 – 175 0.003 
Vitamin B6 
(nmol/L)
a 
88.5 70.8 – 
121.0 
48 – 1561 52 45.5 – 67  31 – 106 <0.0001 
Zinc (μmol/L) 12.3 ±1.48 9.3 – 14.8 12.7 ±0.92 11.2 – 14.4 0.372 
Phosphate 
(mmol/L) 
0.99 ±016 0.60 – 1.28 1.04 ±0.25 0.74 – 1.60 0.464 
Magnesium 
(mmol/L) 
0.79 ±0.08 0.60 – 0.92 0.79 ±0.06 0.69 – 0.87 0.920 
MCV: mean cell volume, TIBC: total-iron-binding capacity, PTH: parathyroid hormone 
A p-value <0.05 was considered significant 
aValues are mean ± standard deviation (SD) for normal distributed variable, otherwise reflected as median (inter-
quartile ranges (IQR) p25–p75) 
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Table 2b. Number of deficiencies at the end of follow-up for compliant and non-compliant 
patients 
  Compliant patients Non-compliant patients  
 Overall no. 
of patients 
No. of 
deficiencies 
% No. of 
deficiencies 
%   P-
value 
Haemoglobin  51 6 17.1 6 37.5 0.112 
Ferritin  51 9 25.7 9 56.3 0.034 
Folate  49 0 0 1 7.1 0.341 
Vitamin B12  51 4 11.4 4 25.0 0.404 
Vitamin D  51 16 45.7 12 75 0.051 
Parathyroid hormone  51 0 0 0 0 - 
Calcium 50 0 0 0 0 - 
Albumin  50 3 8.6 1 6.7 1.000 
Magnesium  49 5 14.3 1 7.1 0.659 
Phosphate  49 5 14.3 5 35.7 0.108 
Zinc  43 0 0 0 0 - 
Vitamin A  38 6 22.2 0 0 0.150 
Vitamin B1  48 0 0 1 7.7 0.433 
Vitamin B6  47 0 0 0 0 - 
A p-value <0.05 was considered significant 
 
Vitamin D deficiency was diagnosed in 28 (54.9%) patients, including 16 
(45.7%) patients within the compliant group and 12 (75%) non-compliant patients 
(p = 0.07). Seven (13.7%) patients used vitamin D supplements (oral cholecalciferol) 
in addition to the multivitamin supplements, and two of them had vitamin D deficiency. 
The mean serum 25-OHD tended to be somewhat higher for patients with additional 
vitamin D supplementation compared to non-users (62.4 ± 37.2 (range 11–109) nmol/L 
vs. 44.3 ± 23.0 (range 5–115) nmol/L; p = 0.22). No hypocalcemia was found at the 
last follow-up visit. Twenty-four (47.1%) patients used calcium tablets or sachets (with 
or without cholecalciferol). Elevated PTH levels were found in seven (43.8%) non-
compliant patients compared to ten (28.6%) compliant patients (p = 0.286). 
 
Weight and nutritional status 
Both mean weight (−36.9 ± 15.8 kg) and BMI (−12.2 ± 5.1 kg/m
2
) were 
significantly reduced (p < 0.0001) compared to baseline. Overall mean %EWL was 
59.9 ± 24.5% and %TBWL was 26.3 ± 10.2%, at the last follow-up. Thirty-one (60.8%) 
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Table 2b. Number of deficiencies at the end of follow-up for compliant and non-compliant 
patients 
  Compliant patients Non-compliant patients  
 Overall no. 
of patients 
No. of 
deficiencies 
% No. of 
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value 
Haemoglobin  51 6 17.1 6 37.5 0.112 
Ferritin  51 9 25.7 9 56.3 0.034 
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Vitamin B1  48 0 0 1 7.7 0.433 
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A p-value <0.05 was considered significant 
 
Vitamin D deficiency was diagnosed in 28 (54.9%) patients, including 16 
(45.7%) patients within the compliant group and 12 (75%) non-compliant patients 
(p = 0.07). Seven (13.7%) patients used vitamin D supplements (oral cholecalciferol) 
in addition to the multivitamin supplements, and two of them had vitamin D deficiency. 
The mean serum 25-OHD tended to be somewhat higher for patients with additional 
vitamin D supplementation compared to non-users (62.4 ± 37.2 (range 11–109) nmol/L 
vs. 44.3 ± 23.0 (range 5–115) nmol/L; p = 0.22). No hypocalcemia was found at the 
last follow-up visit. Twenty-four (47.1%) patients used calcium tablets or sachets (with 
or without cholecalciferol). Elevated PTH levels were found in seven (43.8%) non-
compliant patients compared to ten (28.6%) compliant patients (p = 0.286). 
 
Weight and nutritional status 
Both mean weight (−36.9 ± 15.8 kg) and BMI (−12.2 ± 5.1 kg/m
2
) were 
significantly reduced (p < 0.0001) compared to baseline. Overall mean %EWL was 
59.9 ± 24.5% and %TBWL was 26.3 ± 10.2%, at the last follow-up. Thirty-one (60.8%) 
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patients had an %EWL of >50% (‘successful’), while 48 (94.1%) patients had an 
‘acceptable’ %EWL of >25%.
24 
Patients with successful weight reduction (n = 25; 80.6%) were more often 
compliant to multivitamin use than ‘unsuccessful’ patients (n = 10; 50%; p = 0.02). 
Patients with an EWL>50% had significantly higher 25-OHD levels (53.6 ± 25.7 (range 
11–115) nmol/L) than patients with an EWL<50% (37.2 ± 24.0 (range 5–109) nmol/L; 
p = 0.027). No significant differences were found for other vitamins and minerals. 
 
Hypervitaminosis vitamin B1 and B6 
The mean serum level of vitamin B1 was significantly higher in compliant 
patients than in non-compliant patients (175.5 ± 44.7 (range 103–291) nmol/L vs. 
133.5 ± 26.5 (range 91–175) nmol/L; p = 0.003). Additionally, hypervitaminosis of 
vitamin B1 was more common in compliant group (18 (51.4%) vs. 0 (0%), p = 0.002). 
The mean serum level of vitamin B6 for the compliant group was 88.5 [IQR 70.8–
121.0] (range 48–1561) nmol/L, while the non-compliant group had a serum level of 52 
[45.5–67] (range 31–106) nmol/L (p < 0.0001). Thirteen (38.2%) vitamin users had 
hypervitaminosis of vitamin B6 compared to one (7.7%) non-compliant patient 
(p = 0.072). 
There was no significant difference in mean serum levels of vitamin A for 
patients with (1.9 ± 0.7 (range 0.46–3.64) μmol/L) and without multivitamin 
supplements (2.3 ± 0.9 (range 1.16–3.71) μmol/L; p = 0.19). The number of patients 
suffering hypervitaminosis for vitamin A was four (14.8%) in vitamin users compared 
to two (18.2%) non-compliant patients (p = 0.23). 
 
DISCUSSION 
It is known that patients who have undergone bariatric surgery are prone to 
develop nutritional deficiencies.
6-19
 This can lead in worst case scenarios to serious 
irreversible complications such as blindness, encephalopathy and osteoporosis.
6
 Use 
of (specialized) multivitamin supplements after RYGB surgery seems to be an 
important factor in managing these deficiencies. Therefore, multivitamin 
supplementation on a daily basis is advised in all bariatric guidelines.
6,22
 Some 
deficiencies, however, may be revealed many years after operation, making lifelong 
intake a necessity. The present study showed deficiencies of iron in 35%, vitamin B12 
in 16% and vitamin D in 55% of patients after a mean 81 months. 
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Anemia and related deficiencies 
In the current study, approximately a quarter of the patients had anemia at the 
last follow-up visit (mean 81 months). The reported prevalence of anemia after RYGB 
surgery in the literature varies from 20 to 50% after wide period of 12–120 months.
7,18-
21,25-27
 Patients developing anemia after RYGB operation, usually have iron, vitamin 
B12 or folate deficiency.
2,7,9,17,21,25-27
 Several studies reported that anemia and the 
related deficiencies were already present in a huge amount of patients prior to their 
operation. This suggest that anemia detected during the first post-operative year after 
RYGB may be related to the pre-operatively existing deficiencies.
7,25-28
 Weng 
et al.
25
 reported in a systematic review twofold increase of anemia after 12 months of 
surgery. In line with this review, Van der Beek et al.
28
 illustrated significantly higher 
incidence of deficiencies in pre-operatively deficit patients compared to patients without 
deficiency. However, pre-operative deficiencies may not influence the nutritional status 
on the long term which is observed in this study. Impairment in several anatomic and 
functional mechanisms after a RYGB operation may decline the absorbability of iron 
and vitamin B12, even on the long term. Iron deficiency after a RYGB is due to a 
combination of factors. Iron absorption is dependent on the pH of the stomach and 
uptake usually takes place through the intestinal wall of the duodenum and proximal 
part of the jejunum. The passage of iron through the small gastric pouch is too fast, 
while duodenum and jejunum are bypassed in gastric bypass surgery. Additionally, 
patient changes their dietary behavior with reduced caloric intake. Therefore, a higher 
intake of iron is usually needed to overcome these post-surgical impairments in iron 
absorption capacity. However, anemia may still persist after reduction of iron deficiency 
in gastric bypass patients.
27
 This is probably due to the reduced availability of vitamin 
B12. Vitamin B12 is less available after RYGB due to the exclusion of the distal 
stomach, the site of the production of intrinsic factor, which is required for the uptake 
of vitamin B12 in the distal ileum. The available literature regarding post-operative 
vitamin B12 deficiency demonstrates a prevalence varying from 10% to 60%.
7,17-19
 
Next to megaloblastic anemia, vitamin B12 deficiency can cause serious co-morbidities 
such as ataxia, optic atrophy, memory loss, and weakness, which reduce the quality 
of life of these patients.
6
 The low percentage of vitamin B12 deficiencies in this study 
is due to the fact that 37% of the study group already used additional vitamin B12 
medication due to deficiencies diagnosed in an earlier stage. This indicates that 
additional supplementation of vitamin B12 is important and that a standard multivitamin 
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‘acceptable’ %EWL of >25%.
24 
Patients with successful weight reduction (n = 25; 80.6%) were more often 
compliant to multivitamin use than ‘unsuccessful’ patients (n = 10; 50%; p = 0.02). 
Patients with an EWL>50% had significantly higher 25-OHD levels (53.6 ± 25.7 (range 
11–115) nmol/L) than patients with an EWL<50% (37.2 ± 24.0 (range 5–109) nmol/L; 
p = 0.027). No significant differences were found for other vitamins and minerals. 
 
Hypervitaminosis vitamin B1 and B6 
The mean serum level of vitamin B1 was significantly higher in compliant 
patients than in non-compliant patients (175.5 ± 44.7 (range 103–291) nmol/L vs. 
133.5 ± 26.5 (range 91–175) nmol/L; p = 0.003). Additionally, hypervitaminosis of 
vitamin B1 was more common in compliant group (18 (51.4%) vs. 0 (0%), p = 0.002). 
The mean serum level of vitamin B6 for the compliant group was 88.5 [IQR 70.8–
121.0] (range 48–1561) nmol/L, while the non-compliant group had a serum level of 52 
[45.5–67] (range 31–106) nmol/L (p < 0.0001). Thirteen (38.2%) vitamin users had 
hypervitaminosis of vitamin B6 compared to one (7.7%) non-compliant patient 
(p = 0.072). 
There was no significant difference in mean serum levels of vitamin A for 
patients with (1.9 ± 0.7 (range 0.46–3.64) μmol/L) and without multivitamin 
supplements (2.3 ± 0.9 (range 1.16–3.71) μmol/L; p = 0.19). The number of patients 
suffering hypervitaminosis for vitamin A was four (14.8%) in vitamin users compared 
to two (18.2%) non-compliant patients (p = 0.23). 
 
DISCUSSION 
It is known that patients who have undergone bariatric surgery are prone to 
develop nutritional deficiencies.
6-19
 This can lead in worst case scenarios to serious 
irreversible complications such as blindness, encephalopathy and osteoporosis.
6
 Use 
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is completely insufficient to prevent vitamin B12 deficiency. Due to this substantial 
incidence of iron and vitamin B12 deficiency, the American Society for Metabolic and 
Bariatric Surgery (ASMBS) guideline advises daily use of additional iron of 45–60 mg 
orally and vitamin B12 of 1000 mcg orally.
22
 Additionally, regular follow-up on the long 
term is required to detect iron and vitamin B12 deficiencies in an early phase. 
 
Vitamin D deficiency 
Vitamin D deficiency is one of the most commonly reported deficiencies in obese 
and bariatric patients. Obesity itself is associated with vitamin D deficiency as a result 
of several factors, including low exposure to sunlight, lack of vitamin D consumption 
and sequestration of vitamin D in adipose tissue.
29,30
 Deficit vitamin D is related to 
decreased bone density, osteoporosis, an increased risk of fractures, muscle 
weakness or bone pain.
6
 In the present study, 55% of the patients had vitamin D 
deficiency. In the literature, the short term prevalence of vitamin D depletion was 
demonstrated to be 58% preoperatively and 42% one year postoperatively.
31
 Long 
term results on vitamin D deficiency are scarce and vary between 24% and 65%.
18,19,32
 
In this study a significantly higher 25-OHD level was found in patients with 
increased %EWL. Carlin et al.
29
 support this finding and suggest that this may be due 
to better compliance with diet and vitamin supplements and because of a greater 
reduction in adiposity resulting in increased vitamin D availability. Calcium absorption 
is associated with 25-OHD levels and occurs in the duodenum and proximal jejunum. 
Since this part of the intestine is excluded by performing a RYGB, morbidly obese 
patients are also prone to develop calcium deficiency. Long-term results on calcium 
status in the literature show deficiencies in around 2% in patients after RYGB, which is 
consistent with the present study.
18,19
 Because of these deficiencies, additional calcium 
citrate of 1200–1500 mg per day and vitamin D of 3000 IU per day is advised in the 
ASMBS guidelines.
22
 
 
Hypervitaminosis 
Post-operative use of vitamin and mineral supplements is widely advised in 
bariatric patients to prevent serious co-morbidities as described above. Nevertheless, 
with the introduction of a multivitamin supplementation after bariatric surgery a new 
phenomenon was observed: hypervitaminosis. This is probably due to use of 
multivitamin use rather than the operations itself. Hypervitaminosis is also observed in 
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patients after biliopancreatic diversion (with or without duodenal switch), which are 
malabsorptive procedures and associated with severe nutritional deficiencies.
33
 The 
consequences of hypervitaminosis may be just as important as deficiencies; however, 
the clinical symptoms are rare or hard to recognize. For example, low serum vitamin 
B1 levels are associated with neurological abnormalities (i.e. Wernicke 
encephalopathy).
6
 And the most common symptom of vitamin B6 hypervitaminosis is 
progressive neuropathy, since vitamin B6 plays a role in neurotransmitter synthesis.
34
 
In this study, serum vitamin B1 was most frequently elevated (51%) whereas vitamin 
B1 was deficient in only one (2%) patient. Furthermore, hypervitaminosis of vitamin B6 
was seen in 14 (30%) patients in the present study, while no deficiencies of vitamin B6 
were observed. 
 
Compliance and multivitamin supplements 
This study confirms that differentiated vitamin and mineral supplement regimes 
are necessary to prevent nutritional complications after bariatric surgery, especially in 
the long term. Despite a high compliance rate for regular supplements, high prevalence 
of nutritional deficiencies was observed. Regular supplements contain lower dosages 
of the vitamins and minerals advised in the ASMBS guidelines.
22
 Therefore, regular 
supplements are insufficient to prevent these deficiencies. However, it is difficult to 
determine the optimal dosage of the supplements based on the present research 
(being a descriptive study). Recent randomized clinical trial showed that an optimized 
multivitamin supplement can reduce iron and vitamin B12 deficiencies after RYGB 
surgery.
35
 This multivitamin supplement is effective up to 3 years after the operation.
36
 
However, additional prospective studies are needed to determine how to optimize 
nutritional deficiencies postoperatively in the long term, both for the specific nutrients 
as for the type of bariatric surgery and for the compliance status of patients. Obesity 
itself is accompanied by several deficiencies, and therefore pre-operative screening 
and treatment are advised to reduce post-surgical complications. Hence, lifelong 
compliance of patients to multivitamin regimes is hard to achieve, with underestimation 
of the sometimes severe consequences of deficiencies by both patients and 
professionals. Patients with successful weight loss were more compliant to multivitamin 
regimes, probably due to greater self-awareness and the ability to achieve lifestyle 
changes. For some, financial reasons contribute to the cessation of vitamin use, since 
most patients have to pay for their own supplements. Despite these barriers, 
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is completely insufficient to prevent vitamin B12 deficiency. Due to this substantial 
incidence of iron and vitamin B12 deficiency, the American Society for Metabolic and 
Bariatric Surgery (ASMBS) guideline advises daily use of additional iron of 45–60 mg 
orally and vitamin B12 of 1000 mcg orally.
22
 Additionally, regular follow-up on the long 
term is required to detect iron and vitamin B12 deficiencies in an early phase. 
 
Vitamin D deficiency 
Vitamin D deficiency is one of the most commonly reported deficiencies in obese 
and bariatric patients. Obesity itself is associated with vitamin D deficiency as a result 
of several factors, including low exposure to sunlight, lack of vitamin D consumption 
and sequestration of vitamin D in adipose tissue.
29,30
 Deficit vitamin D is related to 
decreased bone density, osteoporosis, an increased risk of fractures, muscle 
weakness or bone pain.
6
 In the present study, 55% of the patients had vitamin D 
deficiency. In the literature, the short term prevalence of vitamin D depletion was 
demonstrated to be 58% preoperatively and 42% one year postoperatively.
31
 Long 
term results on vitamin D deficiency are scarce and vary between 24% and 65%.
18,19,32
 
In this study a significantly higher 25-OHD level was found in patients with 
increased %EWL. Carlin et al.
29
 support this finding and suggest that this may be due 
to better compliance with diet and vitamin supplements and because of a greater 
reduction in adiposity resulting in increased vitamin D availability. Calcium absorption 
is associated with 25-OHD levels and occurs in the duodenum and proximal jejunum. 
Since this part of the intestine is excluded by performing a RYGB, morbidly obese 
patients are also prone to develop calcium deficiency. Long-term results on calcium 
status in the literature show deficiencies in around 2% in patients after RYGB, which is 
consistent with the present study.
18,19
 Because of these deficiencies, additional calcium 
citrate of 1200–1500 mg per day and vitamin D of 3000 IU per day is advised in the 
ASMBS guidelines.
22
 
 
Hypervitaminosis 
Post-operative use of vitamin and mineral supplements is widely advised in 
bariatric patients to prevent serious co-morbidities as described above. Nevertheless, 
with the introduction of a multivitamin supplementation after bariatric surgery a new 
phenomenon was observed: hypervitaminosis. This is probably due to use of 
multivitamin use rather than the operations itself. Hypervitaminosis is also observed in 
LONG-TERM NUTRITIONAL STATUS 
  137 
patients after biliopancreatic diversion (with or without duodenal switch), which are 
malabsorptive procedures and associated with severe nutritional deficiencies.
33
 The 
consequences of hypervitaminosis may be just as important as deficiencies; however, 
the clinical symptoms are rare or hard to recognize. For example, low serum vitamin 
B1 levels are associated with neurological abnormalities (i.e. Wernicke 
encephalopathy).
6
 And the most common symptom of vitamin B6 hypervitaminosis is 
progressive neuropathy, since vitamin B6 plays a role in neurotransmitter synthesis.
34
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22
 Therefore, regular 
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35
 This multivitamin supplement is effective up to 3 years after the operation.
36
 
However, additional prospective studies are needed to determine how to optimize 
nutritional deficiencies postoperatively in the long term, both for the specific nutrients 
as for the type of bariatric surgery and for the compliance status of patients. Obesity 
itself is accompanied by several deficiencies, and therefore pre-operative screening 
and treatment are advised to reduce post-surgical complications. Hence, lifelong 
compliance of patients to multivitamin regimes is hard to achieve, with underestimation 
of the sometimes severe consequences of deficiencies by both patients and 
professionals. Patients with successful weight loss were more compliant to multivitamin 
regimes, probably due to greater self-awareness and the ability to achieve lifestyle 
changes. For some, financial reasons contribute to the cessation of vitamin use, since 
most patients have to pay for their own supplements. Despite these barriers, 
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approximately two-third of the patients used a supplement in the present study. On the 
other hand, patients lost to follow-up (43%) are prone to be non-compliant and not able 
to achieve lifestyle changes. Therefore, this study may underestimate the deficiency 
rate. 
 
Limitations 
Some limitations must be pointed out regarding the present study. First, despite 
several attempts to reach all patients, a substantial lost to follow-up occurred which 
may have influenced the study outcomes, while we know that especially these patients 
do worse in terms of deficiencies.
20
 It is sometimes hard to motivate patients to fill out 
questionnaires and to provide blood samples after several years of operation. 
Therefore, further studies with long term data are needed to detect the risks and 
consequences of bariatric surgery to increase awareness of the patients and to define 
optimal post-bariatric multivitamin supplements. Secondly, collecting data about the 
use of multivitamin supplements were based on the questionnaires and interviews. 
Therefore, the information may have inaccuracies. Finally, it was not possible to 
determine the optimal dosages of the individual vitamins or minerals because patients 
used multiple different multivitamin supplements. 
 
CONCLUSION 
RYGB surgery results in significant sustained weight loss. However, it is 
accompanied by a high rate of nutritional deficiencies, especially of iron, vitamin B12 
and vitamin D. Use of regular multivitamins does not completely prevent these 
deficiencies, since they do not meet the advised dosages in the ASMBS guidelines. 
On the other hand, hypervitaminosis may be observed for some vitamins. Although 
optimal regimes are not yet available, multivitamin supplementation, individualized for 
patients, should be implemented on a permanent basis for all patients after RYGB. 
New criteria to optimize such suppletion therapies should be researched. Bariatric 
surgeons, endocrinologists and general practitioners should be committed to a strict 
lifelong follow-up. 
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ABSTRACT 
Iron, vitamin B12, and folic acid deficiencies are among the most common deficiencies 
occurring after laparoscopic Roux-en-Y gastric bypass (LRYGB). The present study evaluates 
the effectiveness of a specially designed multivitamin supplement (WLS Forte, FitForMe, 
Rotterdam, the Netherlands) specifically developed for LRYGB patients. 
 
A triple-blind, randomized, 12-month study was conducted comparing WLS forte with a 
standard multivitamin supplement (sMVS) containing approximately 100% of the 
recommended daily allowance (RDA) for iron, vitamin B12, and folic acid. WLS Forte contains 
vitamin B12 14000% RDA, iron 500% RDA, and folic acid 300% RDA. 
 
In total, 148 patients (74 in each group) underwent a LRYGB procedure. Baseline 
characteristics were similar for both groups. Per protocol analysis demonstrated that sMVS 
treatment was associated with a decline in ferritin (−24.4 ± 70.1 μg/L) and vitamin B12 
(−45.9 ± 150.3 pmol/L) over 12 months, whereas in WLS Forte patients, ferritin remained stable 
(+3.2 ± 93.2 μg/L) and vitamin B12 increased significantly (+55.1 ± 144.2 pmol/L). The number 
of patients developing ferritin or vitamin B12 deficiency was significantly lower with WLS Forte 
compared with sMVS (P < 0.05). Iron deficiency (ID) was reduced by 88% after WLS Forte 
compared with sMVS. Adverse events related to supplement use did not occur. 
 
An optimized multivitamin supplement is safe and reduces the development of iron and 
vitamin B12 deficiencies after LRYGB. 
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INTRODUCTION 
 Bariatric surgery has proven itself as an effective treatment to establish 
sustained weight loss in morbidly obese patients, and to reduce obesity-related 
comorbidities such as type 2 diabetes mellitus, hypertension, and sleep apnea 
syndrome.
1-6
 The Roux-en-Y gastric bypass (RYGB) is one of the most frequently 
performed surgical procedures worldwide to induce weight loss.
7
 However, as a result 
of the created restriction of intake and partial bypass of the upper intestinal tract, it also 
increases the risk of nutritional deficiencies. Most commonly diagnosed postsurgical 
deficiencies are iron (47%–66%), vitamin B12 (37%–50%), folic acid (15%–38%), 
vitamin D (20%–51%), and calcium (± 10%).
8-25
 To prevent these postsurgical 
deficiencies, daily use of a multivitamin and mineral supplements are generally 
recommended;
26
 however, guidelines vary and RYGB-specific, multivitamin 
supplements (MVS) are currently not available.
12,15,23,27
 
Based on the literature and pilot studies performed in our hospital, a customized 
MVS for RYGB patients was developed (WLS Forte, FitForMe, Rotterdam, the 
Netherlands). The present study evaluates the effectiveness and safety of WLS Forte 
compared with standard MVS (sMVS, commercially available tablets) after RYGB in a 
triple-blind randomized controlled trial. 
 
PATIENTS AND METHODS 
The study protocol was approved by the National Medical Ethics Review 
Committee of the Radboud University Medical Centre and Local Ethical Committee of 
the Rijnstate Hospital Arnhem (RHA), and was conducted in concordance with the 
principles of the Declaration of Helsinki. The study protocol was registered at the 
clinical trials registry of the National Institutes of Health (ClinicalTrials.gov; identifier 
NCT 01609387). 
 
Study Design 
The present study was a triple-blind, randomized, clinical trial. The patients were 
randomized in 2 groups, receiving 2 different multivitamin supplements (standard 
multivitamin supplement and WLS Forte) after a primary laparoscopic Roux-en-Y 
gastric bypass (LRYGB) operation. Patients were included by bariatric surgeons, 
(supervised) specialized obesity nurses, or researchers at the outpatient surgery 
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department of the RHA. RHA is a teaching hospital for surgical residents and a center 
of excellence in bariatric surgery. 
 
Patients 
Patients who were scheduled for a LRYGB operation between June 2011 and 
March 2012 were invited for participation in the study and written informed consent 
was obtained from each patient. 
Adult patients (age >18 years) with morbid obesity (body mass index [BMI] of 
>40 or >35 kg/m
2
 with an obesity-related comorbidity) who met the criteria for bariatric 
surgery according to the National Institutes of Health Consensus Development 
Conference Panel for bariatric surgery
28 
were eligible for the study. Exclusion criteria 
were a secondary LRYGB operation or other type of a bariatric procedure. 
 
Surgical Procedure 
All procedures were performed by 1 of 3 experienced bariatric surgeons (>750 
procedures each). They performed an antecolic antegastric LRYGB, with a proximal 
gastric pouch of 30 mL, a biliopancreatic limb of 50 cm, and a Roux limb of 150 cm. All 
patients received low-molecular heparin (nadroparin 5700 IU daily) for 6 weeks and 
proton-pump inhibitor (omeprazol 40 mg daily) for 6 months, as part of our standard 
postoperative protocol. 
 
Intervention and Control 
WLS Forte, a customized multivitamin supplement for RYGB patients, contains 
high doses of multiple vitamins and minerals, in particular iron (5 times recommended 
daily allowance [RDA]), folic acid (3 times RDA), and vitamin B12 (140 times RDA). A 
standard multivitamin supplement (sMVS, FitForMe) served as control and contains 
the compounds of interest in a dose equivalent to the RDA. The composition of both 
supplements is shown in Table 1. Both supplements were dosed as 1 capsule daily. 
In both groups, all patients also received calcium carbonate/cholecalciferol 500/400 
tablets 3 times daily (a total of 1500 mg calcium and 1200 IU vitamin D). 
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Table 1. Dosages of supplement ingredients 
Ingredients Standard MVS  WLS Forte  
 Dosage RDA (%) Dosage RDA (%) 
Biotin (μg) 25.00 50.0 600.00 1200.0 
Calcium (mg) 91.43 11.4 0.0 0.0 
Chloride (mg) 0.14 0.0 0.54 0.1 
Chrome (μg) 40.00 100.0 160.00 400.0 
Copper (μg) 999.60 100.0 3000.20 300.0 
Folic acid (μg) 200.00 100.0 600.00 300.0 
Iodine (μg) 153.70 102.5 225.04 150.0 
Iron (mg) 14.00 100.0 70.00 500.0 
Manganese (mg) 2.00 100.1 3.00 150.0 
Magnesium (mg) 30.00 8.0 0.0 0.0 
Molybdenum (μg) 50.00 100.0 112.40 224.8 
Selenium (μg) 55.00 100.0 105.00 190.9 
Vitamin A (μg) 599.70 75.0 1000.38 125.0 
Vitamin B1 (mg) 1.10 99.7 2.75 249.7 
Vitamin B2 (mg) 1.40 100.0 3.50 250.0 
Vitamin B3 (mg) 16.0 100.0 32.00 200.0 
Vitamin B5 (mg) 6.00 100.0 18.00 300.1 
Vitamin B6 (mg) 1.40 100.2 2.80 199.7 
Vitamin B12 (μg) 12.50 100.0 350.00 14000.0 
Vitamin C (mg) 80.00 100.0 120.00 150.0 
Vitamin D (μg) 4.00 80.0 12.50 250.0 
Vitamin E (mg) 10.00 83.4 24.00 200.0 
Vitamin K1 (μg) 25.00 33.3 120.00 160.0 
Zinc (mg) 10.00 100.0 22.50 225.0 
MVS: Multivitamin Supplement; RDA: Recommended Daily Allowance 
 
Randomization and Blinding 
The allocation sequence was computer generated. Variable block schedule was 
used for randomization and conducted by the independent trial pharmacist. Allocation 
concealment was achieved by generating a randomization list that was only available 
to the pharmacist. All supplements were packaged in a nonmarked sealed box at the 
hospital pharmacy, which was similar for both supplements, and numbered according 
to the randomization list. This was performed before the inclusion of the participants. 
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The included participants received the sealed box with the supplements according to 
the list, which was delivered by the pharmacist. Both supplements were similar in color, 
size, and taste. Therefore, patients, surgeons, and researchers were unaware of the 
type of the supplements. After the last visit of the last study patient, the randomization 
list was available for the research team. No earlier unblinding occurred. Patients with 
a nutritional deficiency before or during the study were treated with a predefined 
medication, independent of the trial group. 
 
Data Collection, Follow-Up, and Outcome 
All patients followed a strict postoperative schedule consisting of 17 visits in the 
first year, and on each visit patients were encouraged to keep taking their supplements. 
Standard laboratory blood tests were performed at baseline, and at 6 and 12 months. 
This included a complete blood count, calcium, phosphate, magnesium, zinc, albumin, 
iron, total iron-binding capacity, ferritin, folic acid, vitamin B12, 25-hydroxyvitamin D 
(25-OHD), parathyroid hormone (PTH), vitamin B1, and vitamin B6 (normal ranges are 
presented in tables). 
Primary outcome variables were the percentage of iron, folic acid, and vitamin 
B12 deficiencies developed during the 12 months after LRYGB. Iron deficiency (ID) 
was defined as a serum ferritin <20 μg/L, folic acid deficiency if the level 
was < 9.0 nmol/L, and vitamin B12 deficiency if the level was < 150 pmol/L. Anemia was 
defined as hemoglobin level of <7.4 mmol/L for females and <8.4 for males. Vitamin D 
deficiency was diagnosed if 25-OHD was <50 nmol/L, hypocalcaemia if serum total 
calcium was <2.1 mmol/L, and zinc deficiency of the serum level was <9.2 μmol/L. 
Calcium data are shown as calcium levels corrected for albumin (Cacorr), according to 
the following equation: Cacorr = Total Calcium – (0.025 x albumin) + 1. 
 
Correction of Deficiencies 
Preoperative deficiencies for iron, folic acid, vitamin B12, and vitamin D were 
treated with predefined medication until 2 months preoperatively so that it would not 
intervene with the postoperative multivitamin supplements. If a postoperative 
deficiency occurred, it was recorded for the purpose of this study. Subsequently the 
deficiency was corrected. 
ID with or without anemia was treated with ferrous gluconate 695 mg 3 times 
daily for 3 months. Vitamin B12 deficiency was corrected with intramuscular injection 
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of 1000 μg hydroxocobalamin once every 2 months for 12 months. Vitamin D deficiency 
was corrected with oral solubilized cholecalciferolFNA 50,000 IU/mL. First, a loading 
dose (IU) was calculated with the formula: 40 × (75 – actual serum 25-OHD level) × 
body weight in kilograms, as described previously.
29,30
 Thereafter, a maintenance 
dosage of 25,000 IU cholecalciferol
FNA 
per week was prescribed for a period of 3 
months. For other deficiencies the endocrinologist was consulted. 
 
Analysis and Sample Size Calculation 
Intention-to-treat analysis was conducted to present the outcomes. Additionally, 
per protocol analysis was performed, excluding patients who received additional 
medication because of a nutritional deficiency during the study. 
All data were analyzed using IBM SPSS Statistics (IBM Software Group, 
Chicago, IL, USA) 20 for Windows. Data are expressed as mean (±standard deviation), 
unless otherwise specified. Differences between groups were calculated using Student 
t-test for continuous data and chi-square test for ordinal/nominal data. A P value <0.05 
was considered statistically significant. 
Sample size calculation was performed by the epidemiologist of the Research 
Department of RHA using Openepi.com. Sample size calculation was based on the 
number of patients developing ID. To detect a 25% reduction of ID 12 months after 
surgery, with 95% sensitivity and a power of 90%, a minimum of 56 patients per group 
were needed. Taking into account a 10% dropout and 15% of cases excluded because 
of ID diagnosed and treated at 6 months, it was decided to include 75 patients per 
treatment group. 
 
RESULTS 
Two patients were excluded after randomization: 1 patient in the WLS Forte 
group because he underwent a sleeve gastrectomy instead of a LRYGB because of 
multiple adhesions during surgery, and 1 patient in the sMVS group because he 
cancelled the scheduled operation procedure. In total, 148 patients (74 in each group) 
underwent a LRYGB and were included for analysis. Baseline patient characteristics 
are shown in Table 2. Both groups were similar with respect to age, sex, weight, BMI, 
and preoperative deficiencies. However, dyslipidemia was twice as frequent in the 
WLS Forte group as compared with the sMVS group (P = 0.04).  
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Table 2. Baseline characteristics of patients  
 Standard MVS WLS Forte P value  
Age, y 43.4 ±10.0 45.3 ±10.2 0.26 
Weight, kg 132.1  ±17.7 134.8  ±20.7 0.39 
BMI, kg/m
2
 44.8  ±4.8 44.8  ±6.4 1.00 
Male/Female (N, %) 24/51 32%/68% 22/53 29%/71% 0.86 
Co-morbidities (N, %) 
T2DM 24 32% 25 33.3% 0.86 
Hypertension 33 44% 28 37.3% 0.41 
Dyslipidemia 10 13.3% 20 26.7% 0.04 
OSAS 11 14.7% 14 18.7% 0.51 
Preoperative deficiencies (N, %) 
Folic acid 1 1.4% 1 1.4% 0.90 
Vitamin B12 5 6.8% 4 5.4% 0.23 
Iron 17 23% 13 20.3% 0.42 
Ferritin 5 6.7% 3 4.0% 0.19 
Vitamin D 46 63% 50 67.6% 0.56 
MVS: Multivitamin Supplement; OSAS: Obstructive apnea syndrome; T2DM: Type 2 Diabetes Mellitus  
 
Weight Loss 
The degree of weight loss over 12 months was similar in both groups. Weight 
dropped to 90.6 ± 17.4 kg in the sMVS group versus 93.8 ± 16.9 kg in the WLS Forte 
group (P = 0.24), respectively. Percentage excess weight loss, defined as weight loss 
divided by excess weight based on ideal body weight at BMI 25 kg/m
2
, were after 12 
months 72.5 ± 20.9 kg/m2 versus 72.1 ± 23.2 kg/m
2
 for MVS and WLS Forte (P = 0.92), 
respectively.  
 
Iron, Vitamin B12, and Folic Acid Deficiency 
In Table 3, laboratory serum levels of hemoglobin metabolism are shown. Mean 
hemoglobin levels at baseline were 8.5 ± 0.7 mmol/L (sMVS) and 8.6 ± 0.7 mmol/L (WLS 
Forte) (P = 0.24), and did not change over 12 months. Mean cell volumes also did not 
change (data not shown). In total, 10 (6.8%) patients had anemia preoperatively: 6 
(8.1%) patients in the sMVS and 4 (5.4%) in the WLS Forte group (P = 0.50). Three of 
them (1.4%), 2 patients in sMVS and 1 patient in WLS Forte, had ID anemia. After 12 
months postoperatively, 3 patients (4.3%) versus 5 patients (7.4%) had anemia 
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(P = 0.75), respectively. Of these patients, 2 patients had anemia de novo in both 
groups. Two patients (1.5%), 1 patient in each group, had ID anemia. 
 
Table 3. Evaluation of hemoglobin metabolism 
Parameters (Normal range) Standard MVS WLS Forte P value  
Haemoglobin  
(female: 7.4 – 9.9 mmol/l,  
male: 8.4 – 10.8 mmol/l) 
     
Baseline 8.5 ±0.7 8.6 ±0.7 0.24 
6 months 8.6 ±0.7 8.5 ±0.7 0.56 
12 months 8.5 ±0.8 8.6 ±0.7 0.50 
Δ 0 – 12 months 0.029 ±0.7 -0.063 ±0.5 0.40 
MCV (80 – 100 fL)      
Baseline 88.8 ±4.6 88.6 ±4.1 0.79 
6 months 90.2 ±4.5 89.4 ±6.5 0.41 
12 months 90.6 ±4.1 91.4 ±3.7 0.22 
Δ 0 – 12 months 1.96 ±3.2 2.55 ±2.7 0.24 
Iron (9.0 – 31.0 μmol/l)      
Baseline 13.1 ±5.9 12.5 ±4.0 0.43 
6 months 15.1 ±4.3 14.7 ±4.9 0.66 
12 months 16.0 ±5.3 16.8 ±5.5 0.42 
Δ 0 – 12 months 2.9 ±6.9 4.5 ±5.2 0.14 
Ferritin (20 – 200 μg/L)      
Baseline 114.3 ±101.6 142.5 ±122.7 0.13 
6 months 94.3 ±92.5 119.9 ±89.1 0.10 
12 months 89.8 ±88.5 130.7 ±99.1 0.10 
Δ 0 – 12 months -23.4 ±70.1 -18.4 ±105.3 0.74 
TIBC (45.0 – 81.0 μmol/l)      
Baseline 66.7 ±9.8 64.4 ±10.6 0.18 
6 months 62.4 ±10.4 59.4 ±9.8 0.09 
12 months 63.8 ±11.2 59.1 ±9.3 0.01 
Δ 0 – 12 months -3.8 ±11.7 -5.35 ±8.3 0.41 
Folic acid (9.0 – 36.0 nmol/l)      
Baseline 17.6 ±7.3 17.9 ±7.4 0.83 
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12 months 22.9 ±8.0 29.3 ±11.5 <0.001 
Δ 0 – 12 months 5.7 ±7.3 11.2 ±11.9 0.002 
Vitamin B12 (150 – 640 pmol/l)      
Baseline 350.4 ±211.1 311.8 ±115.1 0.17 
6 months 285.0 ±176.5 418.1 ±250.4 <0.001 
12 months 348.3 ±297.9 421.9 ±250.4 0.12 
Δ 0 – 12 months -4.9 ±353.8 112.8 ±270.3 0.03 
Numbers are mean (±SD). MCV: mean cell volume; MVS: Multivitamin Supplement; TIBC: total iron-binding 
capacity 
 
The total number of patients developing ferritin deficiency during follow-up was 
8 (10.7%) in sMVS and 1 (1.3%) in WLS Forte (P = 0.03). In total, 55 (37.2%) patients, 
28 (37.8%) in the sMVS group and 27 (36.5%) in the WLS Forte group, received 
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Table 2. Baseline characteristics of patients  
 Standard MVS WLS Forte P value  
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Weight Loss 
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2
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2
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Iron, Vitamin B12, and Folic Acid Deficiency 
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OPTIMIZATION OF VITAMIN SUPPLETION: A RANDOMIZED CONTROLLED TRIAL 
  151 
(P = 0.75), respectively. Of these patients, 2 patients had anemia de novo in both 
groups. Two patients (1.5%), 1 patient in each group, had ID anemia. 
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additional iron medication at any time during the 12 month follow-up. Results after 
exclusion of these patients are shown in Table 4. Mean serum ferritin decreased by 
18.4 ± 61.8 μg/L in the sMVS group, but remained stable in the WLS Forte group 
(P = 0.08). 
 
Table 4. Results of hemoglobin metabolism, after exclusion of patients who received additional 
iron and/or vitamin B12 medication 
Parameters (Normal range) Standard MVS WLS Forte P value 
Haemoglobin  
(female: 7.4 – 9.9 mmol/l,  
male: 8.4 – 10.8 mmol/l) 
     
Baseline 8.5 ±0.6 8.6 ±0.7 0.38 
6 months 8.6 ±0.7 8.4 ±0.7 0.25 
12 months 8.5 ±0.8 8.5 ±0.6 1.00 
Δ 0 – 12 months 0.029 ±0.7 -0.063 ±0.5 0.64 
Ferritin (20 – 200 μg/L)      
Baseline  103.0 ±86.1 102.1 ±71.0 0.95 
6 months 84.5 ±73.2 97.8 ±66.7 0.29 
12 months 80.8 ±71.0 108.3 ±83.1 0.05 
Δ 0 – 12 months -18.4 ±61.8 4.9 ±81.3 0.08 
Vitamin B12 (150 – 640 pmol/l)       
Baseline  305.4 ±107.1 302.8 ±100.9 0.88 
6 months 249.9 ±85.6 351.3 ±135.6 <0.001 
12 months 267.2 ±100.1 349.8 ±122.1 <0.001 
Δ 0 – 12 months -38.9 ±141.3 44.1 ±138.8 0.002 
Numbers are mean (±SD). MVS: Multivitamin Supplement 
 
At baseline, vitamin B12 deficiency was diagnosed in 9 (6.1%) patients, that is, 
5 (6.8%) patients in the sMVS group and 4 (5.4%) patients in the WLS Forte group. 
These patients received vitamin B12 injections by protocol. In total, 27 (18.2%) 
additional patients were treated with vitamin B12 injections at any time during the 12-
month follow-up: 17 (23%) in the sMVS group and 10 (13.5%) in the WLS Forte group 
(P = 0.14). The results obtained after exclusion of these patients receiving vitamin B12 
injections are shown in Table 4. Mean vitamin B12 serum levels decreased by 
38.9 ± 141.3 pmol/L in the sMVS group and increased by 44.1 ± 138.8 pmol/L in the WLS 
Forte group (P<0.001) after 12 months, and as a result mean vitamin B12 blood serum 
levels at 6 months and 12 months were significantly higher with WLS Forte compared 
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with sMVS (P < 0.05). After 12 months, vitamin B12 deficiency had developed in 5 
(7.9%) patients receiving sMVS versus 1 patient (1.6%) in the WLS Forte group 
(P = 0.207). 
Mean serum folic acid levels were similar at baseline: 17.6 ± 7.3 nmol/L and 
17.9 ± 7.4 nmol/L (P = 0.83) for sMVS and WLS Forte, respectively. In both groups, 1 
patient (1.4%) had folic acid deficiency at baseline. During the study period, folic acid 
deficiency developed in 5 (6.8%) patients taking sMVS and 2 (2.7%) patients in the 
WLS Forte group (P = 0.441). After 6 and 12 months, mean serum folic acid levels were 
significant higher in the WLS Forte group (P < 0.05). 
 
Vitamin D Metabolism 
In total, 96 (65.3%) patients, 46 (63.0%) patients in the sMVS group and 50 
(67.6%) patients in the WLS Forte group (P = 0.56), had vitamin D deficiency before 
surgery. Mean serum vitamin D levels were 42.5 ± 17.9 nmol/L and 44.3 ± 20.6 nmol/L at 
baseline (P = 0.58), respectively. Vitamin D deficiencies were corrected according to 
the protocol and this resulted in mean 25-OHD levels close to the target of 75 nmol/L 
in both groups. The mean loading dose was 226,087 ± 60,442 IU with a maintenance 
dose of 25,000 IU/month. At 12 months, 7 (10.1%) patients in the sMVS and 12 (18.5%) 
patients in the WLS Forte group had vitamin D deficiency (P = 0.168). Excluding the 
patients who received extra vitamin D supplementation additional to the standard 
suppletion, mean vitamin D levels at baseline were 61.8 ± 10.8 versus 
66.8 ± 19.3 nmol/L (P = 0.29) for sMVS and WLS Forte; after 12 months 
84.6 ± 20.8 nmol/L versus 83.4 ± 24.8 nmol/L (P = 0.87), respectively. There were no 
differences in PTH levels and calcium levels between the 2 groups (P ≥ 0.05), although 
PTH levels rose by 1.26 ± 2.39 and 1.75 ± 3.1 pmol/L. Table 5 shows serum blood tests 
of the vitamin D metabolism at fixed time points. 
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Table 5. Results of calcium and vitamin D metabolism  
Parameters (Normal range) Standard MVS WLS Forte P value  
Vitamin D (>50 nmol/L)      
Baseline 42.5 ±17.9 44.3 ±20.6 0.58 
6 months 74.0 ±21.3 73.6 ±26.1 0.92 
12 months 76.7 ±24.6 70.4 ±25.4 0.92 
Δ 0 – 12 months 33.0 ±27.2 25.0 ±27.0 0.09 
PTH (1.3 – 6.8 pmol/L)      
Baseline 3.46 ±2.0 3.88 ±3.7 0.40 
6 months 4.10 ±1.9 4.38 ±2.1 0.41 
12 months 4.81 ±2.4 5.80 ±3.4 0.052 
Δ 0 – 12 months 1.26 ±2.39 1.75 ±3.1 0.31 
Calcium (2.10 – 2.55 mmol/L)      
Baseline 2.31 ±0.08 2.32 ±0.09 0.28 
6 months 2.32 ±0.10 2.31 ±0.09 0.48 
12 months 2.32 ±0.21 2.32 ±0.10 1.00 
Δ 0 – 12 months 0.009 ±0.21 0.001 ±0.09 0.77 
Albumin (35 – 50 g/l)      
Baseline 39.0 ±2.9 38.4 ±5.0 0.43 
6 months 39.9 ±3.7 38.4 ±3.1 0.008 
12 months 40.0 ±2.7 38.1 ±3.3 <0.001 
Δ 0 – 12 months 1.04 ±2.8 -0.015 ±5.1 0.14 
Phosphate (0.87 – 1.45 mmol/L)      
Baseline 0.99 ±0.19 0.98 ±0.19 0.86 
6 months 1.03 ±0.22 1.00 ±0.20 0.44 
12 months 1.08 ±0.21 1.03 ±0.17 0.14 
Δ 0 – 12 months 0.09 ±0.24 0.05 ±0.25 0.38 
Numbers are mean (±SD). MVS: Multivitamin Supplement; PTH: parathyroid hormone 
 
Other Vitamins and Minerals 
Results of monitoring vitamin B1, vitamin B6, zinc, and magnesium are shown 
in Table 6. Vitamin B6 levels were at baseline 68.6 ± 22.1 nmol/L versus 
74.9 ± 22.8 nmol/L for the sMVS and WLS Forte groups (P = 0.13), respectively. There 
were no vitamin B6 deficiencies observed at baseline. In total, 15 (10.1%) patients, 5 
(6.8%) patients in sMVS versus 10 (13.5%) patients in WLS Forte (P = 0.173), had 
elevated serum vitamin B6 levels at baseline. After 12 months, there were no 
deficiencies in either group and elevated serum vitamin B6 levels were observed in a 
total of 52 (40.6%) patients, that is, in 21 (31.8%) patients in the sMVS group and 31 
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(50%) patients in the WLS Forte group (P = 0.036). In 1 patient, an extremely high level 
of vitamin B6 (2777 nmol/L), without any neurological symptoms, was detected in the 
WLS Forte group; however, this patient had used additional multivitamin supplements 
on advice of his general practitioner in addition to the study medication. Two months 
after withdrawal of these additional medications, the serum level had dropped to 
110 nmol/L. 
For vitamin B1, zinc, phosphate, and magnesium, no differences were observed 
between the groups. 
  
Table 6. Results of monitoring vitamin B1 and B6, and minerals Zinc and Magnesium 
Parameters (Normal range) Standard MVS WLS Forte P value  
Vitamin B1 (95 – 175  nmol/L)      
Baseline 154.4 ±23.3 160.6 ±29.7 0.16 
6 months 154.4 ±27.6 154.4 ±30.8 1.00 
12 months 147.3 ±31.8 151.2 ±31.3 0.49 
Δ 0 – 12 months -7.05 ±30.1 -11.2 ±35.4 0.47 
Vitamin B6 (25 – 100 nmol/L)      
Baseline 68.6 ±22.1 74.9 ±28.8 0.13 
6 months 90.6 ±38.5 116.7 ±77.1 0.01 
12 months 96.0 ±37.5 111.5 ±57.8 0.07 
Δ 0 – 12 months 28.0 ±36.8 39.2 ±58.1 0.20 
Zinc (9.2 – 18.4 μmol/L)      
Baseline 11.73 ±1.73 11.23 ±1.74 0.08 
6 months 11.61 ±1.96 12.10 ±2.56 0.21 
12 months 12.31 ±3.12 12.52 ±2.20 0.66 
Δ 0 – 12 months 0.35 ±3.38 1.36 ±2.44 0.06 
Magnesium (0.71 – 0.93 mmol/L)      
Baseline 0.78 ±0.06 0.78 ±0.06 0.85 
6 months 0.81 ±0.07 0.79 ±0.07 0.17 
12 months 0.89 ±0.52 0.81 ±0.06 0.29 
Δ 0 – 12 months 0.11 ±0.52 0.03 ±0.05 0.25 
Numbers are mean (±SD). MVS: Multivitamin Supplement  
 
DISCUSSION 
  The present study illustrates that a multivitamin supplement specifically 
developed to prevent deficiencies in LRYGB patients has advantages over standard 
supplementation. sMVS was associated with a substantial decline in serum ferritin and 
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DISCUSSION 
  The present study illustrates that a multivitamin supplement specifically 
developed to prevent deficiencies in LRYGB patients has advantages over standard 
supplementation. sMVS was associated with a substantial decline in serum ferritin and 
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vitamin B12 levels over 1 year, whereas, in patients on WLS Forte, ferritin remained 
stable and vitamin B12 increased significantly. Moreover, the numbers of patients 
developing ferritin or vitamin B12 deficiencies were significantly fewer with the LRYGB-
specific multivitamin. These results were achieved by raising the iron content from 1 to 
5 times RDA and vitamin B12 from 1 to 140 times RDA. No benefit was found with 
respect to folic acid, despite a difference between the supplements in folic acid content 
of 1 and 3 times RDA. 
 
Iron Deficiency 
Decreased acid production in the small gastric pouch, exclusion of the 
duodenum and proximal part of the jejunum, use of proton-pump inhibitors during the 
first months of surgery, and intolerance of iron-rich foods, such as red meat, are the 
main factors increasing the risk of iron deficiency.
27,31
 ID in the first year after LRYGB 
has been reported to occur in 44% to 66% of patients not using supplements. These 
figures should be interpreted with caution because of marked differences in the 
definition of iron deficiency between these studies. Sometimes serum iron levels are 
erroneously used to diagnose iron deficiency. Serum iron levels do not reflect the body 
iron store. In the absence of inflammation, serum ferritin is the gold standard. 
Standardized supplementation of 14 mg iron daily reduced the incidence of iron 
deficiency in the first year after LRYGB to 11%. The American Society of Metabolic 
and Bariatric Surgery (ASMBS) guidelines advise a minimum of 18 mg iron per day for 
patients after RYGB. An additional minimum of 18 to 27 mg per day elemental iron is 
advised for high-risk patients including menstruating women.
32
 However, Vargas-Ruiz 
et al
22
 demonstrated that 18 mg iron per day was insufficient in LRYGB patients. ID 
was diagnosed in 20% of the patients after 12 months and rose to 55% after 3 years. 
This is in line with the observation of Aarts et al
8
 where ID was diagnosed in 21% of 
the patients despite a daily intake of a minimum of 21 mg iron. In addition, female 
patients had a higher risk of developing ID than men (38% versus 17%, P = 0.02). Brolin 
et al
11
 demonstrated, in a double-blind, randomized controlled trial, the effectiveness 
of 320 mg ferrous sulphate twice daily (total of 130 mg elemental iron) in young women 
who underwent a RYGB for prevention of ID. 
Based on the literature that advises 40 to 65 mg intake of iron in men and 100 mg 
in female patients after RYGB, the iron content in WLS Forte was increased to 70 mg, 
that is, 5 times RDA.
8,23,33,34
 In the present study with a male to female ratio of 1 : 2.3, 
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this was sufficient to maintain serum ferritin at baseline level, whereas, in patients on 
sMVS, ferritin steadily decreased over the year. The fact that the difference in ferritin 
levels at 12 months did not reach statistical significance is attributed to a lack of power 
in this study. 
 
Vitamin B12 Deficiency 
Vitamin B12 in food is bound to proteins, and needs to be liberated by the action 
of hydrochloric acid, pepsin, and pancreatic enzymes. This process is compromised 
after RYGB. In addition, intrinsic factor release is also reduced, which further 
compromises vitamin B12 absorption. Finally, preoperative vitamin B12 deficiencies 
are not uncommon in the morbidly obese, probably because of their dietary habits. In 
the present study, 9% of patients had vitamin B12 deficiency preoperatively. Published 
data of postoperative vitamin B12 deficiencies diagnosed after variable periods of time 
vary from 10% to 50%.
11,21,22,24
 Vargas-Ruiz et al
22
 reported a post-RYGB incidence of 
vitamin B12 deficiency of 10% after 12 months and 18% after 3 years, despite the use 
of a multivitamin containing cobalamin 6 μg daily. Brolin et al
11
 reported that 37% of the 
patients had vitamin B12 deficiency after a mean follow-up period of 42 months. 
ASMBS guidelines advise vitamin B12 supplements of 350 to 500 μg daily, and as-
needed addition of intramuscular injections of 1000 μg per month.32 WLS Forte 
contains high doses of 350 μg vitamin B12, which is 14,000% ADH. After 12 months, 
vitamin B12 hypervitaminosis was observed in 9 patients on WLS Forte compared with 
7 patients in sMVS (P = 0.58). No adverse events of vitamin B12 hypervitaminosis were 
observed during the study period. 
ID, vitamin B12 deficiency, and folic acid deficiencies are associated with 
anemia after LRYGB.
8,11,22
 A previous study of our group demonstrated high incidence 
of deficiencies for iron (66%), vitamin B12 (50%), and folic acid (15%) in patients with 
anemia after LRYGB.
8
 Based on these results, minimal daily intake of 65 mg of iron in 
males and 100 mg in female patients, 350 μg of vitamin B12, and 400 μg of folic acid 
were advised after LRYGB. In our current study, the prevalence of anemia was, in total, 
11.7% after 12 months, that is, in 4.3% on sMVS versus 7.4% on WLS Forte (P = 0.75). 
However, only 1 patient had an ID anemia in the sMVS group. The fact that 23% of the 
patients received additional oral iron medication at baseline and 10% received vitamin 
B12 injections at baseline or 6 months may have resulted in lower nutrient-related 
anemia. A previous study of Brolin et al
35
 showed also reduction in ID with additional 
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iron supplements; however, incidence of anemia was not reduced compared with 
placebo. Other pathophysiological aspects play probably a role in anemia after RYGB 
surgery. 
 
Vitamin D 
Vitamin D, a fat-soluble vitamin, can be produced in the skin under influence of 
sunlight, and ingested through the diet (eg, certain fish and milk products) or by dietary 
supplements.
36,37
 It is metabolized in the liver into 25-OH-D, the best parameter for 
patients’ vitamin D status.
10,33
 Several studies claimed high incidence of vitamin D 
(34%–73%) deficiency after RYGB;
38-40
 however, the exact mechanisms of 
postoperative vitamin D deficiency are not completely clear yet. Obesity itself seems 
to be a risk factor of developing vitamin deficiency. 
Despite the high incidence of postoperative vitamin D deficiency, optimal 
prevention strategies are lacking. The ASMBS guidelines advise daily intake of 2000 IU 
vitamin D. In addition, 1500 to 2000 mg per day of calcium was recommended.
32
 In 
contrast to these guidelines, reports in the literature advise postoperative vitamin D 
supplements varying between 320 IU and 2000 IU per day,
12,27,41,42
 and a calcium intake 
of 1000 to 1500 mg daily.
27,34,42
 
Carlin et al
43
 demonstrated that despite daily intake of 800 IU vitamin D, 44% of 
the population still remained insufficient for vitamin D. Goldner et al
41
 conducted a 
prospective, randomized controlled trial comparing 3 different doses of vitamin D 
supplementation of 800 IU, 2000 IU and 5000 IU daily following RYGB. The 
postoperative increase of mean serum vitamin D level at 12 months was higher with 
higher doses (800–5000 IU) of vitamin D supplement. Therefore, a minimum of 2000 IU 
daily intake of vitamin D was advised. However, Signori et al
44
 reported that daily use 
of prophylactic vitamin D of 1200 to 2000 IU did not prevent postoperative vitamin D 
deficiency. 
In the current study, all patients received 1500 mg calcium carbonate and 
1200 IU vitamin D daily as standard postoperative protocol. Furthermore, sMVS 
(control group) contained 160 IU (4 μg) vitamin D, whereas WLS Forte contained 500 IU 
(12.5 μg). In total, 29% of the cohort had developed vitamin D deficiency after 12 
months, without significant differences between the 2 supplementation regimes. At 12 
months, 10% in the sMVS group and 19% of patients in the WLS Forte group had 
developed vitamin D deficiency (P = 0.168). 
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A previous study from our group demonstrated a 25% reduction of peak 
cholecalciferol levels after intake of oral cholecalciferol of 50,000 IU, corresponding 
with impaired absorption.
30
 These results in combination with previously reported 
studies suggest that vitamin D deficiency after LRYGB is difficult to prevent with a 
standard multivitamin supplement, and that much higher doses of vitamin D are 
needed to prevent vitamin D deficiency. 
 
Other Vitamin and Minerals 
In our study, no differences were found in vitamin B1, vitamin B6, zinc, 
magnesium, or phosphate serum levels between standard MVS and WLS Forte. A 
notable finding is the high incidence (10%) of hypervitaminosis of vitamin B6 before 
the surgery. In addition, in total, 41% had high levels of vitamin B6 after surgery, which 
was significantly higher for WLS Forte compared with sMVS at 12 months. Increased 
levels of vitamin B6 were also observed in the literature,
45-47
 but no adverse events 
were reported. As 100% ADH of vitamin B6 is associated with increased serum levels 
after surgery and no deficiencies, no higher concentrations were needed as in WLS 
Forte. Therefore, vitamin B6 dose was decreased to 0.98 mg (70%) RDA in the WLS 
Forte supplements. 
 
Compliance 
Vitamin and mineral deficiencies are common both before and after LRYGB 
surgery. Therefore additional supplements are advised after weight-loss surgery. 
However, life-long compliance of daily supplement intake is hard to achieve. To 
measure adequate intake of MVS, one can monitor the serum concentration of highly 
absorbable vitamins. Navarro et al
48
 demonstrated a serum folic acid concentration of 
five-fold compared with baseline, 4 hours after oral intake of standard MVS containing 
1.6 mg folic acid. Therefore, folic acid can be used as a marker for compliance of MVS 
intake. 
The capsules in both groups had a cherry flavor with powder, nevertheless, 
several patients complained about vitamin B aftertaste for a period of 30 minutes after 
ingestion. This had no influence for the compliance of the patients. After the end of the 
study, commercially available capsules have a bubblegum taste with microcapsulation 
to prevent this aftertaste. 
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Limitations 
Despite the double-blind, prospective, randomized character of the study, 
several limitations of the study should be considered. High prevalence of preoperative 
nutritional and mineral deficiencies, which are linked to morbid obesity, required 
additional treatment, and some patients received additional supplements after surgery 
outside of protocol. This will have obscured differences of the suppletion regimens to 
some extent. In Table 4, all patients receiving extra supplements have been excluded 
and, therefore, these data reflect the comparison of standard and optimized 
supplements most accurately. The demonstrated deficiencies develop gradually and 
progressively. Because of adequate reserves in the human body, many vitamin and 
nutrient deficiencies only occur after a few years. Although a significant difference in 
the first year has been shown in this study, we expect an even greater effect of 
optimized supplements compared with standard supplements in the long term. It is still 
uncertain whether customized multivitamin supplements can completely prevent 
postsurgical deficiencies. Continued surveillance is therefore needed to evaluate the 
effectiveness and safety on the long term, as patients will need life-long supplements 
after bariatric surgery.
49,50
 For example, excess vitamin B12 intake may be associated 
with prostate cancer.
50
 
The compliance of patients was inquired during the follow-up interviews; 
however, the answers depended on the honesty of the patients and could only be 
compared with their folic acid levels. On the contrary, patients were blinded for the 
nature of their supplements and, thus, it is plausible that any noncompliant patients 
were equally distributed in both groups. 
 
CONCLUSION 
In summary, prevention of mineral and vitamin deficiencies after LRYGB is hard 
to achieve with standard multivitamin supplements, especially when deficits before the 
operation are present. WLS Forte was introduced as a customized multivitamin 
supplement for post-RYGB intake, including 14,000% RDA (350 μg) vitamin B12, 500% 
RDA (70 mg) iron, and 300% RDA (600 μg) folic acid. Using WLS Forte after LRYGB 
surgery results in fewer deficiencies in iron, vitamin B12, and folic acid compared with 
sMVS. Despite the decreased risk of vitamin deficiencies with WLS Forte supplements 
after LRYGB, a strict follow-up regime remains necessary to prevent patients becoming 
vitamin deficient. 
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9.1 SUMMARY AND GENERAL DISCUSSION 
 
The main goals in the treatment of obesity is to achieve sustained weight loss, 
to improve quality of life and to reduce obesity related co-morbidities. Bariatric surgery, 
i.e. metabolic surgery, has an established role in the treatment of obesity and its related 
co-morbidities. While the obesity epidemic is rising, the demand for surgical 
interventions increases as well. Ideally, surgical procedures ensure low procedure-
related morbidity and mortality, without compromising the main outcome. The 
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) surgery is currently designated as 
the ‘gold standard’ in metabolic surgery, although it is a more challenging procedure 
compared to the Laparoscopic Adjustable Gastric Banding (LAGB) and Laparoscopic 
Sleeve Gastrectomy (LSG). In this thesis, the rise and evolution of the LRYGB surgery 
is discussed. Other main topics were the optimization of the surgical technique of the 
LRYGB, refinement of the peri- and post-operative care, and detection and prevention 
of post-surgical nutritional complications after the LRYGB procedure. 
 
PART I 
Part I of this thesis focused on the long-term effectiveness and complications of 
the LAGB procedure. Restrictive procedures, such as the LAGB, were introduced to 
reduce dietary intake (restrictive surgery). Short-term outcomes were promising, 
however, disappointing results due to several reasons have been reported on the long-
term.
1-10
  
 
LAGB 
The LAGB, first introduced in 1993,
11,12
 and accounted approximately 42% of all 
bariatric procedures globally in 2008.
13
 Because, it was considered as a reversible, 
relative safe and easy to perform procedure with low peri-operative mortality and 
morbidity rates.
14,15
 In addition, in the most optimistic series, patients lose up to 60% 
of their excess weight within 3-5 years.
3,7,15
 However, many patients suffered from 
band-related complications, such as pouch dilatation, migration or slippage of the band, 
and dislocation or pain of the injection port. Different operative techniques were 
introduced to prevent these complications, such as complete encirclement of the cardia 
and smaller omentum, the pars flaccida technique, or access port fixation positioning 
on the left pectoral muscle.
7,16
 Despite these changes, in our experience, many 
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patients suffered from insufficient weight loss or weight regain, had low quality of life 
and had their band removed on the long-term (Chapter 2). These facts may reflect the 
unsuitability of the LAGB as a definitive option for the treatment of obesity. Therefore, 
many surgeons have abandoned LAGB as a valid weight loss option. Worldwide, the 
LAGB procedures dropped to 18% of all bariatric procedures in 2011 and declined 
further to 10% in 2013.
13,17
  
However, is the failure of this treatment fully attributable the LAGB itself or was 
there a structural problem of treatment in morbid obesity? The LAGB placement had 
an exponential growth in a period that morbidly obese patients had no strict follow-up 
program. Today, patients have pre-operatively an intensive program to prepare them 
for an operation and are post-operatively followed-up for many years. It is known that 
the operation is only a part in treatment of obesity. Thus, many failures may be a result 
of undertreatment of the patients. Therefore, it is questionable what would have 
happened when these patients would have received a multidisciplinary approach from 
the start? Hypothetically, some failures could have prevented, while some 
complications like band migration or slippage could have been detected and treated in 
an early phase. Low patients’ compliance was already a known indicator for poor 
results, however, where these patients adequately informed? Therefore, it is 
worthwhile to search for patients’ characteristics which could differentiate between 
suitable and unsuitable patients for LAGB.
18,19
 
 
 
Complications after LAGB 
In patients who suffer from band-related complications which require band 
removal, a second bariatric procedure is advised to prevent weight regain and 
recurrence of their obesity related diseases. Some patients, however, reject a second 
operation. In Rijnstate Hospital, all patients who did not receive a second bariatric 
procedure gained weight, while patients who underwent a secondary bariatric 
operation (LRYGB) achieved an additional significant weight reduction (Chapter 2). 
Revision to a LRYGB procedure after a failed LAGB operation is commonly 
performed.
20-27
 However, the second operation is considered as a technically 
challenging procedure and may be accompanied by a higher risk for peri-operative 
complications compared to a primary operation.
20
 Therefore, some authors advocate 
to perform the revision in two-steps. In contrast, in Chapter 2 it is described that 
conversion of a failed LAGB to a LRYGB in a one-step procedure is feasible and safe. 
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In 90% of the patients, an uncomplicated procedure was performed and only 4% 
required a reoperation within 30-days after surgery. However, many poor-responders 
to the LAGB also demonstrate suboptimal results after a redo-RYGB. Patient-related 
factors, such as eating habits or failure to lifestyle changes may negatively influence 
the outcome. Therefore, as mentioned earlier, close post-operative counseling of these 
patients by a multidisciplinary team, including a specialized obesity nurse, dietician, 
physiotherapist and psychologist, is necessary.  
 
Revisional operations 
Alternatives to the LRYGB procedure for revisional surgery after failed LAGB, 
are the LSG and Laparoscopic Biliopancreatic Diversion and Duodenal Switch 
(LBPDDS).
20,21
 It seems to be irrational to perform a restrictive operation (LSG) after a 
failed restrictive procedure (LAGB), however, patients with good weight loss results 
with the LAGB that require revisional surgery because of a complication may benefit 
from the LSG. In the literature, conflicting data regarding the safety and effectiveness 
of a redo-LSG are reported.
21,28,29
 Weight regain or unsuccessful weight reduction after 
LAGB may be an indication to perform a malabsorptive procedure rather than a 
secondary restrictive operation. These type of procedures result in a more weight loss, 
however, are accompanied with a higher risk for nutritional deficiencies.
21,30-32
 In 
conclusion, the optimal revisional operation after a failed LAGB procedure is not yet 
defined.  
 
PART II 
Part II of this thesis concentrated on the effectiveness and safety of the LRYGB 
procedure and is divided in four chapters. First, the comparison between the LRYGB 
and the LAGB and LSG is made. Second, the effect of altering the length of the bypass 
is described. Then the outcome in co-morbidities is discussed. At last, peri-operative 
optimization in LRYGB surgery is pointed out.  
 
Most performed bariatric procedures 
Despite the enormous growth of bariatric surgery in the beginning of the 21
th
 
century, especially for the LAGB, LSG and LRYG, comparative trials between these 
procedures were scarce. Some authors claimed the superiority of the LRYGB 
procedure compared to a LAGB in terms of weight loss in a small number of 
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randomized clinical trials with small cohorts.
33-35
 On the other hand, the LRYGB holds 
a higher risk for peri- and post-operative complications compared to the LAGB. 
Therefore, an alternative restrictive procedure with a low peri-operative complication 
rate, and good result in terms of reduction of weight and obesity related diseases, was 
added to the surgical options by means of the LSG. Several studies demonstrated 
comparable results of the LSG to the LRYGB procedure in terms of weight loss on the 
short-term.
36-40
 Therefore, the LSG was suggested as the most designated alternative 
operation. However, some concerns were expressed for the long-term period, because 
of reports of a high percentage of patients regaining weight after a period of 5 years.
41
 
To determine the clinical outcome of these 3 most performed bariatric procedures, a 
multicenter matched cohort study was conducted in 2 high-volume bariatric centers in 
The Netherlands. The results of this study were described in Chapter 3.  In total 735 
patients who received a LAGB, a LSG or a LRYGB procedure were matched for gender 
and age. In accordance with the literature, weight loss was comparable for the LSG 
and the LRYGB procedures during the first 5 post-operative years. However, in 9% of 
the patients after LSG, a conversion to a LRYGB was performed after a mean period 
of 2 years. In contrast, no revisional procedure was performed in the LRYGB group. 
The LAGB group had significantly lower weight loss compared to other procedures, 
while in 20% of the patients a conversion to another procedure was needed because 
of a complication. Therefore, the LSG is a better restrictive therapeutic option 
compared to a LAGB, and a potential alternative to the LRYGB in many patients. 
 
Small bowel length 
In order to improve the outcome of the RYGB procedure, several technical 
adaptations are made to the construction of the RYGB itself. One of the non-resolved 
issues is the total length of the bypass and the length of the created limbs. In the last 
two decades, many authors focused on the length of the alimentary limb (AL, figure 1 
in Chapter 1). Most of the time the AL length varies from 75 cm to 200 cm and a 
biliopancreatic limb (BPL, figure 1 in Chapter 1) of approximately 50 cm is created. 
Many surgeons use a longer AL in patients with a higher BMI, at an arbitrary cut-off 
point of a BMI of 50 kg/m
2
 (super obesity), which was also the strategy in the Rijnstate 
hospital. Since 2009, a fixed AL length (150 cm) is used in all patients receiving a 
LRYGB, independently of the BMI. In Chapter 4, the results of the retrospective 
analysis of a prospectively collected database to determine the effect of the limb length 
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PART II 
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th
 
century, especially for the LAGB, LSG and LRYG, comparative trials between these 
procedures were scarce. Some authors claimed the superiority of the LRYGB 
procedure compared to a LAGB in terms of weight loss in a small number of 
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randomized clinical trials with small cohorts.
33-35
 On the other hand, the LRYGB holds 
a higher risk for peri- and post-operative complications compared to the LAGB. 
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36-40
 Therefore, the LSG was suggested as the most designated alternative 
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41
 
To determine the clinical outcome of these 3 most performed bariatric procedures, a 
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the patients after LSG, a conversion to a LRYGB was performed after a mean period 
of 2 years. In contrast, no revisional procedure was performed in the LRYGB group. 
The LAGB group had significantly lower weight loss compared to other procedures, 
while in 20% of the patients a conversion to another procedure was needed because 
of a complication. Therefore, the LSG is a better restrictive therapeutic option 
compared to a LAGB, and a potential alternative to the LRYGB in many patients. 
 
Small bowel length 
In order to improve the outcome of the RYGB procedure, several technical 
adaptations are made to the construction of the RYGB itself. One of the non-resolved 
issues is the total length of the bypass and the length of the created limbs. In the last 
two decades, many authors focused on the length of the alimentary limb (AL, figure 1 
in Chapter 1). Most of the time the AL length varies from 75 cm to 200 cm and a 
biliopancreatic limb (BPL, figure 1 in Chapter 1) of approximately 50 cm is created. 
Many surgeons use a longer AL in patients with a higher BMI, at an arbitrary cut-off 
point of a BMI of 50 kg/m
2
 (super obesity), which was also the strategy in the Rijnstate 
hospital. Since 2009, a fixed AL length (150 cm) is used in all patients receiving a 
LRYGB, independently of the BMI. In Chapter 4, the results of the retrospective 
analysis of a prospectively collected database to determine the effect of the limb length 
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on BMI and weight loss in patients receiving a primary LRYGB procedure is described. 
During a 5-years follow-up, no difference in weight loss outcome was observed for the 
different AL lengths. Additionally, an overview of the available literature comparing 
short versus long AL RYGB is presented, which are also conflicting. Therefore, it is 
arguable if the AL length is the determining factor for the amount of weight loss. Further 
evolution of the technique is in progress, but it is uncertain which adaptation will be of 
added value. A systematic review by Mahawar et al.
42
 regarding small bowel limb 
lengths demonstrated a huge variation in practice amongst surgeons. Some claim 
significant more weight reduction after lengthening the BPL in the Roux-en-Y 
construction.
43,44
 Additionally, the mini-gastric bypass (or omega-loop gastric bypass) 
is an operation with a long BPL without an AL. Several studies demonstrated similar or 
even greater weight loss compared to the traditional RYGB.
45-48
 Therefore, the 
question remains whether the BPL or the AL is a more essential component for weight 
loss? To answer this question, a randomized clinical trial is started in the Rijnstate 
hospital to determine the effect of a long BPL RYGB (BPL limb of 150 cm) compared 
to standard RYGB (as described in Chapter 1) in patients who are scheduled for a 
primary or revisional RYGB operation (ELEGANCE trial, Clinical Trials Identifier: 
NCT01686997). The preliminary results of this study were presented at the 18
th
 and 
19
th
 edition of the world congress of the international federation for the surgery of 
obesity & metabolic disorders (IFSO). It seems that patients who received a long BPL 
RYGB have more weight loss after both primary as revisional operation, however, long-
term data should show whether this trend continues.  
 
Fast track surgery 
The introduction of the laparoscopic surgery in bariatric procedures resulted in 
a dramatic reduction of the peri-operative complications, hospital stay and considered 
to be cost effective.
49,50
 But the increasing number of lengthier and challenging 
procedures, such as the LRYGB, remains a dilemma for operation planning and 
logistics. High-volume bariatric centers have better peri-operative outcomes compared 
to low-volume centers,
51
 however, capacity and manpower are the main restrictions for 
growth in most hospitals. Therefore, a multimodal Fast Track Surgery (FTS) program 
was implemented to improve both operation logistics and peri-operative care. Earlier 
studies in colon surgery demonstrated the safety and feasibility of this approach.
52-57
 
The FTS program was introduced in stages in the Rijnstate hospital in Arnhem during 
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a one-year period. In Chapter 5 the clinical outcome of this FTS program were 
compared to the Conventional Peri-operative Care (CPC) program. The basis of the 
FTS program is a multidisciplinary approach, structural organization during operation 
and recovery, cooperation between different contributing disciplines, exclusion of non-
contributing attributes and motivation of the patient. The FTS program resulted in an 
improvement of the peri-operative care and faster recovery of the patients: a 34% 
decrease of length of hospital stay duration and a 31% reduction of the operation time. 
Additionally, the FTS enables the operation team to perform more operations in the 
same time, resulting in an increase from five to six patients a day in the Rijnstate 
hospital. At the same time a higher turnover of patients on the surgical ward was 
realized without an increase of manpower or the number of beds needed.  
 
Metabolic surgery 
Obesity is associated with metabolic co-morbidities such as type 2 diabetes 
mellitus (T2DM), hypertension (HT) and dyslipidemia (DL). Therefore, obese patients 
have a significant risk to develop micro- and macrovascular disease which lead to a 
decrease of quality of life and life expectancy.
58
 Weight loss is the backbone of 
therapeutic interventions for obese patients with T2DM. The Diabetes Surgery Summit 
Consensus Conference (DSSCC), including the American Diabetes Association (ADA), 
the IFSO, and the International Diabetes Federation (IDF), accept bariatric surgery as 
an alternative therapy for treatment of obesity related T2DM.
59,60
 Remission rates up 
to 80% of T2DM after a RYGB procedure within 5 years have been reported.
61-64
 
However, part of the patients (9 – 24%) who had initial remission of their disease, 
suffered from a recurrence of their diabetes during the follow-up. In Chapter 6 the 
effect of the LRYGB on remission of T2DM, HT and DL after a mean period of 82 
months is investigated. In total 71% of the patients had a complete remission of their 
diabetes during the first years of follow-up after surgery.  However, 52% had a 
maintained remission at the end of the follow-up, while 19% had a recurrence after 
initial remission. Pre-operative HbA1c level and duration of T2DM prior to the operation 
were independent predictors for remission of diabetes on the long-term. Furthermore, 
overall medication use for T2DM decreased from 85% to 37% of the patients, and 
insulin usage declined from 40% to 6% for all patients. Additionally, in one of four 
patients a reduction of HT and DL is observed. Therefore, metabolic surgery is a more 
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appropriate and accepted definition than bariatric or weight loss surgery for patients 
receiving a bariatric procedure.   
The find that the LSG is mentioned as an alternative procedure for the LRYGB 
regarding weight loss, raises the question whether this also applies for metabolic 
changes. A significant reduction of T2DM on the short- and mid-long-term is also 
reported after a LSG, however data regarding the durability of remission of T2DM after 
a LSG on the long-term is limited.
64-68
 Some authors claim remission rates up to 68% 
after 5 years,
67,68
 while others reporting a low complete remission rate of 9% with a 
recurrence rate of 38% after a similar period.
64
 Independent predictors for successful 
remission are postulated such as age, female gender, BMI, use of medication, c-
peptide level, duration of diabetes prior to surgery, or amount of weight loss and/ or 
weight regain post-operatively. Long-term follow-up of 10-years after LSG shows a 
huge amount of weight regain (approximately 60% of the patients),
69
 which may 
inherent to recurrence of metabolic disorders.  
Several mechanisms are postulated regarding resolution of T2DM after RYGB 
procedure.  The effect on (improved) glucose metabolism occurs within two time 
frames.
70-72
 Early effect acts within days to weeks after operation due to calorie 
restriction and accelerated transit of nutrients through the small intestine. These 
actions result in decreased hepatic glucose production and increased insulin secretion, 
respectively. Rapid exposure of nutrients stimulates secretion of incretins like 
glucagon-like peptide-1 (GLP-1) hormone from the L-cells in the distal part of the small 
intestine, which mediates insulin secretion and reduction of glucose levels after meal. 
Additionally, other gut hormones like polypeptide tyrosine-tyrosine (PYY) and 
oxyntomodulin (OXM) which are also secreted from the L-cells (appetite-regulating gut 
hormones), induce satiety, reduction of food intake and delayed gastric emptying. A 
late effect occurs after months to years because of weight loss, which leads to 
increased peripheral insulin sensitivity. Increased serum levels of GLP-1 have also 
anorexigenic effect with a positive effect on satiety. Furthermore, ghrelin (a hormone 
which is primary produced in the stomach) also known as appetite stimulating hormone, 
is decreased after operation and therefore helpful in maintaining weight loss. Thus, 
restoring of the insulin sensitivity and preserving beta-cell function of the pancreas, the 
core defects in patients with T2DM, is the main goal in obese patients with diabetes.
73,74 
The RYGB procedure typically interacts on these defects. With these mechanisms, the 
greater effectiveness of the RYGB compared to the LSG on the resolution of T2DM 
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can be explained.
70,75,76
 Interestingly, several hormonal changes, similar to the RYGB, 
are also observed after a sleeve gastrectomy (SG) operation despite anatomical 
differences.
71,72
 Accelerated gastric emptying after SG is used as an explanation for 
this effect.
77 
Today, some authors claim in their meta-analysis no difference in 
resolution of T2DM after a RYGB and SG.
78,79
 This indicates that the SG, which was 
initially appointed as a restrictive procedure, may also be a potential metabolic 
procedure and an alternative for the RYGB. Therefore, more long-term data for both 
RYGB and SG regarding metabolic co-morbidities is required.  
 
PART III 
 Part III of the thesis focuses on the post-operative effect on nutritional status in 
RYGB surgery. Untreated nutritional deficiencies are a potential health risk factor. In 
the last decade, vitamin and mineral deficiencies after a LRYGB procedure gain more 
(international) attention. Dietary intake restriction and reduced resorptional capacity of 
the small intestine can be held responsible. Most reported deficiencies in vitamin and 
minerals are iron (47-66%), vitamin B12 (37-50%), folic acid (15-38%), vitamin D (20-
51%) and calcium (±10%).
80-90
 Therefore, according to the American Society for 
Metabolic and Bariatric Surgery (ASMBS) guidelines, patients are advised to use 
multivitamins, vitamin D and calcium supplements on a daily basis after their 
operation.
91
 The hazard is in the non-compliant patient, because its known that these 
patients are more prone to develop post-operative deficiencies.
92
 However, life-long 
compliance to the daily use of multivitamins is sometimes hard to achieve. For some, 
the reason for cessation of vitamin intake is underestimation of the problem, while 
some patients quite due to financial reasons since most patients must pay themselves 
for their supplements. In Chapter 7, the nutritional status in patients who received a 
LRYGB after a long-term period (81 months) is researched. Additionally, the effect of 
usage of multivitamin supplement is described. Eighty percent of the patients used an 
additional supplement or medication, while 69% of the patients used a multivitamin 
supplement at their last follow-up visit. It is noticeable that almost one in four patients 
suffered from anemia and that in half of the patients a vitamin D deficiency was 
observed, despite additional medication use. Patients who used a multivitamin 
(compliant patients) had less iron, vitamin B12 and vitamin D deficiencies. These 
numbers also suggest that the use of a standard multivitamin does not adequately 
prevent post-surgical deficiencies since they contain lower dosages of the vitamins and 
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minerals that are advised in the ASMBS guidelines. Remarkably, despite of performing 
hundreds of thousands of LRYGB procedures worldwide, in the past no RYGB specific 
multivitamin existed. Therefore, a customized multivitamin supplement (WLS Forte
®
, 
FitForMe, Rotterdam, The Netherlands) is developed for RYGB patients in the 
Rijnstate hospital. This supplement contains vitamin B12 14000% RDA, iron 500% 
RDA, and folic acid 300% RDA. This supplement is compared to a standard 
multivitamin supplement, containing approximately 100% RDA of these vitamins and 
minerals, in a triple-blind randomized clinical trial (Chapter 8). Using WLS Forte® after 
LRYGB surgery results in less iron, vitamin B12 and folic acid deficiencies compared 
to a standard supplement during the first post-operative year. However, because of 
adequate reserves in the human body, many vitamin and nutrient deficiencies only 
occur after a few years. A follow-up study of this randomized clinical trial reports also 
less anemia, and ferritin and vitamin B12 deficiencies after a WLS Forte® supplement 
compared to a standard vitamin 3 years after surgery.
93 
But, these deficiencies were 
not completely eliminated. Therefore, it is still uncertain whether customized 
multivitamin supplements can completely prevent post-surgical deficiencies. 
 
9.2 FUTURE PERSPECTIVES 
 
Since the introduction of bariatric surgery, many modifications are made in 
choice of operations and in peri- and post-operative care. For examples, there is a shift 
from open to minimally invasive surgery (MIS), from purely restrictive operations to 
more metabolic procedures, from standard care to fast track surgery, and from no 
coaching to multidisciplinary pre- and post-operative programs. Some of these are 
discussed in this thesis, however, these changes and evolutions are continuing. 
 
Minimally invasive surgery (MIS) - Robotics 
One of the most important changes in metabolic surgery was the introduction of 
the laparoscopic surgery.
94,95
 Compared to open bariatric surgery, laparoscopy has 
resulted in shorter hospitalization, lower peri-operative morbidity and mortality, and 
lower hospital costs.
49
 Furthermore, MIS improves the post-operative esthetics, as a 
result of a few small incisions instead of a large laparotomy scar. Along with the 
advancement of technology, opportunities in MIS are increasing, the main goal being 
to minimize ‘surgical damage’ and to improve (peri-)operative outcome. The Robotic-
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Assisted Surgery (RAS) gains popularity and is widely accepted in urologic and 
gynecologic interventions.
96-98
 RAS offers the possibility of improved accuracy and 
enhanced precision with a three-dimensional visualization, and may improve the 
ergonomics for the surgeon. Therefore, RAS is likely to be a next step in bariatric 
surgery as well. Robotic-assisted-RYGB (RRYGB) surgery seems safe and feasible, 
and some studies reported similar results to conventional laparoscopy.
99-107
 Longer 
operation time (partly due to docking of the robot) and the additional costs, however, 
are factors that may deter surgeons to make the transition to RRYGB.
108
 Reported 
operation time in RRYGB is approximately 3 hours,
109,110
 while fast track LRYGB 
reduces operation time to approximately 45 minutes (Chapter 5). This allows the 
operation teams in a high volume bariatric centers to perform 5-6 procedures per day. 
Therefore, introduction of a more time-consuming operation like the RRYGB (in its 
current form) may not be suitable in a fast track surgery program. In the future, 
adaptation of the logistics is necessary to make a transition to fast track RRYGB.  
 
Indications for surgery – Metabolic surgery 
An important discussion issue is the criteria that determine which patients are 
suitable for bariatric surgery. The leading indication for bariatric surgery traditionally 
was overweight with arbitrary borders. As part of this thesis, more evidence is available 
regarding metabolic effects, especially T2DM. This evolution may influence the 
indication and criteria for metabolic surgery. Some trials demonstrate that patients with 
moderate obesity (BMI < 35 kg/m
2
) and T2DM also benefit from a RYGB operation.
111
 
Therefore, international workgroups suggest widening of the criteria for surgery 
especially regarding lower BMI.
112
 They propose that patients with lower BMI with 
T2DM should be eligible for surgical intervention if conventional treatment fails. In line 
with this, surgery should be incorporated in diabetes treatment guidelines as an 
alternative treatment option for patients with uncontrolled T2DM.
113
 For implementation 
of these changes, governments, insurance companies and patient associations should 
be agreeing with these opinions. It seems that it’s a matter of time that these changes 
will be incorporated in the national and international guidelines. 
 
Novel techniques in gastric band and gastric bypass operations 
 As described in this thesis, it is commonly accepted that the LAGB no longer 
has prominent place in the routine treatment of morbid obesity. High band-related 
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9.2 FUTURE PERSPECTIVES 
 
Since the introduction of bariatric surgery, many modifications are made in 
choice of operations and in peri- and post-operative care. For examples, there is a shift 
from open to minimally invasive surgery (MIS), from purely restrictive operations to 
more metabolic procedures, from standard care to fast track surgery, and from no 
coaching to multidisciplinary pre- and post-operative programs. Some of these are 
discussed in this thesis, however, these changes and evolutions are continuing. 
 
Minimally invasive surgery (MIS) - Robotics 
One of the most important changes in metabolic surgery was the introduction of 
the laparoscopic surgery.
94,95
 Compared to open bariatric surgery, laparoscopy has 
resulted in shorter hospitalization, lower peri-operative morbidity and mortality, and 
lower hospital costs.
49
 Furthermore, MIS improves the post-operative esthetics, as a 
result of a few small incisions instead of a large laparotomy scar. Along with the 
advancement of technology, opportunities in MIS are increasing, the main goal being 
to minimize ‘surgical damage’ and to improve (peri-)operative outcome. The Robotic-
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Assisted Surgery (RAS) gains popularity and is widely accepted in urologic and 
gynecologic interventions.
96-98
 RAS offers the possibility of improved accuracy and 
enhanced precision with a three-dimensional visualization, and may improve the 
ergonomics for the surgeon. Therefore, RAS is likely to be a next step in bariatric 
surgery as well. Robotic-assisted-RYGB (RRYGB) surgery seems safe and feasible, 
and some studies reported similar results to conventional laparoscopy.
99-107
 Longer 
operation time (partly due to docking of the robot) and the additional costs, however, 
are factors that may deter surgeons to make the transition to RRYGB.
108
 Reported 
operation time in RRYGB is approximately 3 hours,
109,110
 while fast track LRYGB 
reduces operation time to approximately 45 minutes (Chapter 5). This allows the 
operation teams in a high volume bariatric centers to perform 5-6 procedures per day. 
Therefore, introduction of a more time-consuming operation like the RRYGB (in its 
current form) may not be suitable in a fast track surgery program. In the future, 
adaptation of the logistics is necessary to make a transition to fast track RRYGB.  
 
Indications for surgery – Metabolic surgery 
An important discussion issue is the criteria that determine which patients are 
suitable for bariatric surgery. The leading indication for bariatric surgery traditionally 
was overweight with arbitrary borders. As part of this thesis, more evidence is available 
regarding metabolic effects, especially T2DM. This evolution may influence the 
indication and criteria for metabolic surgery. Some trials demonstrate that patients with 
moderate obesity (BMI < 35 kg/m
2
) and T2DM also benefit from a RYGB operation.
111
 
Therefore, international workgroups suggest widening of the criteria for surgery 
especially regarding lower BMI.
112
 They propose that patients with lower BMI with 
T2DM should be eligible for surgical intervention if conventional treatment fails. In line 
with this, surgery should be incorporated in diabetes treatment guidelines as an 
alternative treatment option for patients with uncontrolled T2DM.
113
 For implementation 
of these changes, governments, insurance companies and patient associations should 
be agreeing with these opinions. It seems that it’s a matter of time that these changes 
will be incorporated in the national and international guidelines. 
 
Novel techniques in gastric band and gastric bypass operations 
 As described in this thesis, it is commonly accepted that the LAGB no longer 
has prominent place in the routine treatment of morbid obesity. High band-related 
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complication rates are the main reason for cessation of band placements. To overcome 
these problems, many modifications of the adjustable gastric bands are made since 
their introduction. These changes result in a significant reduction of band-related 
complications.
114
 Therefore, further improvement of the band may result in an improved 
durability of the gastric band. In addition, novel techniques with the (adjustable and 
non-adjustable) gastric bands are introduced. The Laparoscopic Adjustable Gastric 
Banded Plication (LAGBP) is a combination of the LAGB with plication of the 
stomach.
115,116
 The LAGBP increases the efficacy in terms of weight loss compared to 
conventional LAGB, and may have similar effect as the LSG on the short-term. Long-
term follow-up is needed to determine its safety and feasibility. Furthermore, non-
adjustable gastric bands are used in combination with the RYGB procedure, so called 
banded Roux-en-Y gastric bypass (BRYGB).
117,118
 A non-adjustable band is placed 
around the gastric pouch to realize additional weight loss with preventing weight regain 
due to dilatation of the pouch or pouch outlet. Non-randomized studies report %EWL 
of 60 – 80% after 2 years, and even up to 85% after 4 years.
117-119
 However, 
randomized clinical trials comparing conventional LRYGB with BRYGB are not 
available. Bessler et al.
120
 first described in a randomized setting greater weight loss 
after 36 months in banded gastric bypass patients compared to conventional gastric 
bypass patients, however, they included only super obese patients (BMI > 50 kg/m
2
) 
and performed open procedures. To our knowledge, long-term data of this study is not 
yet available. Therefore, a randomized clinical trial is started in the Rijnstate hospital 
to research the effectiveness of the laparoscopic BRYGB with a silicone band 
compared to a conventional LRYGB procedure (BANDOLERA trial, Clinical Trials 
Identifier: NCT02545647).  
 Furthermore, some anatomical changes of the RYGB itself are performed and 
the effectiveness is currently being studied. An important conclusion of this thesis is 
that elongation of the Roux limb in RYGB procedure does not increase weight loss 
(Chapter 4). In terms of future perspectives, one of our own studies (the ELEGANCE 
trail) will provide us information about the effectiveness and feasibility of the long BPL 
RYGB in a randomized setting. The omega-loop (or mini-) gastric bypass with only a 
BPL created a base for this study. Notable, the omega-loop gastric bypass is performed 
with a ‘sleeved’ gastric pouch which theoretically induces more restriction.
45-48
 The 
‘sleeved’ pouch is equally narrow but longer than the pouch in a standard RYGB 
procedure. To investigate the effect of this extended pouch in RYGB patients, a 
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randomized clinical trial is launched in the Rijnstate hospital (Extended pouch Roux-
en-Y gastric bypass study, Clinical Trials Identifer: NCT02218957). 
In the future, these studies will provide us information about weight loss, 
complication rate, quality of life and nutritional deficiencies in patients who received 
these alternative  LRYGB procedures. It is obvious that the currently performed LRYGB 
procedure is not the end of the evolution, and it is expected that these studies will help 
us to create an ‘optimal’ LRYGB procedure. 
 
9. 3 GENERAL CONCLUSION 
 
In conclusion, the LAGB procedure must be offered in selected patients as a 
primary option because of high risk for late complications and need for removal of the 
band. In case of a complication which requires a conversion, the LRYGB operation 
now seems the appropriate procedure, based on weight reduction results and 
complication rates. The LRYGB still remains the first choice for patients seeking 
bariatric surgery, because of sustained weight loss and reduction of obesity related 
metabolic diseases, especially T2DM. The optimal LRYGB technique is not yet clarified 
and the role of the limb lengths must be further studied in prospective clinical trials. 
The LRYGB procedure is accompanied by numerous potential peri- and post-operative 
side effects and complications. Introduction of the FTS program results in a faster 
recovery of the patient and improve the peri-operative efficacy. Developing a 
customized multivitamin supplement resulted in less post-surgical nutritional 
deficiencies, although it did not yet provide complete prevention. These are important 
changes in metabolic surgery and already had a huge impact in the bariatric landscape.  
The evolution of the RYGB surgery is still going on! 
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10.1 SAMENVATTING EN ALGEMENE DISCUSSIE 
 
 De hoofddoelen in het behandelen van overgewicht zijn blijvend gewichtsverlies, 
verbetering van kwaliteit van leven en het reduceren van overgewicht gerelateerde 
ziekten (co-morbiditeit). Bariatrische chirurgie, ook wel metabole chirurgie genoemd, 
is een geaccepteerde behandeling van overgewicht en co-morbiditeiten. De groei van 
de overgewichtsepidemie resulteert in een toename van vraag naar chirurgische 
interventies. Idealiter heeft een chirurgische interventie lage procedure-gerelateerde 
morbiditeit (complicaties) en mortaliteit, zonder kwaliteit in te leveren. De 
Laparoscopische Roux-en-Y Gastric Bypass (LRYGB, ‘de maagomleiding’) operatie 
wordt momenteel beschouwd als de ‘gouden standaard’ in metabole chirurgie, 
ondanks de complexiteit van de operatie vergeleken met de Laparoscopische 
Adjustable Gastric Band (LAGB, ‘de opblaasbare maagband’) en de Laparoscopische 
Sleeve Gastrectomie (LSG, ‘de buismaag’) operatie. In dit proefschrift wordt de 
impopulariteit van de LAGB-operatie, en de opkomst en evolutie van de LRYGB 
besproken. Andere hoofdonderwerpen zijn het optimaliseren van de chirurgische 
techniek van de LRYGB, het verfijnen van de zorg rondom de operaties en het 
detecteren en voorkomen van postoperatieve tekorten aan nutriënten na een LRYGB-
operatie.  
 
DEEL I 
 Deel I van dit proefschrift vat de effectiviteit en complicaties van de LAGB-
operatie op de lange termijn samen. Volume verkleinende operaties, zoals de 
maagband, zijn geïntroduceerd om de voedingsinname te reduceren (restrictieve 
chirurgie). Ondanks de veelbelovende resultaten op de korte termijn, zijn de 
gerapporteerde resultaten op de lange termijn om diverse redenen teleurstellend.
1-10
  
 
LAGB 
 The LAGB, is voor het eerst geïntroduceerd in 1993,
11,12
 en bedroeg wereldwijd 
ongeveer 42% van alle bariatrische ingrepen in 2008.
13
 Dit kwam doordat deze 
operatie werd beschouwd als een omkeerbare, relatief veilige en makkelijk uit te 
voeren operatie met lage mortaliteit en morbiditeit.
14,15
 Daarnaast waren er studies die 
rapporteerden dat patiënten tot 60% van hun overgewicht verloren binnen 3-5 jaar na 
de operatie.
3,7,15
 Echter veel patiënten hadden te kampen met band-gerelateerde 
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complicaties, zoals verwijding van de maagpouch, migratie of slippen van de band en 
dislocatie of pijn van de injectie poort. Verschillende operatieve technieken zijn over 
de jaren heen geïntroduceerd om deze complicaties te vermijden.
7,16
 Desondanks, was 
de ervaring dat veel patiënten op de lange termijn onvoldoende gewicht verloren of 
een sterke gewichtstoename hadden, een lage kwaliteit van leven scoorden of de band 
hadden laten verwijderen (Hoofdstuk 2). Deze feiten reflecteren wellicht de 
ongeschiktheid van een LAGB als definitieve oplossing voor behandeling van 
overgewicht. Daarom zijn veel chirurgen gestopt met het plaatsen van een maagband. 
Het aantal LAGB-operaties is afgenomen tot 18% van alle bariatrische operaties in 
2011 en zelfs verder gedaald tot 10% in 2013.
13,17
 
 Maar is het falen van deze behandeling compleet te wijten aan de maagband 
zelf of was er sprake van een structureel probleem in de behandeling van morbide 
obesitas? De maagband operatie had een exponentiële groei in een periode dat 
morbide obese patiënten geen strikt begeleidingsprogramma hadden. Hedendaags 
hebben patiënten voor de operatie een intensief begeleidingstraject ter voorbereiding 
op de operatie en worden na de operatie gedurende enkele jaren gevolgd. Het is 
namelijk bekend dat een operatie maar een deel van de behandeling van overgewicht 
is. Het is dus mogelijk dat veel van de gefaalde behandelingen komt door onder 
behandeling van deze patiënten. Daarom is het gerechtvaardigd om ons af te vragen 
wat er was gebeurd als deze patiënten vanaf het begin een multidisciplinaire 
behandeling kregen. Wellicht hadden sommige gefaalde behandelingen voorkomen 
kunnen worden. Mogelijk hadden de complicaties als migratie of slippen van de band 
vroeg opgespoord en behandeld kunnen worden. Zoals eerder gezegd is slechte 
naleving van dokters afspraken door patiënten een indicator voor een matige uitkomst, 
maar waren deze patiënten wel voldoende geïnformeerd? Daarom is het waard om te 
zoeken naar patiëntkarakteristieken die een onderscheid kunnen maken tussen 
patiënten die geschikt en ongeschikt zijn voor behandeling met een maagband.
18,19
  
 
Complicaties na LAGB 
 Patiënten die door een bandgerelateerde complicatie de maagband hebben 
laten verwijderen, worden geadviseerd een tweede bariatrische operatie te ondergaan 
om gewichtstoename en het ontwikkelen van overgewicht gerelateerde ziekten te 
voorkomen. Sommige patiënten weigeren echter een tweede operatie. In het Rijnstate 
ziekenhuis, hadden alle patiënten die geen tweede operatie ondergingen kwamen in 
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gewicht aan, terwijl patiënten die wel een operatie ondergingen (een LRYGB-operatie) 
hadden additioneel significant gewichtsverlies (Hoofdstuk 2). Revisie naar een 
LRYGB-operatie na een gefaalde LAGB-operatie wordt veelvuldig uitgevoerd.
20-27
 
Echter, deze tweede operatie wordt beschouwd als een technisch complexere operatie 
met hogere risico op complicaties in vergelijking tot een primaire operatie.
20
 Daarom 
pleiten sommige chirurgen om deze revisie operatie in twee stappen uit te voeren. 
Echter, in Hoofdstuk 2 wordt beschreven dat een revisie van een gefaalde band naar 
een LRYGB wel degelijk in één operatie veilig en uitvoerbaar is. In 90% van de 
patiënten verliep de operatie ongecompliceerd en slechts 4% van patiënten hadden 
een chirurgische interventie nodig binnen 30 dagen na de operatie. Echter, hebben 
falende patiënten op een maagband ook suboptimale resultaten na een redo-RYGB. 
Patiënt gerelateerde factoren, zoals eetstoornissen of falen in leefstijlveranderingen, 
hebben mogelijk negatieve invloeden op het resultaat. Zoals eerder aangegeven is 
strikte begeleiding na een operatie door multidisciplinaire team door gespecialiseerde 
obesitas verpleegkundige, diëtist, fysiotherapeut en psycholoog noodzakelijk.  
 
Revisie operaties 
 Alternatieven voor een LRYGB-operatie als een revisie operatie voor een 
gefaalde LAGB, zijn de LSG en de Laparoscopische Biliopancreatische Diversie met 
Duodenal Switch (LBPDDS) operaties.
20,21
 Het lijkt irrationeel om nog een om 
restrictieve operatie, zoals een LSG (‘buismaag’), uit te voeren na een maagband. 
Echter, patiënten die een goed resultaat hebben gehad op de maagband maar een 
revisie operatie nodig hebben door een complicatie, hebben mogelijk profijt van deze 
operatie. In de literatuur worden echter tegenstrijdige data beschreven met betrekking 
tot de veiligheid en effectiviteit van een redo-LSG.
21,28,29
 Gewichtstoename of 
onvoldoende gewichtsverlies na een maagband is wellicht een indicatie voor een 
operatie die ook malabsorptie (minder opname van voedingsstoffen) bewerkstelligd in 
tegen stelling tot alleen volumereductie. Deze type operaties geven meer 
gewichtsreductie, echter gaan gepaard met hogere kans op voedingsdeficiënties.
21,30-
32
 Concluderend, de optimale revisie operatie na een gefaalde maagband is nog niet 
gedefinieerd.  
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DEEL II 
 Deel II van dit proefschrift concentreert zich op de effectiviteit en veiligheid van 
de LRYGB-operatie en is opgedeeld in vier hoofdstukken. De eerste hoofdstuk 
vergelijkt de LRYGB met de LAGB en LSG-operaties. De tweede hoofdstuk beschrijft 
de effecten van aanpassingen in de lengtes van de gastric bypass operatie. Als derde 
wordt het effect op co-morbiteiten beschreven. Tot slot is de optimalisatie van de 
perioperatieve zorg bij LRYGB-operatie onderzocht.  
 
Meest uitgevoerde bariatrische operaties 
 Ondanks een enorme groei van het aantal bariatrische operaties in het begin 
van de 21
e
 eeuw, voornamelijk de LAGB, LSG en de LRYGB, zijn er weinig 
onderzoeken die deze procedures vergelijken. Sommige auteurs beweren dat de 
LRYGB superieur is boven de LAGB met betrekking tot gewichtsverlies, echter deze 
kleine aantal gerandomiseerde studies hebben een klein aantal patiënten 
vergeleken.
33-35
 Aan de andere kant heeft de LRYGB een hoger operatierisico ten 
opzichte van de LAGB. Daarom is er een alternatieve restrictieve operatie, in de vorm 
van LSG en met lage operatierisico en goede resultaten met betrekking tot 
gewichtsverlies en overgewicht gerelateerde co-morbiditeiten, toegevoegd aan de 
operatieve opties. Verschillende studies tonen vergelijkbare gewichtsreductie op de 
korte termijn na LSG en LRYGB.
36-40
 Daarom wordt de LSG als een meest geschikte 
alternatief beschouwd. Er zijn echter enkele zorgen geuit voor de lange termijn, omdat 
relatief veel patiënten na 5 jaar weer aankomen.
41
 Om de klinische uitkomsten van 
deze 3 meest uitgevoerde operaties vast te stellen, is er een multicentrische gepaarde 
cohortstudie uitgevoerd in 2 hoog-volume bariatrische klinieken in Nederland. De 
resultaten van de studie worden beschreven in Hoofdstuk 3. In totaal zijn er 735 
patiënten die een LAGB, LSG of een LRYGB-operatie hebben ondergaan gepaard 
voor geslacht en leeftijd. Het gewichtsverlies was vergelijkbaar voor de LSG en de 
LRYGB operaties gedurende de eerste 5 jaren na de operatie. Dit komt overeen met 
de beschikbare literatuur. Echter, bij 9% van de patiënten die een LSG-operatie 
hebben ondergaan is er na gemiddeld 2 jaar een conversie van de LSG naar een 
LRYGB verricht, terwijl er geen revisie operaties waren na een LRYGB procedure. De 
LAGB groep had significant lager gewichtsverlies in vergelijking tot de andere twee 
groepen, terwijl in 20% van de patiënten een revisie operatie nodig was in verband met 
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DEEL II 
 Deel II van dit proefschrift concentreert zich op de effectiviteit en veiligheid van 
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e
 eeuw, voornamelijk de LAGB, LSG en de LRYGB, zijn er weinig 
onderzoeken die deze procedures vergelijken. Sommige auteurs beweren dat de 
LRYGB superieur is boven de LAGB met betrekking tot gewichtsverlies, echter deze 
kleine aantal gerandomiseerde studies hebben een klein aantal patiënten 
vergeleken.
33-35
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36-40
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complicaties. Daarom is een LSG een betere restrictieve behandeling dan een LAGB 
en voor veel patiënten een potentieel alternatief voor een LRYGB. 
 
Dunne darm lengtes 
 Om de uitkomsten van een RYGB-operatie te verbeteren zijn er verschillende 
technische aanpassingen gedaan aan de constructie van de RYGB zelf. Eén van de 
niet-opgeloste items zijn de totale lengte van de bypass en de lengte van de separate 
darmlissen. In de laatste decennia hebben veel auteurs zich gefocust op de alimentaire 
lis (AL, ‘voedings-lis’, figuur 1 in Hoofdstuk 1). In veel gevallen varieerde de lengte 
van de AL tussen de 75 cm en 200 cm, met een biliopancreatische lis (BPL, 
‘verteringssappen-lis’, figuur 1 in Hoofdstuk 1) van ongeveer 50 cm. Veel chirurgen 
legden een langere AL aan in patiënten met een hoger BMI, met een arbitraire grens 
van BMI van 50 kg/m
2
 (super obees). Dit was ook de strategie in het Rijnstate 
ziekenhuis. Sinds 2009 wordt er een vaste maat (150 cm) voor de AL gebruikt in alle 
patiënten die een RYGB-operatie ondergaan, ongeacht de BMI. In Hoofdstuk 4 wordt 
het effect op BMI en gewichtsverlies van de verschillende toegepaste dunne 
darmlissen beschreven afkomstig van een database die bijgehouden is van alle 
primaire LRYGB-operaties die in het Rijnstate ziekenhuis zijn verricht. Gedurende de 
eerste 5 jaar na de operatie is er geen verschil ontdekt in gewichtsverlies tussen de 
operaties met verschillende AL lengtes. Verder wordt er een overzicht gegeven van de 
beschikbare literatuur die korte en lange AL lengtes in RYGB-operaties vergelijken, 
hetgeen conflicterende resultaten tonen. Daarom is het betwistbaar of de AL lengte de 
bepalende factor is voor de mate van gewichtsverlies. Verdere evolutie van de techniek 
is aan de gang, maar het is onduidelijk welke aanpassing van toegevoegde waarde zal 
zijn. Een systematische review door Mahawar et al. 
42
 met betrekking tot de dunne 
darm lengtes demonstreert een grote variatie in praktijk tussen de chirurgen. Sommige 
beweren significant meer gewichtsverlies te bereiken na verlenging van de BPL in de 
Roux-en-Y constructie.
43,44
 Een mini-gastric bypass (ook wel omega-loop gastric 
bypass genoemd) is een operatie met een lange BPL zonder een AL. Verschillende 
studies demonstreren vergelijkbare of zelfs meer gewichtsverlies in vergelijking tot de 
traditionele RYGB.
45-48
 Daardoor blijft de vraag welke dunne darm lis (de BPL of de 
AL) belangrijker is met betrekking gewichtsverlies? Om deze vraag te beantwoorden 
is er in het Rijnstate ziekenhuis een gerandomiseerde klinische studie opgestart. Dit 
om het effect van een lange BPL RYGB (BPL lengte van 150 cm) in vergelijking tot 
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een standaard RYGB (zoals beschreven in Hoofdstuk 1) in patiënten die een primaire 
of een revisie RYGB ondergaan, te onderzoeken (ELEGANCE trial, Clinical Trials 
Identifier: NCT01686997). De eerste resultaten van deze studie zijn gepresenteerd op 
de 18
e
 en 19
e
 editie van het wereldcongres van de internationale federatie voor 
chirurgie van overgewicht en metabole ziekten (IFSO). Het lijkt dat de patiënten die 
zowel een primaire als revisie operatie met een lange BPL ondergaan, meer 
gewichtsreductie hebben op de korte termijn. Het is afwachten of deze trend zich 
voortzet op de lange termijn. 
 
Fast track chirurgie 
 De introductie van laparoscopische chirurgie (‘kijkoperatie’) in bariatrische 
ingrepen resulteerde in een extreme daling van peri-operatieve complicaties en 
ziekenhuis opname, en is daarnaast kosteneffectief.
49,50
 Echter, de toename van meer 
uitdagendere operaties, zoals een LRYGB, zorgt voor dilemma’s in operatie planning 
en logistiek. Hoog-volume ziekenhuizen hebben betere peri-operatieve uitkomsten ten 
opzichte van laag-volume centra,
51
 maar capaciteit en bezetting zijn de grootste 
belemmeringen tot groei in de meeste ziekenhuizen. Om die reden is er een Fast Track 
Surgery (FTS) programma geïmplementeerd om de logistiek en de zorg rondom een 
operatie te verbeteren. Eerdere onderzoeken naar dikke darm operaties heeft 
aangetoond dat deze benadering veilig en toepasbaar is.
52-57
 Dit FTS-programma is 
gedurende 1 jaar in verschillende stappen geïntroduceerd in het Rijnstate ziekenhuis 
in Arnhem. In Hoofdstuk 5 worden de uitkomsten van dit FTS-programma vergeleken 
met de conventionele programma. Dit FTS-programma is gebaseerd op een: 
multidisciplinaire benadering; structurele organisatie gedurende de operatie en 
herstelperiode; samenwerking tussen de disciplines; elimineren van onnodige 
handelingen en de motivatie van de patiënt. Dit FTS-programma resulteerde in een 
verbetering van peri-operatieve zorg en sneller herstel van de patiënten.  Opnameduur 
in het ziekenhuis was gereduceerd met 34% en de operatietijd daalde met 31%. 
Daarnaast kon het operatieteam meer operaties uitvoeren binnen dezelfde tijd. Dit 
resulteerde in een stijging van vijf naar zes operaties in een dag in het Rijnstate 
ziekenhuis. Tot slot was er een grotere turnover van patiënten op de chirurgische 
afdeling zonder noodzaak van extra mankracht of bedden. 
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Metabole chirurgie 
 Obesitas wordt geassocieerd met metabole ziekten als type 2 diabetes mellitus 
(T2DM), hoge bloeddruk (hypertensie) en verhoogd cholesterol (dyslipidemie). 
Daardoor hebben obese patiënten een significant verhoogd risico op micro- en 
macrovasculaire ziekten, wat leidt tot verminderde kwaliteit van leven en 
levensverwachting.
58
 Gewichtsverlies is de hoeksteen van behandeling in obese 
patiënten met T2DM. De Diabetes Surgery Summit Consensus Conference (DSSCC), 
met o.a. de American Diabetes Association (ADA), de IFSO en de International 
Diabetes Federation (IDF), accepteren bariatrische chirurgie als een alternatieve 
behandeling van obesitas gerelateerde T2DM.
59,60
 Er zijn studies die tot 80% herstel 
van suikerziekte (remissie) na een RYGB-operatie rapporteren.
61-64
 Echter, een deel 
van de patiënten (9 – 24%) die initieel herstelde, had een terugval van ziekte. In 
Hoofdstuk 6 wordt het effect van LRYGB op remissie van T2DM, hypertensie en 
verhoogd cholesterol na een gemiddelde periode van 82 maanden onderzocht. In 
totaal had 71% van de patiënten een complete remissie van suikerziekte gedurende 
de eerste jaren na de operatie. Negentien procent van de patiënten had een terugval 
van de suikerziekte en behield 52% van de patiënten hun remissie tot het eind van de 
follow-up. Onafhankelijke voorspellers voor behoudt van remissie op de lange termijn 
waren HbA1c waarde en de duur van suikerziekte voor de operatie. Totale medicatie 
gebruik voor T2DM daalde van 85% naar 37% van de patiënten, en insuline gebruik 
daalde van 40% naar 6% van alle patiënten. Daarnaast had een op de vier patiënten 
verbetering van hypertensie en dyslipidemie. Daarvoor is metabole chirurgie een meer 
geschikte en geaccepteerde definitie dan bariatrische of overgewichtschirurgie voor 
patiënten die een bariatrische procedure ondergaan.  
 Het feit dat de LSG als een alternatief voor een LRYGB wordt beschouwd met 
betrekking tot gewichtsverlies, werpt de vraag op of dit ook geldt voor metabole 
veranderingen. Een significante vermindering van T2DM op de korte en middellange 
termijn zijn ook gerapporteerd na een LSG-operatie, echter data over het effect op de 
lange termijn is beperkt.
64-68
 Sommige studies tonen remissie tot 68% na 5 jaar,
67,68
 
terwijl er ook studies zijn die een lage remissie percentage van 9% en terugval van 
38% rapporteren in een vergelijkbare periode.
64
 Mogelijke onafhankelijke voorspellers 
voor succesvolle remissie zijn leeftijd, vrouwelijk geslacht, BMI, medicatiegebruik, c-
peptide waarde, duur van suikerziekte voor de operatie of mate van gewichtsverlies 
en/ of gewichtstoename na de operatie. Opnieuw enorme toename van gewicht op de 
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lange termijn tot 10 jaar na een LSG-operatie (ongeveer 60% van de patiënten),
69
 gaat 
mogelijk gepaard met recidief (terugval) van metabole ziekten. 
 Er zijn verschillende mechanismen beschreven met betrekking tot herstel van 
suikerziekte na een RYGB-operatie. Het effect op (verbetering van) 
glucosemetabolisme vindt plaats in twee episodes.
70-72
 Het vroege effect ontstaat 
binnen enkele dagen tot weken na de operatie door calorie vermindering en versnelde 
passage van nutriënten (voedingsmiddelen) door de dunne darm. Dit resulteert 
respectievelijk in verminderde glucose productie door de lever en verhoogde insuline 
uitscheiding. Daarnaast stimuleert de versnelde passage de uitscheiding van 
darmhormonen, zoals glucagon-like peptide-1 (GLP-1) uit de L-cellen vanuit het laatste 
deel van de dunne darm, die zorgen voor insuline uitscheiding en vermindering van 
glucosewaarden na het eten. Verder zorgen andere darmhormonen, zoals polypeptide 
tyrosine-tyrosine (PYY) en oxyntomoduline (OXM), die ook door de L-cellen worden 
geproduceerd (ook wel eetlust-regulerende darmhormonen genoemd), voor 
(over)verzadiging, vermindering van voedselinname en vertraagde maagontlediging. 
Het late effect ontstaat na maanden tot jaren door gewichtsverlies wat leidt tot 
verhoogde insuline gevoeligheid. Verhoogde GLP-1 waarden in het bloed heeft ook 
een positief effect op het verzadigingsgevoel. Daarnaast daalt de ghreline waarden in 
het bloed (ook wel bekend met als eetlust stimulerende hormoon) wat nuttig is voor het 
behoudt van gewichtsverlies. Dus, herstellen van insuline gevoeligheid en behoudt van 
beta-cel functie van de alvleesklier, de kernproblemen bij T2DM, is het hoofddoel in 
obese patiënten met suikerziekte.
74,74
 De RYGB-operatie grijpt voornamelijk in op deze 
defecten. Hierdoor kan mogelijk de grotere effectiviteit op herstel van T2DM van RYGB 
ten opzichte van LSG-operatie verklaard worden.
70,75,76
 Opvallend is dat de 
verschillende hormonale veranderingen, vergelijkbaar aan de RYGB, ondanks de 
anatomische verschillen ook na een sleeve operatie zijn waargenomen.
71,72
 Versnelde 
maagontlediging na een sleeve operatie wordt als een mogelijke verklaring 
genoemd.
77
 Sommige onderzoekers beweren dat er geen verschil is in herstel van 
T2DM na een gastric bypass en sleeve operatie.
78,79
 Hierdoor kan een sleeve operatie 
niet alleen als een restrictieve operatie, maar potentieel ook als een metabole 
procedure beschouwd worden en mogelijk een alternatief zijn voor de RYGB. Daarom 
zijn er meer resultaten op de langere termijn noodzakelijk met betrekking tot metabole 
ziekten voor zowel de LRYGB en LSG.  
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DEEL III 
 Deel III van dit proefschrift focust zich op de effecten op de nutriënten status na 
een RYGB-operatie. Onbehandelde nutriënten tekorten zijn een potentiele risico op de 
gezondheid. In de laatste decennia, is er steeds meer (internationale) aandacht voor 
vitamine en mineralen tekorten na een LRYGB-operatie. Verminderde voedselinname 
en opnamecapaciteit door de dunne darm zijn de mogelijke oorzaken. Meeste vitamine 
en mineralen tekorten zijn ijzer (47-66%), vitamine B12 (37-50%), foliumzuur (15-38%), 
vitamine D (20-51%) en calcium (±10%).
80-90
 Daarom worden de patiënten, conform 
de American Society for Metabolic and Bariatric Surgery (ASMBS) richtlijn, 
geadviseerd om dagelijks multivitaminen, vitamine D en calciumtabletten in te nemen 
na de operatie.
91
 Het gevaar ligt bij de therapieontrouwe patiënten, omdat bekend is 
dat deze patiënten verhoogd risico hebben tot ontwikkelen van deze tekorten.
92
 Echter, 
levenslange therapietrouwheid is moeilijk te waarborgen. Voor sommige patiënten is 
er een financiële reden om te staken met deze supplementen omdat ze meestal niet 
vergoed worden. Terwijl anderen staken door onderschatting van het probleem. In 
Hoofdstuk 7 wordt de nutriënten status op de lange termijn (81 maanden) van de 
patiënten die een LRYGB hebben ondergaan onderzocht.  Daarnaast wordt het effect 
van multivitaminen gebruik beschreven. Tachtig procent van de patiënten gebruikte 
extra supplementen of medicatie, terwijl 69% van de patiënten multivitaminen tabletten 
gebruikte tijdens de laatste controle. Het was opvallend dat, ondanks extra 
medicatiegebruik, bijna een kwart van de patiënten bloedarmoede en de helft van de 
patiënten een vitamine D tekort had. Patiënten die multivitaminen gebruikten 
(therapietrouwe patiënten) hadden minder ijzer, vitamine B12 en vitamine D 
deficiënties. Deze cijfers suggereren echter dat gebruik van standaard multivitaminen 
minder geschikt zijn om deficiënties na de operatie te voorkomen. Deze tabletten 
bevatten lagere doseringen aan vitamines en mineralen dan het advies volgens de 
ASMBS richtlijn. Opmerkelijk is dat er geen RYGB-specifieke multivitaminen bestond, 
ondanks dat er wereldwijd honderdduizenden operaties worden uitgevoerd. Daarom is 
er in het Rijnstate ziekenhuis een speciale multivitaminen (WLS Forte
®
, FitForMe, 
Rotterdam, Nederland), met hogere doseringen aan vitaminen en mineralen, 
ontwikkelt. Deze tablet bevat onder andere vitamine B12 14000% ADH (Aanbevolen 
Dagelijkse Hoeveelheid), ijzer 500% ADH en foliumzuur 300% ADH. In een 
studieverband is deze WLS Forte
®
 vergeleken met een standaard multivitaminen tablet, 
die ongeveer 100% ADH van deze vitamine en mineralen bevatten (beschreven in 
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Hoofdstuk 8). Gebruik van WLS Forte® na LRYGB resulteerde in minder ijzer, 
vitamine B12 en foliumzuur deficiënties vergeleken met de standaard supplement 
gedurende de eerste jaar na de operatie. Echter, door reserves in het menselijk 
lichaam zullen veel vitaminen en mineralen tekorten pas na enkele jaren ontstaan. Een 
vervolgonderzoek op deze gerandomiseerde studie toont aan dat er ook minder 
bloedarmoede, en ijzer en vitamine B12 deficiënties zijn na WLS Forte
® 
vergeleken 
met standaard multivitaminen 3 jaar de na de operatie.
93
 Echter, deze deficiënties zijn 
niet compleet uitgeschakeld. Derhalve is het nog steeds onzeker of aangepaste/ 
gespecialiseerde multivitaminen supplementen volledig deze deficiënties kan 
voorkomen.  
 
10.2 TOEKOMSTPERSPECTIEF 
 
 Sinds de introductie van bariatrische chirurgie zijn er verschillende 
aanpassingen gedaan in de keuze en de zorg rondom de operatie, zoals verschuiving 
van open naar minimaal invasieve operatie (‘kijkoperatie’); van maag (volume) 
verkleinende operaties naar metabole procedures; van standaard zorg naar fast track 
operaties en zorg zonder begeleiding naar multidisciplinaire begeleidingsprogramma’s. 
Enkele veranderingen zijn bediscussieerd in dit proefschrift, echter de evolutie is nog 
steeds gaande.  
 
Minimaal invasieve chirurgie – Robot geassisteerde chirurgie 
 Een van de meest belangrijke verandering was de introductie van 
laparoscopische chirurgie (‘kijkoperatie’).
94,95
 In vergelijking tot open bariatrische 
chirurgie, resulteerde laparoscopie in kortere ziekenhuisopname, lagere morbiditeit en 
mortaliteit, en lagere ziekenhuiskosten.
49
 Daarnaast zorgt minimaal invasieve chirurgie 
voor verbetering van esthetiek door de kleinere littekens in plaats van een groot litteken 
bij een open operatie. De robot geassisteerde chirurgie (RAC) wint populariteit en is 
breed geaccepteerd in urologische en gynaecologische interventies.
96-98
 De voordelen 
van RAC zijn onder andere betere accuratesse en precisie door 3D-beeld en is 
mogelijk ergonomisch beter voor de chirurg. Daardoor is het aannemelijk dat RAC de 
volgende stap is in bariatrische chirurgie. Robot geassisteerde RYGB (RRYGB) lijkt 
veilig en uitvoerbaar. Enkele studies hebben ten opzichte van de conventionele 
laparoscopie vergelijkbare resultaten gerapporteerd.
99-107
 Echter, nadelen als langere 
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operatieduur en hogere kosten zal mogelijk chirurgen weerhouden om de overgang 
naar de robot te maken.
108
 Gerapporteerde operatietijd in RRYGB is ongeveer 3 
uur,
109,110
 terwijl fast track LRYGB de tijd naar ongeveer 45 minuten reduceert 
(Hoofdstuk 5). Hierdoor kunnen er in hoog-volume klinieken 5 tot 6 operaties per dag 
uitgevoerd worden. Daarom zal de introductie van een meer tijdrovende operatie, zoals 
de RRYGB, niet geschikt zijn voor een fast track chirurgie programma. Voor de 
toekomst zullen er logistieke veranderingen noodzakelijk zijn om de transitie naar fast 
track RRYGB te maken.  
 
Indicatie voor operatie – metabole chirurgie 
 Een belangrijk discussiepunt is de criteria die bepalen welke patiënten geschikt 
zijn voor bariatrische chirurgie. Van oudsher was de leidende indicatie overgewicht met 
arbitraire grenswaarden. Zoals beschreven in dit proefschrift, is er meer bewijs 
beschikbaar met betrekking tot de metabole effecten, voornamelijk op T2DM. Dit 
beïnvloedt mogelijk de indicaties en criteria voor metabole chirurgie. Sommige studies 
demonstreren dat patiënten met een matige obesitas (BMI < 35 kg/m
2
) en T2DM ook 
profiteren van een RYGB operatie.
111
 Om die reden stellen internationale werkgroepen 
voor om de criteria voor operatie uit te breiden, voornamelijk met betrekking tot lagere 
BMI waarden.
112
 Ze stellen voor dat patiënten met lagere BMI met T2DM ook geschikt 
zijn voor operatie als de conventionele (medicamenteuze) behandelingen falen. In lijn 
hiermee moet een operatieve interventie als een alternatieve behandeloptie voor 
patiënten met ongecontroleerde T2DM worden opgenomen in richtlijnen voor 
diabetesbehandeling.
113
 Voor implementatie van deze aanpassingen moeten de 
overheden, verzekeraars en patiëntenverenigingen akkoord gaan met deze meningen. 
Het lijkt een kwestie van tijd dat deze veranderingen doorgevoerd zullen worden in 
nationale en internationale richtlijnen.  
 
Nieuwe technieken in maagband en gastric bypass operaties 
  Zoals beschreven in dit proefschrift, is het algemeen geaccepteerd dat de LAGB 
niet meer een prominente plaats inneemt in routinematige behandeling van morbide 
obesitas. Band gerelateerde complicaties is de hoofdoorzaak van deze daling in 
maagband operaties. Om deze problemen om te lossen, zijn er verschillende 
aanpassingen verricht. Deze veranderingen resulteerde in een significante daling van 
band gerelateerde complicaties.
114
 Daarom kan verbetering van de band resulteren in 
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duurzaamheid van de maagband. Daarnaast zijn er nieuwe technieken met 
(opblaasbare en niet-opblaasbare) maagbanden geïntroduceerd. De Laparoscopische 
Adjustable Gastric Banded Plication (LAGBP) is een combinatie van LAGB met 
‘plooiing’ van de maag.
115,116
 De LAGBP verhoogd de effectiviteit in termen van 
gewichtsverlies ten opzichte van de conventionele LAGB en heeft op de korte termijn 
vergelijkbare resultaten in vergelijking tot de LSG. Onderzoek moet uitwijzen of het op 
de lange termijn ook veilig en geschikt is. Daarnaast worden niet-opblaasbare 
maagbanden gebruikt in combinatie met de RYGB operatie, de zogenoemde banded 
Roux-en-Y gastric bypass (BRYGB).
117,118
 Een niet-opblaasbare band wordt geplaatst 
om de maagpouch om extra gewichtsverlies te realiseren en gewichtstoename te 
voorkomen ten gevolge van uitzetting van de pouch. Niet-gerandomiseerde 
onderzoeken rapporteren 60-80% %EWL na 2 jaar en zelfs tot 85% na 4 jaar.
117-119
 
Echter, er zijn geen gerandomiseerde klinische studies beschikbaar die de 
conventionele LRYGB en BRYGB vergelijken. Bessler et al.
120 
beschreef voor het eerst 
in een gerandomiseerde setting meer gewichtsverlies na 36 maanden in BRYGB ten 
opzichte van conventionele bypass, echter deze studie is alleen uitgevoerd bij super 
obese patiënten (BMI > 50 kg/m
2
) en het waren open procedures. De resultaten op de 
lange termijn zijn echter nog niet beschikbaar. Daarom is er een gerandomiseerde 
klinische studie in het Rijnstate ziekenhuis gestart om de effectiviteit van de 
laparoscopische BRYGB met een siliconen band ten opzichte van de conventionele 
LRYGB operatie te vergelijken (BANDOLERA studie, Clinical Trials Identifier: 
NCT02545647). Daarnaast zijn er enkele anatomische aanpassingen aan de RYGB 
gedaan die momenteel in het Rijnstate ziekenhuis wordt onderzocht. Een belangrijke 
conclusie van dit proefschrift is dat de verlenging van de Roux-lis niet resulteert in 
toename van gewichtsverlies (Hoofdstuk 4). Voor in de toekomst zal een van onze 
eigen studies (de ELEGANCE studie) informatie verschaffen met betrekking tot 
effectiviteit en toepasbaarheid van de lange BPL-lis RYGB in een gerandomiseerde 
setting. De omega-loop (of de mini-) gastric bypass met alleen een BPL-lis vormde de 
basis van deze studie. Opvallend is dat de omega-loop gastric bypass wordt uitgevoerd 
met een ‘sleeved’ maagpouch, welke theoretisch tot meer restrictie zorgt.
45-48
 Deze 
‘sleeved’ pouch is net zo smal maar langer dan de pouch in een standaard RYGB 
operatie. Om de effectiviteit van deze techniek te onderzoeken, is er een 
gerandomiseerde studie opgestart in het Rijnstate ziekenhuis (Extended pouch Roux-
en-Y gastric bypass studie, Clinical Trials Identifer: NCT02218957).  
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 In de toekomst zullen deze studies ons informatie verschaffen over 
gewichtsverlies, complicaties, kwaliteit van leven en nutriënt deficiënties in patiënten 
die deze alternatieve LRYGB operaties ondergaan.  Het is duidelijk dat de huidige 
LRYGB-procedure niet het einde van de evolutie is en er wordt verwacht dat deze 
studies ons zullen helpen om een 'optimale' LRYGB-procedure te creëren. 
 
10.3 ALGEMENE CONCLUSIE 
 
 Concluderend, de LAGB-procedure moet alleen aangeboden worden aan 
geselecteerde patiënten in verband met hoog risico op late complicaties en noodzaak 
tot verwijderen van de band. De LRYGB blijft nog steeds de gouden standaard in 
bariatrische/ metabole chirurgie door blijvend gewichtsverlies en reductie van obesitas 
gerelateerde metabole ziekten, voornamelijk T2DM. De optimale LRYGB techniek is 
nog niet gedefinieerd en de rol van de verschillende dunne darm lissen moet verder 
bestudeerd worden prospectieve klinische studies. De LRYGB-procedure gaat 
gepaard met tal van potentiele peri- en postoperatieve bijwerkingen en complicaties. 
Introductie van de FTS programma resulteert in een sneller herstel van de patiënt en 
verbetert de peri-operatieve efficiëntie. Het ontwikkelen van een aangepast 
multivitaminen supplement resulteerde in minder postoperatieve voedingstekorten, 
hoewel het nog geen volledige preventie bood. Dit zijn belangrijke veranderingen in de 
metabole chirurgie en hebben al een grote impact in het bariatrisch landschap. De 
evolutie van de RYGB-chirurgie is nog steeds aan de gang! 
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APPENDIX 1: LIST OF ABBREVIATIONS 
 
%EWL  Percentage Excess Weight Loss 
%TBWL Percentage Total Body Weight Loss 
 25-OHD 25-hydroxyvitamin D 
A 
ADA  American Diabetes Association 
AGB  Adjustable Gastric Band(ing) 
AL  Alimentary Limb 
ASA  American society of anaesthesiologists 
ASMBS American Society for Metabolic and Bariatric Surgery 
B 
BAROS Bariatric Analysis and Reporting Outcome System 
BMI  Body Mass Index 
BPL  Biliopancreatic Limb 
BRYGB Banded Roux-en-Y Gastric Bypass 
C 
CBD  Common Bile Duct 
CPC  Conventional Peri-operative Care 
D 
DDD  Daily Defined Dose 
DL  Dyslipidemia 
DSSCC Diabetes Surgery Summit Consensus Conference 
E 
ERAS  Enhanced Recovery After Surgery 
EtO2  End Tidal O2 
EWL  Excess Weight Loss 
F 
FTS  Fast Track Surgery 
FPG  Fasting Plasma Glucose 
G 
GERD  Gastro Esophageal Reflux Disease 
GLP-1  Glucagon-Like Peptide-1 
H 
HDL-C  HDL-cholesterol 
HT  Hypertension 
I 
IDDM  Insulin-Dependent Diabetes Mellitus 
ID  Iron Deficiency 
IDF  International Diabetes Federation 
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IFSO International Federation for the Surgery of Obesity and metabolic disorders 
L 
LAGB  Laparoscopic Adjustable Gastric Band(ing) 
LAGBP  Laparoscopic Adjustable Gastric Banded Plication 
LBPDDS Laparoscopic Biliopancreatic Diversion and Duodenal Switch 
LDL-C  LDL-cholesterol 
LRA  Loco-Regional Analgesia 
LRYGB  Laparoscopic Roux-en-Y Gastric Bypass 
LSG  Laparoscopic Sleeve Gastrectomy 
M 
MAC  Minimal Alveolair Concentration 
MIS  Minimal Invasive Surgery 
MO  Morbid Obesity 
MCV  Mean Cell Volume 
 MVS  Multivitamin Supplement 
N 
NS  Not Significant 
O 
OR  Operation Room 
OSAS  Obstructive Sleep Apnea Syndrome 
OXM  Oxyntomodulin 
P 
PCA  Patient Controlled Analgesia 
PEEP  Positive End Expiratory Pressure 
PPI  Proton Pump Inhibitors 
PTH  Parathyroid Hormone 
PYY  Polypeptide Tyrosine-Tyrosine 
Q 
QOL  Quality Of Life 
R 
RAS  Robot-assisted Surgery 
RDA  Recommended Daily Allowance 
RHA  Rijnstate Hospital Arnhem 
RYGB  Roux-en-Y Gastric Bypass 
RRYGB Robotic-assisted Roux-en-Y Gastric Bypass 
S 
SG  Sleeve Gastrectomy 
sMVS  Standard Multivitamin Supplement 
SOS  Swedish Obese Subjects 
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T 
T2DM  Type 2 Diabetes Mellitus 
TBWL  Total Body Weight Loss 
TC  Total cholesterol 
TCI  Target Controlled Infusion Target 
TG  Triglycerides 
TIBC  Total Iron-binding Capacity 
TOF  Train-Of-Four stimulation 
V 
VTE  Venous Tromboembolism 
W 
 WHO  World Health Organization 
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PUBLICATIONS 
K Dogan, B Betzel, J Homan, EO Aarts, N Ploeger, H de Boer, TJ Aufenacker, CJHM van 
Laarhoven, IMC Janssen, FJ Berends. Long-term effects of laparoscopic Roux-en-Y gastric 
bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes 
Surg. 2014 Nov;24(11):1835-42.  
 
K Dogan, L Kraaij, EO Aarts, P Koehestanie, E Hammink, CJHM van Laarhoven, TJ 
Aufenacker, IMC Janssen, FJ Berends. Fast-track bariatric surgery improves perioperative 
care and logistics compared to conventional care. Obes Surg. 2015 Jan;25(1):28-35. 
 
K Dogan, R Bakx, PL Klemm. Complicatie van coronairangiografie bij een patiënte met 
sclerodermie. Ned Tijdschr Geneeskd. 2011;155:A2704. 
 
K Dogan, MFP van der Jagt, F van Hoek. Complicatie na aanleggen van een arterioveneuze 
fistel in de bovenarm: ischemische monomelische neuropathie. Ned Tijdschr Geneeskd. 
2011;155:A3824  
 
K Dogan, Homan J, EO Aarts, H de Boer, CJHM van Laarhoven, FJ Berends. Long-term 
nutritional status in patients following Roux-en-Y gastric bypass surgery. Clin Nutr. 2018 
Apr;37(2):612-7. 
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long Roux limb in gastric bypass surgery: does it matter? Surg Endosc. 2017 Apr;31(4):1882-
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Trial. Medicine (Baltimore). 2014 Nov;93(25):e169.  
 
K Dogan, RP Gadiot, EO Aarts, B Betzel, CJHM van Laarhoven, LU Biter, GHH Mannaerts, 
TH J Aufenacker, IMC Janssen, FJ Berends. Effectiveness and safety of Sleeve Gastrectomy, 
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APPENDIX 3: DANKWOORD (WORD OF GRATITUDE) 
 
Jazeker… mijn boekje is af! Maar, winnen doe je niet in je eentje. Pelé (voormalig Braziliaans 
wereldvoetballer, drievoudig WK winnaar) zei ooit: ‘No individual can win a game by himself’. 
Daarom wil ik iedereen die een bijdrage heeft geleverd aan de totstandkoming van dit 
proefschrift heel erg bedanken en een aantal in het bijzonder. 
 
Geachte professor van Laarhoven, beste Kees (promotor), allereerst wil ik je heel erg 
bedanken dat je mijn promotor wilde zijn. Daarnaast heel erg bedankt voor je vertrouwen in dit 
project. Je begeleiding bij het schrijven van de artikelen en afronden van mijn proefschrift was 
onontbeerlijk. Je kennis en ervaring heeft mij en dit proefschrift sterker gemaakt.  
 
Beste Frits (dr. Berends, co-promotor), er komen woorden tekort om jou te bedanken. 
Allereerst dank voor de mogelijkheid om onderzoek bij je te mogen doen. Ik heb enorme 
waardering voor hoe je mij professioneel en persoonlijk hebt begeleid. Naast je 
wetenschappelijke kennis was ik enorm onder de indruk van je chirurgische vaardigheden. Je 
bent een voorbeeld voor mij. Daarom heb ik zelfs een studie naar je genoemd: ELEGANCE. 
Ik hoop je in mijn chirurgische carrière nog vaak tegen te komen! 
 
Beste Ignace (drs. Janssen), voor mij geen onderscheid voor tussen jou en Frits. Je bent een 
mens met duizendpoten. Je visie en ideeën waren onuitputtelijk. Je enthousiasme 
onnavolgbaar en je lach iconisch. Heel erg bedankt voor je begeleiding, onvoorwaardelijke 
vertrouwen en ruimte die ik van je heb gekregen voor mijn persoonlijke ontwikkeling. Je bent 
klaar voor je pensioen, maar je bent er nog niet klaar mee. Respect!  
 
Beste Edo (dr. Aarts, co-promotor), we kwamen elkaar tegen in het Radboudumc. Bij de 
koffieautomaat (oude secretariaat nog) kwam je naar me toe of ik interesse had voor een 
onderzoek naar de bariatrie in het Rijnstate. Daar begon het allemaal. Door de jaren heen wist 
je mij altijd te stimuleren. Mede door jou gedrevenheid en hulp heb ik dit tot een eind kunnen 
brengen. Heel erg bedankt voor de mooie jaren. Inmiddels ben je zelf gepromoveerd en ben 
je mijn co-promotor. Fantastisch.  
 
Beste leden van de manuscriptcommissie (Prof. dr. J.P.H. Drenth, Prof. dr. L.A.M.L. Kiemeney 
en Prof. dr. ir. C. de Graaf), veel dank voor uw tijd en kritische beoordeling van mijn proefschrift. 
 
Beste Theo (dr. Aufenacker), het was een genot om met je samen te werken. Er was altijd wel 
tijd voor een grap. Uiteraard wil ik je ook bedanken voor je hulp en begeleiding tijdens mijn 
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Ik hoop je in mijn chirurgische carrière nog vaak tegen te komen! 
 
Beste Ignace (drs. Janssen), voor mij geen onderscheid voor tussen jou en Frits. Je bent een 
mens met duizendpoten. Je visie en ideeën waren onuitputtelijk. Je enthousiasme 
onnavolgbaar en je lach iconisch. Heel erg bedankt voor je begeleiding, onvoorwaardelijke 
vertrouwen en ruimte die ik van je heb gekregen voor mijn persoonlijke ontwikkeling. Je bent 
klaar voor je pensioen, maar je bent er nog niet klaar mee. Respect!  
 
Beste Edo (dr. Aarts, co-promotor), we kwamen elkaar tegen in het Radboudumc. Bij de 
koffieautomaat (oude secretariaat nog) kwam je naar me toe of ik interesse had voor een 
onderzoek naar de bariatrie in het Rijnstate. Daar begon het allemaal. Door de jaren heen wist 
je mij altijd te stimuleren. Mede door jou gedrevenheid en hulp heb ik dit tot een eind kunnen 
brengen. Heel erg bedankt voor de mooie jaren. Inmiddels ben je zelf gepromoveerd en ben 
je mijn co-promotor. Fantastisch.  
 
Beste leden van de manuscriptcommissie (Prof. dr. J.P.H. Drenth, Prof. dr. L.A.M.L. Kiemeney 
en Prof. dr. ir. C. de Graaf), veel dank voor uw tijd en kritische beoordeling van mijn proefschrift. 
 
Beste Theo (dr. Aufenacker), het was een genot om met je samen te werken. Er was altijd wel 
tijd voor een grap. Uiteraard wil ik je ook bedanken voor je hulp en begeleiding tijdens mijn 
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onderzoek, en de bijdrage die je hebt geleverd aan de artikelen. Als ik straks terug ben in het 
Rijnstate, hoop ik nog veel van je te leren. Tot ziens! 
 
Beste Bart (dr. Witteman), je kwam als nieuw staflid bariatrie binnen; altijd spannend voor de 
jonkies. Het tegendeel was waar, je was vriendelijk en benaderbaar. Dank voor de mooie tijd. 
Ik heb ook een passie voor de robot; hoop deze passie met je te kunnen delen in het Rijnstate. 
 
Beste chirurgen uit het Rijnstate ziekenhuis, ik wil jullie heel erg bedanken voor de leerzame 
en mooie periode. De overdrachten en refereeravonden hebben mij dicht bij de kliniek 
gehouden. Ik heb 2 jaar lang een tafel en een computer met het mooiste uitzicht toe mogen 
eigenen op de assistentenkamer; waarvoor dank. Na zoveel jaar, kom ik terug als assistent 
om bij jullie een volwaardig chirurg te worden. Ik heb er zin in! 
 
Beste Parweez (Koehestanie), de vele uren die ik met je heb doorgebracht zijn het waard 
geweest. Je was een hele fijne en waardevolle collega en vriend! Ik heb met alle plezier je 
geholpen bij de Endobarrier. Al vond ik het jammer dat je voor de MDL koos. Maar een ding is 
zeker, je bent een arts met een hart. Bedankt voor alles. Het ga je goed.  
 
Beste Bark (Betzel), na Parweez had ik met jou te dealen… maar niet minder leuk! Je was een 
hele fijne en betrokken collega. Het was altijd lachen met je. De tripjes naar Velp op en neer 
waren anders niet te doen. Ook voor jou de laatste loodjes, veel succes ermee! Ik weet het 
zeker, komt goed. Bedankt! 
 
Beste Jens (Homan), je was mijn opvolger. Een terechte keuze. Ik wil je bedanken voor de 
bereidheid en de snelheid waarmee je de studies hebt opgepakt. Inmiddels zijn we ook 
collega’s als chirurg in opleiding. Ik wens je ook heel veel succes met het afronden van je 
promotie. 
 
Beste Boy (Rozenberg), de fotograaf, ik wil je heel erg bedanken voor de prachtige foto’s die 
je hebt gemaakt voor mijn proefschrift. Het maakt het er nog mooier op. Daarnaast ben je een 
hele fijne collega. 
 
Beste Davy (Gerhardt) en Thijs (Nijenhuis), de mannen van de orthopedie. We hebben samen 
de assistentenkamer onveilig gemaakt. Dank voor jullie gezellige tijd.  
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Beste Hans (dr. de Boer), bariatrie is meer dan opereren alleen. Dat maakte het voor mij als 
‘chirurgische onderzoeker’ er niet makkelijk op. Hartelijk dank voor je ‘internistische’ 
begeleiding. Door jou was het wel begrijpelijk allemaal.  
 
Beste MDL-artsen (dr. P.J. Wahab en dr. M.J.M. Groenen), dank jullie voor de fijne 
samenwerking. Jullie waren altijd benaderbaar voor overleg. Tijdens het implanteren en 
explanteren van de Endobarrier kon ik altijd terugvallen op jullie expertise. De patiënten waren 
in goede handen. 
 
Beste Ralph (Gadiot), dr. Biter en dr. Mannaerts (collega’s Sint Franciscus Gasthuis, 
Rotterdam), ik wil jullie heel erg bedanken voor de samenwerking en het tot stand komen van 
een prachtig artikel. Wellicht komt er een vervolg.  
 
Beste Edwin (drs. Hammink), het was altijd lachen met je op de OK. Zelfs de patiënten gingen 
met een lach in slaap. Hartelijk dank voor de gezellige tijd en natuurlijk voor de bijdrage die je 
hebt geleverd voor het ontwikkelen van de fast-track programma die geresulteerd heeft in een 
mooi artikel. Tot ziens. 
 
Beste Kristy, Nadine, Annemieke en Gül, waar zou de bariatrie zijn zonder jullie inzet. Ik wil 
jullie enorm bedanken voor de leuke periode die we hebben gehad. Kristy, inmiddels ben je 
doorgegroeid tot manager, het is je gegund. Nadine, een deel van dit boekje had niet bestaan 
zonder jouw hulp. Dank je. Het was voor mij ook een heel plezier om betrokken te zijn bij de 
afronding van je opleiding. Inmiddels vele jaren ervaring als gespecialiseerd bariatrische 
verpleegkundige. Heel veel succes. Annemieke, jij ook heel erg bedankt voor je hulp en inzet. 
Daarnaast ben je van toegevoegde waarde als leefstijlcoach. Succes. Gül, we hebben samen 
het traject voor de Turkse patiënten opgepakt. Je hebt je hard gemaakt voor deze patiënten 
om ze de optimale zorg te bieden.  Je was daar heel fanatiek in, waarvoor dank. Tevens wil ik 
alle betrokkenen die ik niet heb genoemd (secretaresses en verpleegkundigen) heel erg 
bedanken voor hun inzet en hulp. 
 
Beste Willemien, je was ‘de moeder’ van de onderzoekers. Hadden we soms ook nodig. Heel 
erg bedankt voor de fijne tijd. 
 
Beste vrienden van het Leerhuis (Lian Roovers, Bianca Baten, Marc Rinkes en overige leden), 
onderzoek doen kan niet zonder een goed draaiend wetenschapsbureau. Zonder jullie hulp 
was dit niet gelukt. Jullie waren altijd bereid om mij te helpen. Ook al kwam ik te pas en te 
onpas binnenlopen. Heel veel dank. 
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Beste Kurt en Marja (van het lab), jullie zagen me al aan komen lopen, daar was ik weer… 
maar dat was nooit een probleem. Altijd behulpzaam. Dank daarvoor. 
 
Geachte professor Rosman, beste Camiel, en beste Fatih (drs. Polat), na mijn onderzoek 
moest ik het weer waar maken in de kliniek (in het CWZ). Al snel hebben jullie als opleiders 
mij het vertrouwen en steun gegeven. Dit heeft geleid tot een opleidingsplek binnen de 
chirurgie. Daarnaast was het een eer om mijn eerste stappen als chirurg in opleiding in jullie 
handen te zetten. Ik hoop in de toekomst nog veel van jullie te mogen leren. Niet alleen als 
chirurg, maar ook op wetenschappelijk vlak, aangezien we samen onderzoek doen naar de 
robot. Heel veel dank voor alles. 
 
Beste chirurgen uit het Canisius-Wilhelmina ziekenhuis, ik wil jullie allen één voor één 
bedanken voor de mooie en leerzame periode die ik heb gehad in het CWZ. Ik ben ervan 
overtuigd dat ik door jullie een goede basis heb gelegd voor mijn carrière als chirurg. Dank 
voor jullie vertrouwen en de mogelijkheden die ik heb gekregen.  
 
Beste assistenten uit het Rijnstate ziekenhuis, Canisius-Wilhelmina ziekenhuis en 
Radboudumc, wij zijn vaker samen dan wie dan ook. We delen lief en leed. Ik wil jullie allen 
bedanken voor de collegialiteit en gezelligheid. We komen elkaar vast nog vaak genoeg tegen. 
Ik wens in ieder geval iedereen het beste. 
 
Beste Peter (dr. Van Duijvendijk) en chirurgen uit Gelre ziekenhuizen Apeldoorn, mijn eerste 
baan als assistent chirurgie heb ik bij jullie gehad. Ik heb ontzettend veel geleerd. Ik wil jullie 
erg bedanken voor jullie vertrouwen en de tijd die jullie in mij hebben gestoken om een goede 
dokter (chirurg) van mij te maken. Ik kom met alle plezier nog een keer langs om over de 
bariatrie te praten. Tot ziens. 
 
Beste Mostafa (Khalilzada) en Hamid (Afzali), mijn paranimfen, allereerst heel veel dank dat 
jullie mijn paranimfen willen zijn. Samen met jullie studeren was fantastisch. Dat kwam 
natuurlijk door de tijd die we samen buiten de studie hebben meegemaakt. Jullie zijn blijven 
hangen in het westen, dus zien we elkaar helaas niet vaak meer. Maar jullie blijven mijn 
vrienden voor het leven. Heel veel dank voor alles. 
 
Lieve papa en mama (anne ve baba), eindelijk is mijn boekje klaar en nog een hoofdstuk 
afgesloten. Ik heb van jullie geleerd om te strijden voor een beter leven. Ondanks dat jullie het 
niet altijd breed hadden, ben ik niks tekortgekomen. Jullie hadden gehoopt dat ik een rustig 
leventje zou hebben als ik een dokter zou worden, maar de realiteit anders. Dit hebben jullie 
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helaas ook ervaren, want een leven van een chirurg in opleiding, promovendi, en een 
gezinsman, maakt dat we elkaar niet vaak zien. Maar ik weet dat jullie trots op me zijn. Beste 
broers en zussen (Fatih abi, Aysegül, Cangül en Muhammed), ik was altijd de lieveling van 
mijn ouders, maar geloof me, jullie zijn niet anders in hun ogen. Bedankt voor alles. 
 
Beste schoonouders en schoonfamilie, het is weer halfzeven als we Yasin bij jullie droppen… 
hij krijgt te eten en wordt naar school gebracht. Week in week uit. Ik wil jullie heel veel 
bedanken voor jullie onvoorwaardelijke steun.  
 
Mijn lieve Nazli, je bent 10 jaar geleden een weg met me ingeslagen zonder dat je wist wat dit 
voor je zou betekenen. Ik heb heel veel tijd en geduld van je geëist. Het was niet makkelijk. Je 
wilskracht en daadkracht heeft ervoor gezorgd dat ik me volledig kon concentreren op mijn 
werk (opleiding) en promotie. Je hebt veelal in je eentje ervoor gezorgd dat het huis draaiende 
bleef. Daardoor ben ik heel trots op je en daarom is een groot deel van dit boekje ook van jou. 
Dikke kus. 
 
Tot slot, mijn liefste en mijn kanjer, Yasin (mini), jij bent mijn trots. Dit boekje draag ik op aan 
jou. Papa is vaak weg of thuis druk. Je woorden ‘ga ik je vanavond zien?’ spoken door mijn 
hoofd als ik weer dienst heb of weg ben voor congres of cursus. Ik wil je beloven dat het nu 
over is, maar... zoals je zelf zegt (als ik er weer niet ben): ‘papa moet opereren’. Dikke kus.  
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